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Abstract 
 
The Functions of Rictor, Pten, and p53 Signaling Pathways  
in Brain Tumors and Brain Development 
by 
Seckin Akgul 
 
Glioblastoma is the most common malignant neoplasm of the central nervous system. 
Despite intense treatment plans and supportive care, the median survival rate remains 
approximately 12-15 months. Comprehensive analyses have demonstrated that 
approximately 90% of glioblastomas have elevated PI3K/AKT signaling accompanied by 
chromosome-10 (chr10) loss. We, therefore, investigated the clinical implications of 
genetically inhibiting Rictor/mTORC2, a positive regulator of the PI3K/AKT pathway. 
We show that mutant-p53 driven mouse gliomas undergo independent but concurrent loss 
of chr19 and chr7, syntenic to human chr10q, which results in Pten deletion and 
hyperactivation of PI3K/Akt. Removal of Rictor, and by extension PI3K/Akt signaling, 
exerts significant tumor suppressive activity in both initiation and progression of high-
grade gliomas. However, this oncogenic pathway is not absolutely required for a group of 
gliomas, calling for a need to identify the other molecular events that may lead to tumor 
resistance and recurrence. 
 
Unpredictably, embryonic inactivation of Rictor/mTORC2 increases the frequency of 
mutant-p53 driven medulloblastoma development. In contrast to glioblastoma, which is 
mostly associated with adult oncology cases, medulloblastoma is largely a pediatric 
malignancy of the cerebellum affecting infants and children. Our analyses suggest that 
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Rictor loss delays the cell cycle exit and neuronal differentiation in a subset of cerebellar 
progenitors leading to an increased predisposition to mutant-p53 induced 
medulloblastoma formation. These tumors exhibit distinctive genomic alterations that are 
associated with poor clinical outcome, providing a platform to study alternative treatment 
options for incurable kids.  
 
Given the cell type-specific roles of Rictor/mTORC2/Akt signaling in brain 
tumorigenesis, our additional analyses aimed to understand its roles in different neuronal 
populations during the brain development. We show that intact Pten functions, including 
the regulation of PI3K/Akt signaling, are required for the proper neuronal layering, and 
the generation and/or survival of a subset of projection neurons in the cerebral cortex. 
These findings provide valuable insight into cognitive and neurodevelopmental defects 
observed in patients with germline PTEN mutations. 
 
Together, this thesis work identifies Rictor/mTORC2 as a signaling pathway with 
opposing roles in adult and pediatric brain tumors, and uncovers novel roles for Pten in 
the formation of neuronal architecture during the brain development. 
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Chapter I: Introduction 
 
 
1.1 Malignant gliomas and glioblastoma 
 
Malignant gliomas are the most common and lethal primary brain tumors (Furnari et al., 
2007; Louis, 2006).  These deadly intracranial tumors can occur in all age groups, 
however, they are mostly observed in adult patients over the age of forty-five, making 
them the most common adult neuro-oncology cases (Louis, 2006; Watkins and 
Sontheimer, 2012). Gliomas are divided into different degrees of malignancy based on 
World Health Organization (WHO) classification criteria: Grade I gliomas are considered 
to be benign and can be cured with a successful surgical resection, however, grade II-IV 
gliomas (i.e. malignant gliomas) exhibit gradually increased anaplasia, malignancy, and 
proliferation (Furnari et al., 2007). Consequently, while grade-II and grade-III gliomas 
are often associated with 5-15 years and less than 3 years of overall survival rates, 
respectively, grade-IV gliomas (also known as glioblastoma) are highly resistant to 
conventional radiotherapy and chemotherapy leading to extremely low survival rates of 
approximately 12-15 months. (Huse et al., 2013; Louis, 2006; Louis et al., 2007). 
Overall, approximately 60-70% of the malignant gliomas are glioblastomas, while 10-
15% are anaplastic astrocytomas, and 10% are anaplastic oligodendriogliomas and 
oligoastrocytomas. The remaining rare portion includes anaplastic ependymomas and 
anaplastic gangliogliomas (Wen and Kesari, 2008).  
 
Approximately 90% of glioblastomas develop rapidly without any preceding clinical or 
histological evidence of a less malignant lesion (e.g. grade I-III). These de novo tumors 
are called “primary glioblastoma” and they mostly manifest in elderly patients. 
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“Secondary glioblastoma”, on the other hand, gradually progress from an already-
detected low-grade diffuse astrocytoma or anaplastic astrocytoma. These tumors are 
mostly found in younger patients and mostly associated with comparatively better clinical 
outcomes (Furnari et al., 2007; Ohgaki and Kleihues, 2013). Even though these two types 
of glioblastomas have very similar histopathologic features, recent studies identified 
different cell-of-origin and genetic alterations required for their formation (Brennan et al., 
2013; Nobusawa et al., 2009). 
 
Approximately 10,000 new patients are diagnosed with glioblastoma in the USA each 
year (Cloughesy et al., 2014). Typical symptomatic presentation includes headaches, 
seizures, focal neurological deficits, memory loss, confusion and personality changes 
(Watkins and Sontheimer, 2012).  As these tumors exhibit extremely aggressive growth 
characterized by infiltration and widespread invasion surrounding the brain, it is virtually 
impossible to surgically resect the tumor mass completely (Cloughesy et al., 2014). Even 
though the subsequent treatments including ionizing radiation, cytotoxic chemotherapy 
with alkylating agent temozolomide and intense supportive care can increase the survival, 
tumors typically recur after an average of only 6.9 months (Huse et al., 2013; Watkins 
and Sontheimer, 2012). As a result, the overall 5-year survival rate of glioblastoma 
patients remains less than 5%, which is even worse for older patients (Chen et al., 
2012b). Poor drug delivery and tumor heterogeneity are considered to be the other main 
factors that limit the effectiveness of the current treatment strategies (Sottoriva et al., 
2013). The presence of intratumor and intertumor heterogeneity, in particular, suggests 
that molecularly distinct tumors might exhibit differences in progression, prognosis, and 
clinical implications (see below) (Phillips et al., 2006; Verhaak et al., 2010).  
 
1.2 Molecular signature of glioblastoma and key pathway alterations 
 
How does a perfectly normal and functional cell transform into a malignant cell, and 
what are the roles of molecular alterations that it acquires during the initiation and/or 
progression of a disease? Answering these questions requires detailed and careful 
	   3	  
analyses of the tumor cells, and accurate interpretation of the findings. Integrated multi-
dimensional investigations, including large-scale genomic, transcriptomic and epigenetic 
analyses have been performed to increase our knowledge of the molecular basis of 
glioblastoma. For instance, sequencing analyses identified PTEN, TP53, NF1, RB1 
(tumor suppressor genes), EGFR, PIK3CA, PIK3R1, PDGFRA (oncogenes) and IDH1 as 
the significantly mutated genes in glioblastoma (Table 1) (Brennan et al., 2013; Cancer 
Genome Atlas Research, 2008; Parsons et al., 2008). Copy number analyses uncovered 
amplifications in many important oncogenes including EGFR, MET, CDK6, CDK4, 
MDM2 and PDGFRA. In addition, frequent gains of AKT3, SOX2, MYCN, CCDN1 and 
CCNE2 have also been detected. Deletions, which are more frequent than amplifications, 
include CDKN2A/B, PTEN, CDKN2C, RB1, PARK2 and NF1 (Table 1). These altered 
genes normally function in three major signaling pathways. As a result, 90% of the 
glioblastomas have alterations in PI3K/RTK signaling, 86% in p53-signaling and 79% in 
Rb-signaling, underlining the landscape of pathway alterations in glioblastomas (Brennan 
et al., 2013; Cancer Genome Atlas Research, 2008; Parsons et al., 2008).  
 
Table 1. Most common somatic alterations and deregulated core signaling pathways 
in human glioblastomas. 
Gene name Location Frequency Molecular event Assoc. pathway 
CDKN2A/B Chr9 61 % Deletion/mutation p53 & Rb 
EGFR Chr7 57 % Amplification/mutation PI3K/RTK 
PTEN Chr10 41 % Deletion/mutation PI3K/RTK 
TP53 Chr17 28 % Deletion/mutation p53 
PIK3C/R * Multiple chr. 25 % Amplification/mutation PI3K/RTK 
CDK4 Chr12 14 % Amplification/mutation Rb 
PDGFRA Chr4  10 % Amplification/mutation PI3K/RTK 
NF1 Chr17 10 % Deletion/mutation PI3K/RTK 
MDM2 Chr12 7.6% Amplification/mutation p53 
RB1 Chr13 7.6 % Deletion/mutation Rb 
MDM4 Chr1 7.2 % Amplification/mutation p53 
CDKN2C Chr1 5.6 % Deletion/mutation Rb 
*PIK3C/R is a combination of multiple genes, including PIK3CA, PIK3R1, PIK3C2G, 
PIK3CG, PIK3CB, PIK3C2B, PIK3C2A and PIK3R2, which encode for PI3K family. 
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In addition to signaling pathway-associated genes, several epigenetic control genes are 
also deregulated. Of those, IDH1, which is a chromatin modifier and associated with 
lower grade gliomas or secondary glioblastoma, is mutated in 5% of the total cases. 
SWI/SNF complex gene ATRX is also mutated in 6% of the tumors, most of which co-
occurred with IDH1 alterations. Other epigenetic regulators are listed in Table 2 
(Brennan et al., 2013). Deregulation of these genes lead to abnormalities in gene 
expression as a result of altered accessibility of regulatory transcription machinery to 
regulatory DNA sites (Berdasco and Esteller, 2010). 
 
Table 2. Epigenetic regulatory genes that are frequently mutated in glioblastoma. 
Gene name Epigenetic function 
IDH1 (5%), ATRX (6%), SETD2 (2%), CREBBP (2%), TEP1, 
SETD1A, TERT, BAP1, SRCAP, TET2 Chromatin modifier 
MLL3 (3%), MLL2 (2%), MLL4 (2%), MLL, BMI1, EHMT2, EZH2 Histone 
methyltransferase 
HLTF, SMARCA2, ARID1A, SMARCA5, SARCAL1, SMARCC2 SWI/SNF complex 
KDM2B, KDM1B, KDM4D, KDM5A, KDM5C, KDM6A, KDM6B, 
KDM5B, MYSM1 Histone demethylase 
HDAC2, HDAC9 Histone deacetylase 
Alteration frequency is approximately 1% for each gene, unless indicated otherwise in 
parenthesis. 
 
1.3 Intertumor heterogeneity and molecular profiling of glioblastoma 
 
Recent studies identified significantly varying genetic and phenotypic profiles between 
tumors from different individuals (intertumor heterogeneity) and also within a single 
tumor mass (intratumor or cellular heterogeneity) (Burrell et al., 2013). As reflected by 
its original name “glioblastoma multiforme”, glioblastoma is a disease of heterogeneity. 
Numerous efforts to develop effective therapies have been greatly challenged as a result 
of this variation. Though, it has been suggested that classifying tumors from different 
patients into subgroups may help interpreting molecular complexity of the disease, which 
would subsequently allow tailor precise and novel treatment plans (Parsons et al., 2008).  
Glioblastomas, therefore, have been categorized based on their distinct gene mutations, 
	   5	  
genome-wide DNA copy number changes, protein or RNA expression profiles, DNA 
methylation status and chromosomal alterations. (Brennan et al., 2013; Noushmehr et al., 
2010; Phillips et al., 2006; Sturm et al., 2012; Verhaak et al., 2010). Current classification 
system for glioblastomas predicts four molecularly distinct subgroups based on their gene 
expression profiles: Proneural, Classical, Mesenchymal and Neural (Verhaak et al., 
2010). The Proneural subgroup is mainly associated with murine oligodendrocytic gene 
expression signature, high expression levels of OLIG2, amplifications in PDGFRA gene 
and TP53 mutations (Phillips et al., 2006; Verhaak et al., 2010). Based on promoter CpG 
island hypermethylation status, Proneural group is further divided into two subgroups: 
“G-CIMP” tumors (glioma-CpG island methylator phenotype) associated with concerted 
global hypermethylations at numerous loci and others as “non-G-CIMP” tumors 
(Noushmehr et al., 2010). G-CIMP tumors are tightly associated with IDH1 mutation, 
which is a signature molecular event for secondary glioblastomas (Nobusawa et al., 2009) 
and they represent approximately 30% of all Proneural glioblastomas (Noushmehr et al., 
2010). DNA methylation of O6-methylguanine-DNA methyltransferase (MGMT) gene 
promoter, in particular, is enriched in G-CIMP tumors (79% in G-CIMP versus 46% in 
non-G-CIMP) (Brennan et al., 2013). It is worth noting that epigenetic silencing of 
MGMT through this hypermethylation leads to better clinical outcomes in the presence of 
alkylating agent cancer therapy (Hegi et al., 2005). Accordingly, Proneural G-CIMP 
patients had significantly longer survival compared to Proneural non-G-CIMP patients 
(150 weeks versus 42 weeks) (Noushmehr et al., 2010). Despite this favorable prognosis, 
only one third of the G-CIMP patients survived more than three years (Brennan et al., 
2013). Classical group glioblastomas are characterized by murine astrocytic gene 
expression signature and extensive chr7 amplifications. EGFR amplification located in 
this chromosome and the presence of constitutively active “EGFR deletion mutant variant 
III” (EGFRvIII) are typical molecular events for Classical group tumors (Huse et al., 
2013). Consistently, glioblastomas associated with EGFRvIII were found to be sensitive 
to EGFR kinase inhibitors, gefitinib and erlotinib, given that PTEN expression was intact 
(Mellinghoff et al., 2005). Abnormalities in PDGFRA, IDH1 and TP53 are notably 
uncommon in this group as opposed to Proneural tumors. However, deletion of CDKN2A 
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was significantly associated with Classical group tumors, which underlines the distinct 
ways of p53-signaling inactivation in different subgroups (Brennan et al., 2013; Verhaak 
et al., 2010). Mesenchymal glioblastomas predominantly undergo hemizygous deletions 
at a region in chr17q11.2, which harbors NF1 gene. In addition, these tumors highly 
expressed mesenchymal markers YKL40 and MET, and other genes in the tumor necrosis 
factor superfamily and NF-KB pathways, which are attributed to the high incidence of 
necrosis and inflammatory responses observed in Mesenchymal group glioblastomas 
(Bhat et al., 2013; Phillips et al., 2006; Verhaak et al., 2010). Lastly, Neural subgroup 
tumors were categorized mostly based on their gene expression of neuron markers, 
including NEFL, GABRA1, SYT1 and SLC12A5 (Verhaak et al., 2010). These tumors had 
mutations in many genes similar to other three groups and there are not any specific 
alterations attributed to this group alone. Thus, it still remains a debate as to whether 
Neural subgroup is a genuine category or it just represents a combination of the other 
three glioblastoma groups and normal brain (Huse et al., 2013).  
 
As well as the genomic and transcriptomic alterations, epigenetic changes can vary 
significantly among the glioblastomas, as discussed earlier for Proneural G-CIMP and 
non-G-CIMP tumors. Accordingly, six epigenetic glioblastoma subgroups with distinct 
methylation profiles have been identified: IDH, G34 (H3F3A G34R/V mutation), K27 
(H3F3A K27M mutation), RTK I (PDGFRA), Mesenchymal, and RTK II (Classic) 
(Sturm et al., 2012). Consistent with the previous findings, IDH group exhibits concerted, 
global hypermethylation along with IDH1 mutations, similar to G-CIMP tumors 
(Noushmehr et al., 2010). G34 subgroup, on the other hand, display widespread 
hypomethylation, particularly in non-promoter regions and at chromosome ends, and 
therefore called “CpG hypomethylator phenotype (CHOP)” tumors. Interestingly, G34 
and K27 glioblastomas are pediatric/young adult patients while the remaining four groups 
are significantly enriched for elderly patients (Schwartzentruber et al., 2012; Sturm et al., 
2012). In addition, K27 tumors are mostly found in thalamus, pons and spinal cord while 
the remaining groups are almost exclusively in the cerebral hemispheres (Sturm et al., 
2012). This finding indicates a different biological subtype with different cellular origins 
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and/or signaling pathway alterations required for tumor growth. It has also been 
suggested that G34- and K27-mutant H3.3 lead to abnormal patterns of chromatin 
remodeling, which results in distinct gene expression profiles for G34 and K27 mutant 
glioblastomas (Schwartzentruber et al., 2012). Accordingly, K27 patients have 
significantly shorter overall survival than G34 patients. These findings altogether suggest 
that epigenetic alterations may exert further tumor heterogeneity, especially between 
pediatric/young adult and older patients, in terms of tumor cell-of-origin, oncogenic 
pathways leading to tumorigenesis, clinical outcome and drug sensitivity.  
 
These comprehensive studies helped us draw a molecular map of glioblastomas, which 
includes critical alterations distinguishing each clinical case, diverging/converging core 
signaling pathways responsible for tumorigenesis (further discussed in the next sections), 
and connections between transcriptomic, genomic and epigenetic events. The major 
information extrapolated from these studies to the clinical platform is: 1) G34 epigenetic 
group and Proneural group, especially those with IDH1 mutations, may not benefit from 
intensive chemotherapy and radiation compared to less aggressive therapies (Sturm et al., 
2012; Verhaak et al., 2010), 2) Tumors with epigenetic silencing of MGMT gene may 
benefit more from treatment plans that include alkylating agents such as temozolomide 
(Hegi et al., 2005), 3) Pediatric and adult glioblastomas may be different entities that 
require distinct clinical approach and treatment. However, other studies found that some 
tumors have the ability to switch their molecular profile upon the occurrence of certain 
molecular events. For instance, Nf1 loss (Ozawa et al., 2014) or NF-κB activation (Bhat 
et al., 2013) shifted Proneural profile to Mesenchymal, which was associated with poor 
radiation response and shorter survival in glioblastoma patients. Furthermore, Proneural 
to Mesenchymal shift has been reported in glioblastomas after recurrence (Phillips et al., 
2006), which suggests a tumor evolution. Thus, it still remains a challenge as to whether 
and how the identification of molecular subgroups can be translated into novel therapies 
that would actually reflect to the clinical outcome. 
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1.4 Intratumor heterogeneity of glioblastoma and its clinical impact 
 
The study of tumors as a bulk provides large-scale information gained from a mixture of 
heterogeneous tumor population. Accordingly, in addition to the molecular complexities 
pertaining to the molecular differences between individual glioblastoma cases, recent 
studies have also identified individual tumor cells associated with different subgroups or 
with different molecular characteristics within a single tumor mass. For instance, surgical 
multisampling allowed analyses of the spatially separated tumor fragments from each 
glioblastoma patient. Interestingly, each fragment from the same patient belonged to 
different glioblastoma subtype with unique and common copy number alterations 
(Sottoriva et al., 2013). Another study extended the depth of the analysis by isolating 96 
to192 single cells from each glioblastoma tissue and examining the cells individually. 
Surprisingly, while most of the cells exhibited a molecular profile similar to their original 
tumor mass, many of the cells actually crossed into the molecular profile of another 
tumor, which is different from their original tumor mass (Patel et al., 2014). Both of these 
studies and many others (Bonavia et al., 2011; Shi et al., 2012; Snuderl et al., 2011) 
suggest the emergence and maintenance of an extensive level of intratumor heterogeneity 
and tumor evolution.   
 
Intratumoral heterogeneity is a remarkable feature of glioblastoma that is strongly 
relevant to clinical field and current therapies. For instance, recent studies have 
uncovered a mosaic and mutually exclusive amplification of receptor Receptor Tyrosine 
Kinase (RTK) genes (EGFR, MET, PDGFRA) in different subpopulations of single 
tumors, raising the question of whether multiple kinase inhibitors are required to 
eradicate the tumor (Little et al., 2012; Snuderl et al., 2011; Szerlip et al., 2012). 
Similarly, another single-cell investigation revealed that each cellular clone with different 
genetic profile has variable sensitivity to known cancer drugs (Meyer et al., 2015). This 
finding not only emphasizes the presence of intratumor heterogeneity, but also calls for a 
need to identify the resistant clones for a better clinical outcome. Lastly, molecular 
comparison of the original gliomas to matched recurrent tumors extended tumor 
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heterogeneity concept to temporal and spatial clonal evolution. It has been shown that 
both initial and recurrent tumors exist as a mixture of heterogeneous populations formed 
as a result of cellular evolution, and that recurrent tumors might be seeded by an early-
formed clone of the original tumor, which has not acquired many of the mutations found 
in subsequent clones (Deng et al., 2014). This discovery further complicates the use of 
comprehensive genome studies, which presents the full set-of molecular alterations as a 
whole found in a tumor mass. 
 
Intratumor heterogeneity is thought to be formed by multiple cellular mechanisms, 
including 1) clonal evolution, 2) cancer stem cell model 3) microenvironment and 
interclonal cooperativity (Bonavia et al., 2011). According to the clonal evolution, tumor 
cells gain a diversity of molecular alterations throughout the tumor expansion and 
increase the tumor heterogeneity. Upon a selective pressure, such as chemotherapy or 
radiotherapy, only the clones that have acquired treatment-resistant features survive and 
reform a new heterogeneous tumor population, while the others perish or stay dormant 
(Greaves and Maley, 2012). Cancer stem cell model predicts a small population of cancer 
cells with indefinite self-renewing ability, and these cells give rise to a heterogeneous 
progeny that composes the major bulk of the tumor mass (Singh et al., 2004). The 
relatively quiescent cancer stem cells are considered to be drug-resistant population and 
they are thought to be the origin of the recurring tumors after the removal of the daughter 
cells (Vanner et al., 2014). Lastly, interclonal cooperativity defines a mixture of 
heterogeneous population formed either through clonal evolution or cancer stem cell 
model. The interaction of the genetically diverse cells with one another may provide drug 
resistance, invasion, migration, angiogenesis, growth enhancement and 
immunosuppression. Accordingly, it has been shown that a minor EGFRvIII-expressing 
tumor cell population drives the tumorigenic potential of the entire tumor mass by 
inducing wild type EGFR expression in neighboring cells through secreted IL-6 and LIF 
cytokines (Inda et al., 2010). Regardless of the way that it is formed, intratumor 
heterogeneity in glioblastoma still represents one of the major machineries for tumor 
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resistance and ineffective personalized therapies (Almendro et al., 2013), as discussed 
above. 
 
1.5 Oncogene addiction and the Achilles’ heel of glioblastoma 
 
The regulation of numerous genes and signaling pathways is disrupted in cancer cells as a 
result of multiple genomic, epigenetic and chromosomal abnormalities accumulating over 
time in a complex set of events. However, recent studies have identified a phenomenon 
called “oncogene addiction”, which suggests that cancer cells largely depend on a single 
oncogenic pathway for their survival, proliferation, and malignancy. This notion has been 
subsequently supported by various experimental systems and clinical trials in chronic 
myeloid leukemia, breast cancer, gastrointestinal stromal tumor, head and neck cancer, 
pancreas cancer, melanoma, and non-small-cell lung cancer. Therefore, uncovering the 
“Achilles’ heel” of cancer cells is essential to treat the patients effectively even in the 
presence of multiple genetic and epigenetic alterations (Huse et al., 2013; Sharma and 
Settleman, 2007; Weinstein, 2002; Weinstein and Joe, 2006). However, it should be 
noted that cancer cells can escape from their addiction to a specific molecular event and 
acquire further genomic instability accompanied by new oncogenic signals. As the 
original approach will no longer be effective, it is critical to identify the new oncogenic 
pathway(s) and design therapeutic approaches accordingly (Weinstein, 2002). 
 
Glioblastoma displays extreme degrees of intertumor and intratumor heterogeneity 
accompanied by severe molecular alterations (see sections 1.3 and 1.4). As a result, 
glioblastoma remains an incurable disease while many attempts to develop more effective 
therapeutics have been hampered. However, a gain of several chr7 copies (86%) and a 
loss of at least one chr10 copy (90%) remain the most common molecular events in a 
majority of glioblastomas from numerous patients, regardless of the molecular 
classification. More importantly, these two chromosomal abnormalities were consistently 
found in every tumor cell isolated from several glioblastoma samples, even though it has 
been emphasized that distinct molecular profiles and drug sensitivities exist within a 
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single mass (Meyer et al., 2015; Ozawa et al., 2014; Patel et al., 2014). Gain of several 
chr7 and deletion of chr10 are strongly associated with the amplification of EGFR and 
PDGFA, and the loss of PTEN, respectively (Ozawa et al., 2014; Verhaak et al., 2010). 
Consistently, even though significant intratumor heterogeneity has been detected in 
spatially separated tumor fragments in a single tumor mass, EGFR amplification and 
PTEN deletion has been observed in all and majority of the tumor fragments, respectively 
(Sottoriva et al., 2013). These results, altogether, support the previous findings showing 
that PI3K/RTK pathway is altered in 90% of human glioblastomas, leading to highly 
active AKT signaling (Brennan et al., 2013; Cancer Genome Atlas Research, 2008; 
Furnari et al., 2007). The inhibition of PI3K and/or AKT signaling, therefore, has been of 
particular interest in many cancer studies, including glioblastoma (Altomare and Testa, 
2005; Bellacosa et al., 2005; Cully et al., 2006; Momota et al., 2005; Testa and Bellacosa, 
2001; Wen and Kesari, 2008).  
 
1.6 PI3K/RTK/AKT signaling and glioblastoma 
 
1.6.1 PI3K family and activation of RTK/PI3K signaling pathway 
 
Phosphatidylinositol 3-kinases (PI3Ks) are large family of lipid kinases that provide a 
connection between the extracellular signals such as growth factors, cytokines and other 
environmental cues, and the intracellular signals that regulate proliferation, growth, 
motility, differentiation, migration, trafficking and metabolism (Katso et al., 2001). Class 
IA PI3Ks are heterodimers of one of the three catalytic isoforms (p110α (encoded by 
PIK3CA), p110β (PIK3CB) and p110δ (PIK3CD)) that associates with one of the five 
regulatory isoforms (p85α, p55α, p50α (PIK3R1), p85β (PIK3R2), and p55γ (PIK3R3)). 
Class IB PI3Ks are heterodimers of one catalytic subunit (p110γ (PIK3CG)) coupled with 
one of the two regulatory isoforms (p101 (PIK3R5) and p87 (PIK3R6)). Class II RTKs 
are monomeric and formed by one of the three catalytic isoforms, PI3K-C2α (PIK3C2A), 
PI3K-C2β (PIK3C2B), and PI3K-C2γ (PIK3C2G). Class III RTKs are only a dimer of 
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VPS34 (PIK3C3) and VPS15 (PIK3R4). Relatively less is understood about the functions 
and regulations of Class II and Class III PI3Ks (Thorpe et al., 2015).  
 
In the absence of a stimulus, p85 regulatory subunit of a Class IA PI3K interacts with 
p110 catalytic subunit and blocks its kinase activity. Upon binding of an activating ligand 
to a membrane-bound growth factor receptor tyrosine kinase (RTK), dimerized and 
autophosphorylated RTK can activate Class IA PI3Ks in at least three different ways, all 
of which requires a physical interaction between a Src homology 2 (SH2)-domain-
containing molecule with the RTK: 1) Regulatory p85 subunit of PI3K can directly bind 
to a specific phosphorylated site on RTK, leading to the activation of p110 catalytic 
subunit. 2) An adaptor molecule, such as insulin receptor substrate (IRS1), can form a 
bridge between the RTK and PI3Ks leading to activation of p110 catalytic subunit. 3) Ras 
or other small GTPases can integrate signals to activate p110 catalytic subunit of PI3Ks 
independently of the p85 regulatory domain (Cully et al., 2006; Vanhaesebroeck et al., 
2010). Class IB PI3Ks do not have p85 family regulatory subunit, therefore, they are not 
regulated by RTKs. Rather, they are exclusively activated by G-protein-coupled receptors 
(GPCRs) as a result of a physical interaction between p101 or p87 regulatory domains of 
PI3K and Gβγ subunit of trimeric G proteins (Engelman et al., 2006). Upon activation by 
one of these mechanisms, PI3Ks generate a second messenger, lipid phosphatidylinositol 
(3,4,5) triphosphate (PtdIns(3,4,5)P3), by phosphorylating phosphatidylinositol (4,5) 
bisphosphate (PtdIns(4,5)P2). PtdIns(3,4,5)P3, in turn, activates downstream components 
of RTK/PI3K signaling, including AKT (also known as PKB), PDK1, GRP1, BTK1, and 
TEC, by serving as a membrane recruitment site (Miao et al., 2010; Park et al., 2008). Of 
those, the protein serine/threonine kinase AKT is considered to be the major target of 
PtdIns(3,4,5)P3 and, by extension, of RTK/PI3K signaling (Sparks and Guertin, 2010). 
Tumor suppressor PTEN, on the contrary, is a phosphatase, which removes the 3’ 
phosphate from PtdIns(3,4,5)P3 and generates PtdIns(4,5)P2 to inactivate RTK/PI3K 
signaling pathway (see next section for details) (Song et al., 2012).  
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Aberrant PI3K signaling, leading to AKT hyperactivation, has been found frequently in a 
wide range of cancer cases including glioblastoma (see Table 1), making this oncogenic 
pathway as a major therapeutic target. Thus, many pharmaceutical companies are making 
an effort to design more effective pan-PI3K inhibitors, dual pan-PI3K/mTOR inhibitors, 
and isoform-specific PI3K inhibitors. Recent studies have emphasized the potential 
benefits of isoform-specific inhibitors of PI3Ks or inhibitors of downstream molecules, 
such as AKT, which may have better specificity and reduced toxicity compared to pan-
PI3K inhibitors (Lino and Merlo, 2011; Thorpe et al., 2015). 
 
1.6.2 Alterations in PTEN tumor suppressor gene and abnormal PI3K/AKT 
signaling  
 
PTEN is the major negative regulator of PI3K/AKT signaling, underlining the fact that 
41% of the human glioblastomas have mutation/deletion in PTEN, and 90% have loss of 
at least one copy of chr10q, which normally harbors PTEN gene (Brennan et al., 2013; 
Ozawa et al., 2014). Similar to TP53, PTEN is known as one of the most frequently 
mutated/altered tumor suppressor genes in human cancers today (Salmena et al., 2008). 
Identification of PTEN gene dates back to 1984, when loss of chr10 in malignant 
gliomas, concomitantly with amplification of chr7, was first reported (Bigner et al., 
1984). Subsequent studies identified a novel tumor suppressor gene, 
PTEN/MMAC1/TEP1, at the 10q23 locus (Li and Sun, 1997; Li et al., 1997; Steck et al., 
1997), which functions as a lipid phosphatase that opposes the PI3K/AKT signaling 
pathway by dephosphorylating and converting PtdIns(3,4,5)P3 to PtdInst(4,5)P2 
(Maehama and Dixon, 1998; Stambolic et al., 1998).  In addition to its lipid phosphatase 
activity, PTEN also functions as a protein phosphatase, which can dephosphorylate 
serine, threonine and tyrosine residues of protein substrates. PTEN protein has a 
phosphatase (catalytic) domain and a lipid membrane-binding C2 domain, both of which 
are required for its complete tumor suppressor functions. Protein modifications (e.g. 
phosphorylation) at additional two regions, PDZ-binding domain and C-terminal tail 
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(contains two PEST motifs) have been associated with protein stability and activity 
(Hollander et al., 2011; Salmena et al., 2008).   
 
Both germline and somatic alterations in PTEN gene can lead to a wide range of diseases 
including multiple cancer types in different organs. Autosomal dominant syndromes as a 
result of germline mutations can cause developmental disorders, neurological deficits, 
multiple hamartomas and increased susceptibility to develop breast, thyroid, and 
endometrial cancers. These disorders altogether are called “PTEN hamartoma tumor 
syndromes (PHTS)”, which includes Cowden syndrome, Bannayan-Riley-Ruvalcaba 
syndrome, Lhermitte-Duclos disease and Proteus and Proteus-like syndromes. While 
these syndromes have similar clinical representations, Cowden syndrome, particularly, is 
associated with the development of malignant tumors, including breast, endometrial and 
thyroid cancer (Salmena et al., 2008; Sulis and Parsons, 2003). Approximately 60-70% of 
PTEN mutations in Cowden syndrome are found in its phosphatase domain (in exons 5, 
7, 8), while mutations in C-terminal tail (in exon 9), promoter region (both leads to 
reduced expression) and splice donor/acceptor sites (leads to truncated protein) have also 
been detected (Song et al., 2012).  
 
Somatic alterations of PTEN include mutations, deletions, insertions, allelic or complete 
gene loss, promoter methylation (epigenetic silencing), miRNA silencing, alternative 
splicing and chromosomal (chr10q) loss. Mutations, insertions and deletions occur 
throughout the gene, however alterations in Arg130 (mostly in endometrial and ovarian 
cancers), Arg173 (mostly in CNS tumors) and Arg233 have been frequently observed and 
referred as hotspot mutations (Hollander et al., 2011; Song et al., 2012). Approximately 
90% of the human glioblastomas have chromosomal loss in at least one copy of chr10q, 
suggesting that at least 90% of the tumors will have monoallelic PTEN loss (Ozawa et al., 
2014). In addition, 41% the glioblastomas have homozygous deletions or mutation, 
resulting in biallelic PTEN loss (Brennan et al., 2013). Recent studies have also shown 
that overexpression of a non-coding miRNA, miR-26a, targets PTEN transcript and cause 
a reduction in PTEN expression in high-grade gliomas. It has been further demonstrated 
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that miR-26a overexpression is due to amplification in miR-26a-2 locus and that this 
event is strongly associated with monoallelic PTEN loss (Huse et al., 2009). Similarly, 
other studies have shown that PTEN expression is repressed by miR-21, leading to tumor 
proliferation and inhibition of apoptosis (Meng et al., 2007). Other mechanisms, 
including posttranslational modification, promoter methylation and protein delocalization 
might lead to loss of PTEN function (Salmena et al., 2008). These results, altogether, 
suggest that PTEN loss of heterozygosity (LOH) can be achieved functionally by various 
mechanisms other than direct genetic alterations; raising the possibility that biallelic 
inactivation of PTEN in glioblastoma might be more than previously estimated. 
Inactivation of PTEN by any of the mechanisms listed above leads to a balance change in 
the phospholipid molecules, resulting in accumulation of PtdIns(3,4,5)P3 on the cellular 
membrane. Excess levels of PtdIns(3,4,5)P3 promote recruitment of PH-domain 
containing proteins, including AKT and PDK1 (Phosphoinositide-dependent kinase), to 
the cell membrane. Once positioned in the membrane, AKT is activated (hyperactivated 
in this case) upon phosphorylation by PDK1 and mTORC2 (see next section for details) 
(Salmena et al., 2008; Sarbassov et al., 2005).  
 
1.6.3 AKT signaling and its oncogenic functions 
 
PI3K-generated PtdIns(3,4,5)P3 serves as a lipid second messenger that activates many 
downstream molecules by binding to their pleckstrin-homology (PH) domain. As 
discussed earlier, AKT is considered to be the major downstream effector of the 
RTK/PI3K signaling pathway. A physical interaction between AKT and PtdIns(3,4,5)P3 
allows AKT to be recruited to the membrane, where it is subsequently phosphorylated by 
PDK1 at Threonine-308 (Thr308) in the kinase activation loop (T-loop), and by mTORC2 
at Serine-473 (Ser473) in the hydrophobic motif of the carboxyl-terminal tail, respectively 
(see next section for details) (Alessi et al., 1997; Engelman et al., 2006; Guertin et al., 
2006; Ikenoue et al., 2008; Sarbassov et al., 2005; Testa and Bellacosa, 2001). These two 
phosphorylation events are required for full activation of AKT, which in turn 
phosphorylates multiple downstream proteins that function in various cellular functions, 
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including survival, proliferation, cell size/growth, metabolism, and angiogenesis (Table 
3) (Manning and Cantley, 2007). Phosphorylation by AKT changes the activity and/or 
localization of these proteins. Most of the AKT substrates are inhibited upon 
phosphorylation (e.g. FOXO family, BAD, CASP9, AS160, TSC2, PRAS40, p27, GSK-
3β), while a few of them are activated (e.g. eNOS and MDM2) (Table 3) (Engelman et 
al., 2006; Manning and Cantley, 2007; Testa and Bellacosa, 2001). Once activated, AKT 
signaling can be terminated upon dephosphorylation of Ser473 on AKT by a protein 
phosphatase PHLIPP (Gao et al., 2005).  
 
Table 3. Downstream targets of AKT signaling and implications for cancer when 
deregulated.  
Substrate Normal function Regulation by AKT signaling 
Implications for 
cancer 
FOXO family 
(FOXO1, 
FOXO3A, 
FOXO4) 
Apoptosis, cell-cycle arrest, 
induction of pro-apoptotic 
genes such as FasL and Bim) 
Inhibition Cell survival 
BAD Pro-apoptotic Inhibition Cell survival 
CASP9 Pro-apoptotic Inhibition Cell survival 
MDM2 TP53 degradation Activation Cell survival 
p27 (encoded by 
CDKN1B) and 
p21 (encoded by 
CDKN1A) 
Cell-cycle inhibitors Inhibition Cell proliferation 
GSK-3α/β 
Cell-cycle regulation by 
inhibiting cyclin D, cyclin E, 
Myc and c-Jun functions 
Inhibition Cell proliferation 
GSK-3 α/β Negative regulator of glycogen synthesis Inhibition 
Cell metabolism 
(glycogen synthesis) 
TSC2 Negative regulator of mTORC1 signaling Inhibition 
Cell metabolism 
(protein synthesis) 
PRAS40 
(encoded by 
AKT1S1) 
Negative regulator of 
mTORC1 signaling Inhibition 
Cell metabolism 
(protein synthesis) 
AS160 Inhibition of GLUT4 activity and glucose uptake Inhibition 
Cell metabolism 
(glucose uptake) 
eNOS Vasodilation, vascular remodeling and angiogenesis Activation Angiogenesis 
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Several studies have revealed that hyperactivation of AKT signaling as a result of 
sporadic molecular alterations, alone or in cooperation with other abnormalities, can 
cause to human malignancies in numerous organ systems (Bellacosa et al., 2005). More 
specifically, deletion/mutation/downregulation of PTEN and NF1, 
amplification/mutation/upregulation of EGFR, PDGFRA, PDGF and PIK3C genes, 
mutations in PIK3R genes, autocrine or paracrine stimulation of RTKs and aberrant 
activation of Ras are the most common sporadic events that lead to hyperactivation of 
AKT signaling, especially in glioblastomas (see Table 1).  In addition, dominantly 
inherited cancer syndromes associated with germline mutations in PTEN, LKB1, 
TSC2/TSC1, NF1 and VHL lead to aberrant AKT activation, suggesting that several 
tumor suppressor genes are negative regulators of AKT signaling (Altomare and Testa, 
2005).  
 
1.6.4 RICTOR/mTOR complex is a major positive regulator of AKT signaling 
 
mTOR (originally “mammalian target of rapamycin”, now “mechanistic target of 
rapamycin”) is a serine/threonine protein kinase, which interacts with several other 
proteins to form two important complexes called “mTOR complex 1 (mTORC1)” and 
“mTOR complex 2 (mTORC2)” (Table 4). While mTORC1 is regulated by various 
signals, including nutrients (e.g. amino acids), growth factors, oxygen, cellular energy 
and stress pathways, mTORC2 is mainly regulated by growth factors (Laplante and 
Sabatini, 2012; Sparks and Guertin, 2010). Downstream cellular processes of mTORC1 
signaling include protein and lipid synthesis, cellular metabolism, ATP production, 
cellular growth, and inhibition of autophagy and lysosome biogenesis. Main functions of 
mTORC2, on the other hand, are regulating cell survival, cell proliferation and 
cytoskeletal organization (Table 4) (Foster and Fingar, 2010; Laplante and Sabatini, 
2012).  
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mTORC2 regulates several members of AGC kinase family, including AKT, SGK1 
(serum- and glucocorticoid-induced protein kinase 1), and PKC-α (protein kinase C-α) 
by phosphorylating their hydrophobic motif at Ser473 of AKT, Ser422 of SGK1, and Ser657 
of PKC-α (Foster and Fingar, 2010). It should be noted that these protein kinases are 
further phosphorylated by PDK1 in their activation loop at Thr308 of AKT, Thr256 of 
SGK1, and Thr500 of PKC-α (Newton, 2003; Sparks and Guertin, 2010). Upon activation, 
AKT involves in various cellular processes including proliferation, cell survival, 
metabolism, angiogenesis and growth (Table 3, also see the previous section).  
 
Table 4. Common and unique protein components of mTORC1 and mTORC2, and 
their functions within the complexes. 
Protein component Function Complex 
mTOR Serine/threonine kinase. mTORC1     mTORC2 
DEPTOR (DEP domain containing 
mTOR-interacting protein) mTOR inhibitor. 
mTORC1     
mTORC2 
mLST8 (mammalian lethal with sec-
13 protein 8, aka GβL) 
Unknown function, may not be 
essential for mTORC1, essential for 
mTORC2. 
mTORC1     
mTORC2 
Tti1/Tel2 complex Scaffold complex for the assembly and stability of mTORC1. 
mTORC1     
mTORC2 
RPTOR (regulatory-associated 
protein of mammalian target of 
rapamycin) 
Scaffold protein regulating the 
assembly, localization, and the 
substrate binding. 
mTORC1 
PRAS40 (proline-rich AKT 
substrate) mTORC1 inhibitor mTORC1 
RICTOR (Rapamycin-insensitive 
companion of mTOR) 
Scaffold protein regulating the 
assembly and the substrate binding. mTORC2 
mSIN1 (mammalian stress-activated 
map kinase-interacting protein 1) 
Scaffold protein for mTORC2 
assembly and its interaction with 
SGK1. Contains PH-domain at its C-
terminus. 
mTORC2 
PROTOR1/2 (Protein observed with 
with Rictor 1 and 2) 
Increases mTORC2-mediated 
activation of SGK1 mTORC2 
 
SGK1, on the other hand, regulates ion transport (e.g. Sodium), growth, motility and 
apoptosis. SGK1 has approximately 80% similarity to AKT in its kinase domain, and it 
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also shares similar substrate specificity requirements with AKT, suggesting that SGK1 
involves in cellular processes in a comparable  fashion to AKT. Furthermore, since the 
same upstream signals regulate SGK1 and AKT, alterations that trigger AKT signaling 
would, therefore, activate SGK1 concomitantly (Gao et al., 2010; Moniz and 
Vanhaesebroeck, 2013). Even though AKT is considered to be the major mediator of the 
RTK/PI3K signaling pathway, recent studies uncovered critical roles of SGK1 and its 
downstream substrate NDRG1 (N-Myc downstream regulated gene 1) in tumor resistance 
to AKT inhibitors and alkylating chemotherapy. Particular interest is the finding that 
SGK1-activated NDRG1 binds to and stabilizes methyltransferase MGMT, which 
consequently renders glioblastoma cells resistant to alkylating agent Temozolomide. 
Consistently, silencing methylation of MGMT promoter was no longer associated with 
better prognosis in patients who concurrently received corticosteroids, which are known 
to activate SGK1 signaling, compared to the patients without steroid administration 
(Moniz and Vanhaesebroeck, 2013; Sommer et al., 2013; Weiler et al., 2014). Lastly, 
PKC-α is a calcium- and phospholipid-dependent kinase, and upon activation by 
mTORC2 and PDK1, PKC-α is involved in actin cytoskeleton to determine the cellular 
shape and structure. In addition to AGC kinases, mTORC2 phosphorylates Rho GTPases 
and Paxillin in regulation of actin cytoskeleton dynamics (Laplante and Sabatini, 2012).  
 
RICTOR is a critical and defining subunit of mTORC2, as all known mTORC2 functions 
require intact RICTOR protein. Furthermore, its interaction with SIN1 is thought to be 
required for mTORC2 stability and function. Accordingly, Rictor-deficient mice die in 
early embryogenesis, emphasizing the crucial roles of Rictor/mTORC2 during the 
development (Guertin et al., 2006; Huang et al., 2013; Sarbassov et al., 2005; Sparks and 
Guertin, 2010). It has been shown that functional loss of Rictor is sufficient to block Akt 
activation and tumor growth in various cancer models. In the first study, it has been 
shown that mouse prostate epithelial cells transform into prostate cancer in the absence of 
Pten gene, and concurrent Rictor-loss can prevent this tumorigenesis mainly by blocking 
Akt signaling (Guertin et al., 2009). Interestingly, Rictor-loss alone does not affect the 
structural maintenance of normal prostate epithelium, suggesting that tumor cells 
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characterized by elevated Akt signaling are dependent on this molecule for survival, and 
are thus vulnerable to Akt inhibition (Bellacosa et al., 2005; Koul et al., 2006). In a 
similar study, Rictor deletion blocked the Pten-deficiency induced leukemogenesis and 
hematopoietic stem cell depletion in adult mice, underlining the important roles of 
Rictor/mTORC2, and by extension Akt signaling, in stem cell self-renewal and 
tumorigenesis. Rictor-loss alone had minimal effect on the function of normal 
hematopoietic stem cells (Magee et al., 2012). There oncogenic activity of 
Rictor/mTORC2 signaling has been confirmed in an opposite manner to the previous two 
studies. Accordingly, it has been shown that glial cell specific overexpression of Rictor, 
with or without oncogenic EGFRvIII expression, causes oligodendrioglioma-like or 
mixed astrocytic-oligodendrial tumors in the mouse brain (Bashir et al., 2012).  
 
In addition to model organisms, the important roles of Rictor/mTORC2 signaling in 
tumorigenesis are further demonstrated using human tumor samples. For instance, it has 
been uncovered that protein and mRNA levels of RICTOR, as well as the protein levels 
of pAKTSer473 are elevated in human glioblastoma samples. It has been concluded that 
increased RICTOR expression promotes mTORC2 assembly, tumor cell proliferation, 
migration and invasiveness (Masri et al., 2007). Accordingly, RNAi mediated inhibition 
of RICTOR has reversed mTORC2 activity, and consequently impaired cell growth and 
migration ability of the tumor cells, including glioblastoma cell lines (Hietakangas and 
Cohen, 2008; Masri et al., 2007). Furthermore, knockdown of RICTOR in xenograft 
model of human glioblastoma cells has reduced the tumor cell proliferation, but more 
importantly, reversed the chemotherapy resistance to DNA-crosslinking agent cisplatin. 
This finding suggests that mTORC2 inhibition sensitizes the tumor cells to 
chemotherapy-induced DNA-damage, resulting in tumor shrinkage (Tanaka et al., 2011). 
The molecular mechanisms for this phenomenon might be explained by studies from 
yeast models, which have suggested that mTORC2 (tor1 in yeast) has roles in 
maintaining the stability of the genome and telomere length in DNA-damaging 
conditions. As such, inhibition of mTORC2 signaling by targeted mutagenesis renders 
the cells extremely sensitive to DNA-damaging reagents (Schonbrun et al., 2009; 
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Shimada et al., 2013). It is worth noting that mTORC2 signaling might have other 
oncogenic roles independent of its functions in PI3K/AKT signaling pathway. For 
instance, it has been demonstrated that RICTOR/mTORC2 signaling can inhibit FoxO 
activity via acetylation, and upregulate c-Myc expression, which in turn positively affects 
proliferation and glycolytic metabolism in glioblastoma cells (Masui et al., 2013). These 
emerging evidences for the critical roles of RICTOR/mTORC2 in human cancer offer a 
potential therapeutic strategy that aims to inhibit/reduce the activity of 
RICTOR/mTORC2. However, there is not any pharmacological means of targeting 
mTORC2 complex specifically, as it shares many protein components with mTORC1, 
including the catalytic domain mTOR (Laplante and Sabatini, 2012).   
 
Other than its roles pertaining to tumor formation and progression, RICTOR/mTORC2 is 
involved in several neurodevelopmental processes. Multiple studies have shown that 
alterations in mTORC2 activity can lead to several cognitive disorders including 
Huntington’s disease, Parkinsonism, Alzheimer-type dementia and autism spectrum 
disorders. It is thought that deregulation of actin polymerization in neurons, as a 
consequence of altered mTORC2 and/or AKT signaling, might be one of the major 
mechanisms behind these disorders. A recent study has also demonstrated that, genetic 
inactivation of mouse Rictor gene in postnatal forebrain prevents actin polymerization 
and actin regulatory signaling, which in turn leads to a block in conversion of a short-
term synaptic process into a long-term memory (Huang et al., 2013). In a second study, 
deletion of Rictor in dorsal neural progenitors leads to decreased size of neurons and a 
thinner corpus callosum linked to a decrease in the expression of myelin-associated 
proteins. Subsequent behavioral studies revealed that Rictor-mutant mice displayed 
reduced anxiety-like behaviors, though they were hyperactive, suggestive of attention-
deficit hyperactivity disorders (Carson et al., 2013). It has also been revealed that deletion 
of Rictor in cerebellar Purkinje cells leads to a reduction in cell size, a change in cell 
morphology, and abnormal synaptic connectivity, which may altogether lead to cerebellar 
motor deficits and ataxia (Thomanetz et al., 2013). Lastly, Rictor deletion in other organ 
systems have caused a wide range of abnormalities, including defective development in 
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T-lymphocytes, defective glucose transport in skeletal muscle, mild hyperglycemia and 
glucose intolerance in pancreas β-cells, and increased body size, insulin-resistance, and 
hyperinsulinemia in adipose tissue (reviewed in (Oh and Jacinto, 2011)). 
 
1.7 Cell of origin and mouse models for glioblastoma 
 
Identifying the cell of origin for glioblastoma is as imperative as understanding the 
molecular mechanisms promoting the tumor formation and progression. Therefore, 
mouse models provide a unique platform to delineate the complexity of glioblastoma 
formation and progression.  Currently, four cells types have been reported to have 
potential to initiate malignant gliomas, and thus they are thought to be the cell of origin 
for glioblastoma. These cells are neural stem/progenitor cells (NSCs), oligodendrocyte 
precursor cells (OPCs), mature astrocytes and neurons (Friedmann-Morvinski et al., 
2012; Zong et al., 2015).  
 
Due to their self-renewal ability and multi-lineage developmental potential, NSCs have 
been one of the most susceptible cell types that can give rise to malignant gliomas. 
Accordingly, viral infection of constitutively active Ras and Akt genes to nestin-
expressing (encoded by Nes) NSCs in a tissue specific manner has resulted in high-grade 
gliomas with histological features of human glioblastoma (Holland et al., 2000). 
Furthermore, various combinations of mutations in p53, Pten and Nf1 tumor suppressor 
genes in genetically engineered mouse models allow embryonic NSCs to develop 
malignant astrocytomas with high penetrance (Chen et al., 2012a; Kwon et al., 2008; 
Wang et al., 2009; Zheng et al., 2008; Zhu et al., 2005). Additional investigations 
revealed that, adult NSCs also have the potential to form malignant-gliomas in the 
presence of inactivating p53, Nf1, Pten and Rb mutation combinations or activating K-ras 
mutations (Alcantara Llaguno et al., 2009; Jacques et al., 2010; Munoz et al., 2013).   
 
As OPCs are the major proliferating cell population in the adult brain and their number is 
significantly higher than NGCs, it has been a particular interest to test their capacity to 
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form malignant gliomas (Zong et al., 2015). A unique system called “mosaic analysis 
with double markers (MADM)” provides the most definitive evidence demonstrating the 
tumorigenic potential of OPCs (Liu et al., 2011). In this system, the mutant or wild-type 
allele of a gene is tagged with sequences encoding different fluorescent molecules. As the 
cells divide, the sibling cells are labeled with different colors based on their allele 
content. For instance, the mutant sibling is green while the wild type is red. This system, 
consequently, enables investigators to determine whether a gene mutation provides a 
growth advantage to a cell type towards tumorigenesis. Detailed analyses have implicated 
that green OPCs (p53-/-;Nf1-/-) outgrow their red wild type siblings by more than 100-fold. 
However, such difference between siblings of mutant and wild type NSCs, astrocytes and 
neurons has not been detected. Consistently, introducing p53 and Nf1 mutations directly 
into OPCs results in highly penetrant gliomagenesis (Liu et al., 2011). Other evidences 
include the prominent expression of OPC-specific markers (e.g. Olig2, NG2, O4) in 
human glioma samples, and the similarity between the molecular profile of OPCs and the 
proneural subtype of human glioblastoma samples (Zong et al., 2015).  
 
Mature astrocytes have long been thought to be the only replicative cells in the adult 
brain, thus they were also believed to be the cell of origin for glioblastoma. After the 
discovery of neural progenitor cells, several studies tried to determine whether mature 
astrocytes could actually give rise to tumors (Stiles and Rowitch, 2008). Interestingly, 
tamoxifen induced deletion of p53 and Pten genes with or without Rb deletion in mature 
GFAP-CreER mice has allowed mature astrocytes to develop high-grade gliomas that 
shares molecular signatures with human counterparts (Chow et al., 2011). Even though 
GFAP promoter is active in NSCs as well, tumor formation in non-germinal zones, 
including brain stem, cortex, cerebellum and spinal cord, raises the possibility that mature 
astrocytes in these regions are the cell of origin for the observed gliomas. (Chow et al., 
2011) Lastly, a recent study has also demonstrated that both mature neurons in the cortex 
and mature astrocytes can be transformed into glioma cells by specific genetic 
modifications, such as concomitant knockdown of Nf1 and p53 tumor suppressor genes in 
respective cell compartments (Friedmann-Morvinski et al., 2012). These results 
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altogether suggest that many cell types in the brain can be targets of particular genetic 
alterations leading to malignant glioma formation, consistent with the fact that 
glioblastoma is a very complex and heterogeneous disease. Even though these studies 
provide valuable information that elucidates the tumorigenic potential of each cell 
compartment, they still lack a definitive evidence of cell of origin for human 
glioblastomas.  
 
1.8 Medulloblastoma and its pathogenesis 
 
In contrast to glioblastoma, which mainly occurs in adulthood, medulloblastoma is 
largely a childhood malignancy as it predominantly occurs in infants (≤ 3 years old) and 
children (4-17 years old). Medulloblastoma is an embryonic neuroepithelial tumor of the 
cerebellum and it is the most common pediatric brain malignancy, as it accounts for 
approximately 20-25% of all childhood brain tumors. Patients with the presence of 
metastasis (or leptomeningeal dissemination) at diagnosis or of residual disease after the 
surgical operation are classified as “high-risk groups”, while the others are as “average-
risk groups”. Current treatment protocols include surgical removal of the tumor mass, 
craniospinal irradiation, and chemotherapy (Gajjar and Robinson, 2014; Northcott et al., 
2012a). Accordingly, patients younger than 3-5 years old are treated in the absence of 
radiation protocols, while older patients with metastatic disease or imperfect surgical 
resection receive high doses of craniospinal radiation and aggressive chemotherapy. 
Patients with non-disseminating tumors and with near-complete removal of the tumor 
mass receive a combination of low dose irradiation and chemotherapy (Tabori et al., 
2010). Stratification of the patients based on this system improved therapeutic strategies, 
as reducing the treatment exposure in average-risk patients results in decreased toxicity. 
Furthermore, this approach has increased the cure rates for high-risk patients (Gajjar and 
Robinson, 2014). Despite the increased overall survival rates reaching up to 70-80%, a 
significant portion of the treated patients still suffers from long-term adverse sequelae, 
including neurological, neuroendocrine and psychosocial deficits, as well as various 
problems in fertility, cardiopulmonary fitness, hearing, and physical performance. Post-
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treatment cognitive problems, in particular, are common in younger patients. For 
instance, a child’s IQ can drop as much as 30 points after a 36 Gy of craniospinal 
irradiation, or 10-15 points reduction by a lower dose of 24 Gy. Furthermore, tumor 
heterogeneity of medulloblastoma represents a major obstacle to current treatment 
strategies - a phenomenon frequently seen in glioblastoma (Ellison, 2010; Gajjar and 
Robinson, 2014; Northcott et al., 2012a).  
 
Histopathologic analysis based on 2007 WHO classification of CNS tumors categorizes 
medulloblastomas into classic histology and four additional variants: Desmoplastic 
nodular (D/N), medulloblastoma with extensive nodularity (MBEN), anaplastic 
medulloblastoma, and large cell medulloblastoma. Due to their shared features, D/N and 
MBEN are often grouped together as desmoplastic, and also anaplastic and large cell 
medulloblastomas are classified together as large cell/anaplastic (LC/A) medulloblastoma 
(Gajjar and Robinson, 2014; Louis et al., 2007). Classic medulloblastomas consist of 
small rounded cells with a high nuclear-to-cytoplasmic content ratio. D/N and MBEN 
medulloblastomas contain nodular and internodular regions, some of which are filled 
with chains of cells in MBEN tumors. LC/A medulloblastomas have extensive nuclear 
pleomorphism, cell wrapping, apoptotic cells, prominent mitotic figures, large tumor 
nuclei and easily noticeable nucleoli (Ellison, 2010). Majority of the medulloblastomas 
(70%) have classic histology, while 16% are desmoplastic and 10% are LC/A. In general, 
desmoplastic tumors have better prognosis (especially in infants), followed by classic 
tumors. LC/A tumors, however, behave the most aggressively with the presence of 
metastasis and consequently they predict a poor outcome. However, histological 
categorization along with the molecular profiles (see next section 1.10) may exhibit a 
more complex situation (Kool et al., 2012).  
 
Recent studies and clinical findings have suggested that a more comprehensive 
understanding of medulloblastoma based on its molecular and genetic nature is urgently 
needed to treat patients in a more systematic and effective way than the current protocols, 
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which are mainly based on general clinical representation of the disease and sometimes 
histologic features of the tumors (Gajjar and Robinson, 2014). 
 
1.9 Familial syndromes reveal the molecular basis of medulloblastoma 
 
The genetic makeup that triggers the formation of medulloblastomas has been initially 
uncovered by the studies pertaining to familial syndromes. In the 1990s, human homolog 
of drosophila patched (PTCH1 in humans) gene was discovered in Gorlin’s syndrome 
(aka the nevoid basal cell carcinoma syndrome - NBCCS), which is an autosomal 
dominant disorder characterized by predisposition to developmental defects and various 
cancers, including medulloblastoma (Hahn et al., 1996). Concordantly, the frequency of 
medulloblastoma increases approximately from 2/million to 4/hundred in Gorlin’s 
syndrome patients (< 18 years old) (Wetmore et al., 2001). Subsequent studies revealed 
that many sporadic medulloblastomas indeed carry somatic PTCH1 mutations (Kool et 
al., 2012). PTCH1 product is a tumor suppressor protein that negatively regulates Sonic 
Hedgehog (SHH) signaling pathway by inhibiting the release of another transmembrane 
protein Smoothened (encoded by SMO), which otherwise activates downstream signaling 
cascade. Thus, inactivating mutations or loss of PTCH1 gene leads to aberrantly activated 
SHH signaling, which in turn promotes proliferation and inhibits terminal differentiation 
of the granule neuron precursor cells of the cerebellum (Taipale and Beachy, 2001). The 
therapeutic potentials of SMO-inhibitors, therefore, have been extensively studied in 
order to overcome the oncogenic SHH signaling in medulloblastoma and other SHH-
associated malignancies (Amakye et al., 2013). The second heritable form of 
medulloblastoma occurs in Turcot’s syndrome patients, who have germline inactivating 
mutations in adenomatous polyposis coli (APC) gene. APC is a tumor suppressor gene 
and its protein product functions in WNT signaling pathway as a negative regulator of the 
oncogene CTNNB1 (encodes CTNNB1 or β-Catenin), which normally regulates cell-to-
cell adhesion and also functions as a transcription factor (Fearon, 2011; Northcott et al., 
2012a). APC controls β-catenin levels by regulating its degradation, thus inactivating 
APC mutations leads to stabilized β-catenin proteins in the cell nucleus, and subsequent 
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hyperactivation of WNT signaling pathway. Consistently, approximately 95% of the 
medulloblastomas with aberrant WNT signaling have activating somatic mutations in 
CTNNB1 gene, which encodes for mutant β-catenin proteins that are resistant to 
phosphorylation-induced degradation. (Gajjar and Robinson, 2014; Hajra and Fearon, 
2002; Northcott et al., 2012a). Aberrant SHH and WNT signaling pathways are observed 
in approximately 25-30% and 10% of all medulloblastoma patients, respectively. It 
should be noted that SHH signaling is also altered in about 50% of the basal cell 
carcinoma patients, and aberrant WNT signaling is found in roughly 90% of colorectal 
cancer patients (Fearon, 2011; Taipale and Beachy, 2001). Lastly, Li-Fraumeni patients 
with germline TP53 mutations are predisposed to several malignancies, including soft 
tissue sarcomas, osteosarcoma and chondrosarcoma, breast cancer, adrenocortical 
carcinoma, leukemia, and brain tumors - glioblastoma and medulloblastoma (Birch et al., 
2001). Including the somatic mutations, approximately 10% of the medulloblastomas 
have TP53 mutations, while 40% of samples display p53 protein expression, indicating 
the presence of dysfunctional/malfunctioning p53 protein (Tabori et al., 2010; Zhukova et 
al., 2013). Furthermore, loss of chromosome 17p, which harbors TP53 gene, is observed 
in 30-50% of the medulloblastomas. This phenomenon is mostly linked to gain of 17q, 
which consequently causes “isochromosome 17q” (Huse and Holland, 2010). 
Interestingly, concurrent TP53 mutation and SHH activation in medulloblastomas has 
been reported as an adverse prognostic factor associated with poor survival (further 
discussed in next section) (Tabori et al., 2010; Zhukova et al., 2013).  
 
1.10 Molecular classification enhances our understanding of medulloblastoma 
 
Similar to glioblastomas, molecular stratification of medulloblastomas is critical in the 
comprehension of the disease and implementation of targeted therapies based on the 
genetic makeup that defines individual cases (Northcott et al., 2012a; Taylor et al., 2012). 
The current consensus of molecular classification predicts four subgroups with specific 
mutations and genetic alterations, each of which are associated with different survival 
rates (Jones et al., 2012; Kool et al., 2008; Northcott et al., 2011; Northcott et al., 2012b; 
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Pugh et al., 2012; Robinson et al., 2012; Thompson et al., 2006). Wnt-group tumors 
(10%) have the best outcome with 5-year overall survival (OS) of 95% followed by Shh-
group (30%) and Group-4 (35%) tumors with approximately 75% OS. The worst 
outcome was seen in Group-3 or Myc (25%) patients with approximately 50% OS (Table 
5) (Gajjar and Robinson, 2014; Kool et al., 2012; Northcott et al., 2012a). 
 
WNT medulloblastoma has the best prognosis among the four subgroups, as the long-
term survival rates for these patients reach 95% with the current treatment protocols 
(Table 5). However, it is the least common subtype of the medulloblastoma with the 
frequency of only about 10% of all cases. Virtually all of the WNT medulloblastomas 
have classic histology, while very rare cases of LC/A histology is also observed (Kool et 
al., 2012). WNT signaling pathway as a result of nuclear accumulation of β-catenin 
proteins characterizes WNT medulloblastomas, and consistently, over 90% of these 
tumors have CTNNB1 mutation, which renders β-catenin protein resistant to degradation 
by APC-Axin-GSK3β-CK1α destruction complex. WNT tumors are considered to have 
relatively balanced genome, except for the monosomy 6 (presence of only one chr6 copy) 
observed in almost all of the WNT medulloblastomas, and TP53 mutations detected in 
approximately 13% of the patients (Jones et al., 2012; Northcott et al., 2012a). Even 
though concurrent SHH signaling and TP53 mutations are associated with worse 
prognosis compared to TP53 wild type cases, TP53 status seems not to have a prognostic 
factor for WNT medulloblastomas (Zhukova et al., 2013).  
 
SHH medulloblastoma represent roughly 30% of all medulloblastoma cases, and the 5-
year overall survival rate for patients with SHH tumors is approximately 75% (Table 5). 
Classic tumor histology is prominent in this subgroup, followed by desmoplastic and 
LC/A tumors. It is worth noting that desmoplastic histology is almost exclusively 
observed in SHH medulloblastomas (Kool et al., 2012). Characteristic SHH signaling 
pathway can appear as a result of various genomic and epigenetic alterations in this 
pathway, including germline and somatic inactivating mutations in PTCH1 and SUFU 
genes, somatic activating mutations in SMO, and copy number amplifications in N-MYC, 
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GLI1, GLI2 and SHH genes. Furthermore, TP53 mutations (14-21%) and broad 
chromosomal losses of 17p (harbors TP53 gene) are detected in SHH medulloblastomas. 
Other chromosomal aberrations include loss of 9q (harbors PTCH1), loss of 10q (harbors 
PTEN), and gain of chromosomes 3q and 9p (Kool et al., 2012; Northcott et al., 2011).   
 
As discussed earlier, SHH medulloblastomas with TP53 mutations (SHH/TP53mut) are 
associated with early recurrence and extremely poor outcome with a 5-year survival rate 
of 41% compared to 81% in SHH/TP53wt patients. Especially in children between the 
ages of 5-18, TP53 mutation accounts for 72% of the deaths (Tabori et al., 2010; 
Zhukova et al., 2013). Remarkably, TP53 mutations seem to be a critical alteration 
exclusive to childhood (4-17 years old) SHH tumors, as almost 50% of the childhood 
SHH medulloblastomas had TP53 alterations, while similar events were virtually absent 
in the remaining SHH cases, as well as Group-3 and Group-4 medulloblastomas (Kool et 
al., 2014; Zhukova et al., 2013). These findings altogether suggest that the presence of 
TP53 mutation is one of the most decisive adverse prognostic factors in medulloblastoma 
(Tabori et al., 2010; Zhukova et al., 2013). Interestingly, SHH/TP53mut medulloblastomas 
were found to undergo “chromothripsis” (concurrent severe fragmentation of divergent 
chromosomal regions and a subsequent reassembly in an imperfect or random manner), 
resulting in catastrophic DNA rearrangements and also “tetraploidy” (having a 
chromosome number four times the monoploid number). Even though approximately 13-
16% of the WNT medulloblastomas also carry TP53 mutations, none of them have been 
found to undergo chromothripsis, which underlines the context dependent consequences 
of TP53 loss. Importantly, medulloblastoma oncogenes, N-MYC, GLI2, and BOC are 
amplified in SHH/TP53mut medulloblastomas as a result of chromothripsis (Jones and 
Jallepalli, 2012; Rausch et al., 2012). Since both N-MYC and GLI2 products are 
downstream components of the SHH signaling pathway, amplifications in these genes are 
thought to render the tumors inherently resistant to SMO-inhibitors. Consistently, SHH 
medulloblastomas with N-MYC and GLI2 amplification have worse prognosis compared 
to their wild type counterparts, and even the presence of high dose craniospinal radiation 
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and adjuvant chemotherapy is mostly ineffective (Gajjar and Robinson, 2014; Kool et al., 
2014; Northcott et al., 2012a; Northcott et al., 2012b; Pfister et al., 2009).  
 
Approximately 25% of the medulloblastomas belong to Group-3, which has the worst 
clinical outcome of the four subgroups with a 50% 5-year overall survival rate (Table 5). 
These tumors are characterized by classic and LC/A histology, metastasis with 40-45% 
frequency, and occurrence in pediatric patients exclusively, all of which might underline 
the aggressive nature of the disease (Gajjar and Robinson, 2014; Kool et al., 2012). 
Group-3 medulloblastomas are also called “MYC medulloblastomas” due to the fact that 
almost all of them have aberrant MYC expression and approximately 17% of them 
acquire high-level amplifications in MYC oncogene. Recent studies have also uncovered 
the presence of PVT1-MYC fusion genes, which is thought to promote tumorigenesis in a 
combinatory manner (Northcott et al., 2012b). In addition, alterations in chromatin 
remodeling and histone modification genes, including SMARCA4 (11%), KMT2D (4%), 
MLL2 (4%), and KDM6A are noticeable in Group-3 medulloblastomas (Pugh et al., 2012; 
Robinson et al., 2012). Group-3 tumors, particularly, exhibit severe genomic alterations 
that include loss of chromosomes 8, 10q, 11, 16q, and 17p, and gain of chromosomes 1q, 
7, and 17q (isochromosome 17q), and 18.  
 
Group-4 tumors are the most common subgroup of all medulloblastomas (35%) (Table 
5). Interestingly, these tumors are three times as likely to manifest in males compared to 
females. Classic histology is predominantly observed in Group-4 medulloblastomas, 
while rare cases of LC/A tumors are also reported. Similar to SHH medulloblastomas, 
Group-4 tumors have approximately 75% survival rate in general, though the adult 
patients have significantly worse clinical outcome (Kool et al., 2012; Taylor et al., 2012). 
The biologic disposition underlying the disease formation and/or progression is less 
understood compared to other three subgroups, and there is not a signaling pathway 
associated with Group-4 tumors either. However, amplifications in N-MYC (6%) and 
CDK6 (5%) genes are thought to be among the driver events, and isochromosome 17q is 
detected in majority of the Group-4 medulloblastomas, making this genomic alteration as 
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a hallmark event (Kool et al., 2012; Northcott et al., 2012a; Northcott et al., 2011). 
Similar to Group-3 tumors, somatic alterations in many chromatin modifier genes, 
including KDM6A (13%), MLL3 (5%), KMT2C (5%), CDK6 (5%), ZMYM3 (4%), and 
CHD7 (2%) are typical to Group-4 medulloblastomas (Pugh et al., 2012; Robinson et al., 
2012). Lastly, Group-4 medulloblastomas are also distinguished with their extensive 
genomic alterations, including losses of chromosomes 8, 10, 11, and 17p, and gains of 
chromosomes 4, 7, 17q (isochromosome 17q), and 18 (Kool et al., 2012). 
 
Even though both Group-3 and Group-4 medulloblastomas undergo extensive 
chromosomal alterations and oncogenic chromatin remodeling, recurrent somatic gene 
mutations are mostly rare (Table 5). In general, only aberrant MYC and N-MYC 
signaling is associated with Group-3 and Group-4 medulloblastomas, respectively. Thus, 
identifying the oncogenic driver mutations or signaling pathways, particularly for these 
two subgroups, remain essentially unrevealed (Northcott et al., 2012a). Interestingly, 
recent studies have revealed that activation of an oncogene can be achieved by unusual 
mechanisms in addition to sole gene mutations or amplifications. According to these 
studies, the expression of growth factor independent 1 family proto-oncogenes, GFI1 and 
GFI1B, are hyperactivated upon genomic redistribution of the active enhancers in Group-
3 (25-41%) and Group-4 (5-10%) medulloblastomas. More specifically, “enhancer 
hijacking” occurs when GFI1 and GFI1B loci are genetically redistributed from the 
regions in transcriptionally silent chromatin to regions that are occupied with active 
enhancers by various mechanisms, including deletion, inversion, tandem duplication 
(local enhancer hijacking), and translocation and intrachromosomal structural variation 
(distal enhancer hijacking) (Northcott et al., 2014). These findings implicate the potential 
oncogenic drivers in relatively less understood medulloblastoma subgroups, and pave the 
way for the pursuit of targeted therapy. 
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Table 5. Molecular and clinical properties of medulloblastoma subgroups.  
 WNT SHH Group-3 Group-4 
Overall frequency ~10% ~30% ~25% ~35% 
Age 
distribution 
Infant: 
Child: 
Adult: 
−  
++ 
+ 
+++ 
+ 
+++ 
+++ 
++ 
−  
+ 
+++ 
++ 
Gender 
distribution 
Male: 
Female: 
1 
1 
1.5 
1 
2 
1 
3 
1 
Predominant histology Classic 
Classic > 
desmoplastic > 
LC/A 
Classic > 
LC/A Classic 
Frequency of metastasis ~ 5-10% ~ 15-20% ~ 40-45% ~ 35-40% 
5-year OS rate ~ 95% ~ 75% ~ 50% ~ 75% 
Signaling pathway-specific 
alterations 
CTNNB1 
(91%) 
PTCH1 (28%) 
N-MYC (8%) 
GLI2 (5%) 
MYC (17%) N-MYC (6%) 
Recurrently 
mutated 
chromatin 
modifiers 
SMARCA4: 
MLL2: 
KMT2D: 
BCOR: 
LDB1: 
KDM6A: 
MLL3: 
CDK6: 
ZMYM3: 
KMT2C: 
26% 
13% 
12% 
- 
- 
- 
- 
- 
- 
- 
- 
13% 
13% 
8% 
7% 
- 
- 
- 
- 
- 
11% 
4% 
4% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
13% 
5% 
5% 
4% 
5% 
Other recurrent  
alterations 
DDX3X 
(50%) 
DDX3X (12%) 
TCF4 (6%) 
PVT1 (12%) 
OTX2 (8%) 
CTDNEP1 
(5%) 
LRP1B (5%) 
SNCAIP 
(10%) 
TP53 mutation 13-16% 14-21% - - 
Loss of chr17p - 25% 42% 63% 
Chromosomal 
alterations 
1q + 
3q + 
6 – 
7 + 
8p – 
8q + 
9q – 
10q – 
12q + 
16q – 
17q + 
18 + 
- 
- 
85% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
27% 
- 
- 
- 
- 
47% 
26% 
- 
- 
- 
- 
35% 
- 
- 
55% 
33% 
22% 
21% 
49% 
17% 
50% 
62% 
26% 
- 
- 
- 
47% 
41% 
- 
- 
15% 
20% 
- 
73% 
16% 
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1.11 RTK/PI3K signaling in medulloblastoma 
 
The role of RTK/PI3K/AKT signaling in medulloblastoma formation/progression is 
relatively less studied and understood. Previous research has revealed that the mutations 
and copy number alterations in key pathway components, including PTEN, PIK3CA, 
IGF1R and IRS2 were enriched in SHH medulloblastomas (Northcott et al., 2012a; 
Northcott et al., 2012b; Robinson et al., 2012). Nevertheless, these alterations were still 
rare, as only 10% of the SHH medulloblastomas had copy number changes associated 
with RTK/PI3K/AKT signaling (Northcott et al., 2012b). Furthermore, none of the 
childhood SHH medulloblastomas carried mutations in PIK3CA, PTEN and PIK3C2G 
genes, making these alterations restricted to adults (≥ 18 years old) and infants (Kool et 
al., 2014). Consistently, only less than 10% of the childhood SHH tumors were 
immunoreactive to pAKTS473, while majority of the positive cases were found in the adult 
tumors (Kool et al., 2014), suggesting that AKT activation is mostly associated with adult 
tumorigenesis. In contrast to relatively normal PI3K/AKT signaling, almost 50% of the 
childhood SHH tumors had TP53 alterations, while similar events were virtually absent 
in the remaining SHH medulloblastomas, as well as Group-3 and Group-4 
medulloblastomas. It is, thus, essential to understand the role of PI3K/AKT signaling 
within the context of TP53 alterations in SHH medulloblastomas in order to design and 
implement more effective targeted therapies. 
 
1.12 Cerebellar development, germinal zones and neurogenesis 
 
The vertebrate central nervous system arises from the neural plate, which subsequently 
closes and forms the neural tube. During the development, morphologically distinct 
vesicles are generated along the anterior-posterior axis of the neural tube. The most 
anterior end of the neural tube forms forebrain (prosencephalon), which is further divided 
into two parts named as telencephalon (gives rise to anterior forebrain structures, 
including cerebral cortex, hippocampus, basal ganglia, and olfactory bulb) and 
diencephalon (gives rise to posterior forebrain structures, including thalamus, 
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hypothalamus, and pituitary gland).  More posterior to forebrain, neural tube forms the 
midbrain (mesencephalon), hindbrain (rhombencephalon) and spinal cord. The hindbrain 
is further divided into eight segments called rhombomeres (r1-r8). While the anterior 
region (r1-r3) is named as metencephalon (forms pons and cerebellum), the remaining 
rhombomeres in the posterior hindbrain (r4-r8) are referred to as myelencephalon (forms 
medulla oblongata). The mouse cerebellar primordium arises from the hindbrain r1 at 
around E7-8. Signaling molecules secreted from isthmic organizer (e.g. Fgf and Wnt), a 
ring-like structure that encircles the neural tube at midbrain-hindbrain junction, and IV 
ventricle roof plate (e.g. Bmp, Wnt, retinoic acid) are important for the development, 
maintenance, and regional specification of the midbrain and hindbrain (Marzban et al., 
2014; Millen and Gleeson, 2008). Other molecules including, the homeobox gene 
products engrailed 1 (En1) and En2, and the paired box gene products Pax2 and Pax5 
also have essential functions in the maintenance of the primordial cerebellum (White and 
Sillitoe, 2013). Two primary germinal zones are established in the embryonic cerebellum: 
neuroepithelium of IV ventricle (the ventricular zone - VZ) located at the inner germinal 
layer, and neuroepithelium of the rhombic lip located at the roof plate. These two 
germinal zones are labeled by two distinct bHLH transcription factors: while pancreas 
specific transcription factor 1a (Ptf1a) identifies VZ progenitors, Atonal homolog 1 
(Atoh1) identifies rhombic lip progenitors (Hoshino et al., 2005; Machold and Fishell, 
2005). Both of these neuroepithelia disappear at birth, however secondary germinal zones 
derived from them continue to populate the postnatal cerebellum (Leto et al., 2012).  
 
Initial expansion of the VZ progenitors requires Wnt signaling pathway, while 
subsequent proliferation relies on SHH signaling pathway (White and Sillitoe, 2013). 
Apart from labeling the VZ progenitors, Ptf1a transcription factor has important roles in 
proper differentiation of VZ progenitors to generate GABAergic neurons, as it has been 
shown that loss of Ptf1a causes a failure in producing GABAergic neurons in the 
cerebellum. Interestingly, Ptf1a-deficient VZ progenitor cells acquire rhombic lip 
expression profile, including Atoh1, Reelin and Zic1/2, suggesting that GABAergic 
neuron fate is mainly regulated by Ptf1a activity (Pascual et al., 2007). Notch signaling 
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components and Mash1 transcription factor have also been indicated as other factors 
facilitating the differentiation of the VZ progenitors. All inhibitory GABAergic neurons, 
including basket and stellate cells of the molecular layer, Golgi and Lugaro cells of the 
internal granular layer, Purkinje cells in the Purkinje layer, and nucleo-olivary neurons 
are derived from VZ progenitors. While the projections neurons Purkinje cells (major 
output neuron of the cerebellum) are formed around E1-E13, the interneurons stellate, 
basket and Golgi cells are born postnatally (Leto et al., 2012; White and Sillitoe, 2013). 
 
The rhombic lip progenitors are highly proliferative cells that are positioned along the 
dorsal edge of the IV ventricle. As mentioned earlier, this region is divided into eight 
subunits called rhombomeres (r1-r8). The most anterior rhombomere (r1) is termed as 
upper rhombic lip (URL), while posterior r2-r8 is called lower rhombic lip (LRL), which 
is further divided into auditory rhombic lip (r2-r5) and precerebellar rhombic lip (r6-r8) 
(Grammel et al., 2012; Marzban et al., 2014). Rhombic lip progenitors are distinguished 
with Atoh1 expression, which is induced by Bmp signaling from the IV ventricle roof 
plate. Atoh1 is essential for the subsequent generation of the excitatory glutamatergic 
neuronal lineage; accordingly, it has been shown that inactivation of Atoh1 gene results 
in substantial loss of rhombic lip progeny (Machold and Fishell, 2005; Millen and 
Gleeson, 2008). Rhombic lip undergoes three waves of cell formation at distinct 
developmental stages: 1) Between E10.5-E12.5, rhombic lip progenitors give rise to 
glutamatergic projection neurons of deep cerebellar nuclei under the control of Tbr1, 
Tbr2, Pax6 and NeuroD signals. Upon their formation, these cells migrate rostrally to 
nuclear transitory zone. 2) Between E14-E21, another glutamatergic excitatory neuron 
type, unipolar brush cell, is generated under the control of Bmp, Pax6, Math1 and 
Lmx1a. 3) Lastly, a tangential migration of cerebellar granule cell progenitors (CGNPs) 
from rhombic lip takes place in late embryogenesis to early postnatal stages. Various 
signaling molecules, including Bmi1, N-myc, cyclin D2, Zic and Wnt accompany this 
critical migratory wave (Leto et al., 2012; Marzban et al., 2014).  
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After their tangential migration from the rhombic lip, CGNPs form a thick layer of a 
secondary germinal zone called external germinal zone or external granular layer (EGL) 
located at the subpial surface of the developing cerebellum. This transient structure forms 
as early as E15 and undergoes an extensive proliferation, mainly regulated by SHH 
secreted from Purkinje cells (Gilbertson and Ellison, 2008; Marzban et al., 2014). 
Activation of SHH signaling induces Gli1 and subsequently N-myc and Ccnd1/2 
transcription factors leading to CGNP proliferation and inhibition of cell cycle exit. Wnt 
and Notch2 signaling pathways are also shown to have roles in CGNP proliferation via 
induction of Myc family and Atoh1, respectively. Bmp2/4 and NeuroD1 signaling, on the 
other hand, are considered as negative growth regulators, as their activity leads to 
inhibition of Atoh1 and activation of p27Kip1 and p16Ink4a, which results in cell cycle exit 
and neuronal differentiation (Hatten and Roussel, 2011; Roussel and Hatten, 2011). The 
main cell type that CGNPs give rise to is excitatory glutamatergic interneurons granule 
cells, which are generated only from CGNPs. A minor population of Golgi cells and 
astroglial cells are also produced from CGNPs (Marzban et al., 2014). Even though P8 is 
the peak of granule neuron generation, loss of EGL structure starts as early as P0 due to 
an inward radial migration of the post-mitotic granule cells through molecular layer 
(ML). The newly formed granule neurons migrate against the Bergmann glia fibers, pass 
through Purkinje cells and locate themselves in internal granular layer (IGL). Various 
signals such as neuropeptide somatostatin and NMDA receptor activation by glutamate 
are important for the formation and proper migration of the granule neurons (White and 
Sillitoe, 2013). Once granule cell formation and migration is completed at around P20, 
cerebellar foliation takes its final structure, which corresponds to depletion of CGNPs, 
and therefore EGL. Another secondary germinal zone in the white matter of the postnatal 
cerebellum has been characterized. These CD133+; Nestin+ multipotent neural stem cells 
are thought to generate astrocytes, oligodendrocytes, and neurons (except for granule 
neurons) (Lee et al., 2005).  
 
1.13 Mouse models and cell of origin for medulloblastoma  
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In addition to uncovering chromosomal alterations, gene mutations, epigenetic 
abnormalities, and the specifics of the oncogenic signaling pathways leading to 
tumorigenesis, it is essential to untangle in which cell(s) these tumorigenic events are 
taking place and causing transformation. Therefore, revealing the cell of origin for 
medulloblastoma will expose the cellular context of the oncogenic signals, and 
consequently will allow the pharmacologic approaches to be more precise and effective.  
Current studies utilizing mouse models of medulloblastoma have implied different cell of 
origins for three of the medulloblastoma subgroups (WNT, SHH, Group-3), while efforts 
to understand the cellular origin of Group-4 medulloblastomas continue (Table 6) 
(Northcott et al., 2012a).  
 
Tumor location can provide clues about the origin of the tumors. Almost all of the human 
WNT medulloblastomas are located within the IV ventricle, and they infiltrate the dorsal 
surface of the brain stem. Studies utilizing mouse models have concordantly shown that 
WNT medulloblastomas arise from the lower rhombic lip progenitor cells of the dorsal 
brainstem (in rhombomeres r2-r8) (Table 6). Tissue specific expression of mutant Ctnnb1 
gene in mouse dorsal brainstem progenitors (Blbp-Cre+/-; Ctnnb1+/lox(ex3)) has caused 
aberrant accumulation of lower rhombic lip cells, which initiate medulloblastoma 
formation only in the presence of additional Trp53 mutations (Ctnnb1-mutant; 
Trp53flox/flox (OR +)). Interestingly, mutant Ctnnb1 expression or the Apc-deficiency in EGL 
cells of the cerebellum (Atoh1-Cre+/-; Ctnnb1+/lox(ex3) or Atoh1-Cre; Apcflox/flox) do not lead 
to hyperplasia or cerebellar masses, consistent with the notion that EGL cells are the cell 
of origin for SHH medulloblastomas, which are not associated with WNT signaling 
pathway (Gibson et al., 2010; Lorenz et al., 2011). Even though these studies have clearly 
shown the cell of origin for WNT medulloblastomas, only 4-15% of the Ctnnb1/Trp53-
mutant mice form medulloblastomas. In contrast, introduction of an additional activating 
mutation into Pik3ca gene (Blbp-Cre; Ctnnb1+/lox(ex3); Trp53+/flox; Pik3caE545K) has 
increased the medulloblastoma frequency up to 100% by three months of age. It is 
suggested that consequent elevation in Akt signaling has roles in tumor progression, 
rather than tumor initiation (Robinson et al., 2012).  
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Cerebellar granule neuron precursors (CGNPs) located in the external granule cell layer 
(EGL) are well-characterized cell types that can give rise to SHH medulloblastomas 
(Table 6). Almost all of the mouse models of SHH medulloblastoma rely on the genetic 
manipulations of SHH signaling pathway, and they carry genetically mutated Ptch1 or 
Smo alleles (Northcott et al., 2012a). More specifically, Ptch1 heterozygous mice (Atoh1-
GFP; Ptch1+/-) form GFP-expressing cerebellar pre-neoplastic cells and consequently 
medulloblastomas, indicating that both early tumor-initiating cells and the end-stage 
tumors have come from Atoh1 expressing, therefore GFP+, CGNP lineage (Oliver et al., 
2005). Even though only 16% of these mice form medulloblastoma, additional Trp53 loss 
(Ptch1+/-; Trp53-/-) can increase the tumor penetrance to greater than 95% (Wetmore et 
al., 2001). More definitive studies using tissue-specific knockout of Ptch1 gene have 
confirmed that not only the progenitor cells of the cerebellum (Atoh1-Cre; Ptch1flox/flox), 
but also the neural stem cells of the ventricular zone (hGFAP-Cre; Ptch1flox/flox) can give 
rise to SHH medulloblastomas in the absence of Ptch1 gene. It is worth nothing that both 
cerebellar progenitor cells and the VZ neural stem cells eventually acquire a CGNP 
phenotype rather than a stem cell profile (Yang et al., 2008). Similar to Ptch1 mutation, 
tissue specific expression of constitutively active Smo gene in CGNPs (ND2-SmoA1/+ or 
ND2-SmoA1/SmoA1) leads to persistent proliferation of CGNPs at postnatal stages, 
which eventually form medulloblastomas with high frequency (> 90%). Interestingly, 
some of these medulloblastomas are found to display leptomeningeal spread within the 
brain and/or spine, mimicking metastasis in human counterparts (Hatton et al., 2008). In 
addition to previously identified CGNPs as the origin of SHH medulloblastomas, a recent 
study has suggested that granule cell precursors of the cochlear nuclei of the dorsal 
brainstem can also lead to medulloblastoma formation in the presence of constitutively 
active Smo gene (hGFAP-cre::SmoM2Fl/+ or Atoh1-cre::SmoM2Fl/+). This finding suggests 
that two molecular subgroups of medulloblastomas arise from the lower rhombic lip, as 
opposed to the former conclusions that lower rhombic lip initiates only WNT tumors: 
Cochlear granule neuron precursors (in rhombomeres r2-r5) of the lower rhombic lip can 
form SHH medulloblastomas, while the pontine grey neuron precursors (in rhombomeres 
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r6-r8) of the lower rhombic rip can form WNT medulloblastomas (Grammel et al., 2012). 
Consistent with these findings, a recent study has suggested that Olig1+ progenitor cells 
(in rhombomeres r2-r4) of the lower rhombic lip, which give rise to both oligodendrocyte 
precursors and granule neuron lineage cells, initiate SHH medulloblastomas in the 
absence of Gnas (Olig1-Cre; Gnasflox/flox) - a gene which encodes heterotrimeric 
stimulatory G-protein alpha subunit (Gαs). In accordance with their origin, these tumors 
are enriched between the caudal posterolateral lobe and the dorsal brainstem around the 
IV ventricle, as opposed to the medulloblastomas confined to the cerebellum in hGFAP-
Cre; Gnasflox/flox mice. Interestingly, even though many somatic tumor types in humans 
acquire gain-of-function mutations in GNAS gene, Gαs seems to function as a tumor 
suppressor in cerebellum by controlling the ciliary trafficking of SHH signaling pathway 
components, and also regulating the activation/processing of Gli2 and Gli3. Consistently, 
the chromosomal region containing the GNAS gene is notably lost in human 
medulloblastomas, and GNAS expression is strongly correlated with decreased overall 
survival within SHH subgroup (He et al., 2014). These studies, altogether, suggest that 
there might be multiple cell of origins for SHH medulloblastomas: cerebellar granule 
neuron precursors of the external granule layer and cochlear nucleus of the lower 
rhombic lip, and neural stem cells of the subventricular zone. Detecting the origin of the 
tumors might, therefore, reflect the clinical outcome and treatment response even though 
they belong to the same subgroup (Gajjar and Robinson, 2014). 
 
Group-3 medulloblastomas can be generated from at least two types of cells: cerebellar 
granule neuron precursors and prominin1+/lineage- cerebellar neural stem cells (Table 6). 
Two recent studies have successfully shown that orthotopic transplantation of Atoh1+ 
CGNPs or prominin1+lineage- cerebellar stem cells infected with proto-oncogene Myc 
can give rise to aggressive LC/A medulloblastomas in immunocompromised mice with 
median survival rates of 39 or 48 days, respectively. It is, however, important to note that 
both of these models require concurrent loss of Trp53 functions in order to overcome the 
Myc-induced apoptosis in CGNPs or cerebellar stem cells (Kawauchi et al., 2012; Pei et 
al., 2012). Since TP53 is not directly mutated in human Group-3 medulloblastomas with 
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MYC amplification, it is currently unknown about at what degree these two models 
recapitulate human disease, even though their molecular profiling shares similarities with 
human counterparts (Northcott et al., 2012a). A third study might address these concerns 
by utilizing genetically engineered mouse models that reflect the genomic alterations of 
human medulloblastomas. This study relies on the findings that GFI1 and GFI1B genes 
are hyperactivated upon genomic redistribution of the active enhancer elements in Group-
3 (25-41%) and Group-4 (5-10%) medulloblastomas, and that a subset of Group-3 
medulloblastomas are characterized by simultaneous MYC amplification and GFI1 
activation (see Section 1.10). Accordingly, prominin1+ cerebellar stem cells that are 
concurrently infected with GFI1 (or GFI1B) and MYC expressing retroviruses are 
orthotopically transplanted into the cerebella of immunocompromised mice. Both 
MYC/GFI1 and MYC/GFI1B expressing cerebellar stem cells, but not MYC alone or 
GFI1 (or GFI1B) alone, formed aggressive medulloblastomas in approximately 90% of 
the animals with median survival rates of 38 and 26 days, respectively. Transcriptional 
profiling has demonstrated prominent similarities between these mouse tumors and 
human Group-3 medulloblastomas. Furthermore, 30-50% of the animals from both 
models have exhibited metastatic dissemination, a phenomenon that is frequently 
observed in Group-3 medulloblastomas (Northcott et al., 2014).   
 
Currently, there is not an established mouse model for Group-4 medulloblastomas, and it 
is still unknown which cells give rise to these tumors (Eberhart, 2012). However, it has 
been shown that overexpression of N-Myc in the developing posterior hindbrain can lead 
to the formation of LC/A medulloblastomas, consistent with the fact that N-MYC 
amplification is observed in both SHH (8%) and Group-4 (6%) medulloblastomas 
(Northcott et al., 2012a). According to this model (glutamate transporter 1-tetracycline 
transactivator; tetracycline response element-N-myc/luciferase OR Glt1-tTA;TRE-N-
myc/Luc OR GTML mice), Glt1 promoter drives the expression of tTA, which 
subsequently activates the expression of N-myc only in the absence of doxycycline. Thus, 
N-myc expression can be controlled by administrating doxycycline, which binds to tTA 
and halts its activity on TRE promoter upstream of N-myc (Table 6) (Swartling et al., 
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2010). The tumors formed in this model are considered as SHH-independent 
medulloblastomas, as they lack the expression of SHH downstream target molecules Gli1 
and Sox9, CGNP marker Atoh1, and SHH medulloblastoma identifier SFRP1. 
Furthermore, GTML medulloblastomas are not correlated with WNT and Group-3 
medulloblastoma identifiers, DKK1 and NPR3, respectively. In stark contrast, GTML 
medulloblastomas display significant expression of Group-4 identifier KCNA1. These 
results altogether suggest that N-myc overexpression in developing cerebellum form 
medulloblastomas, which partly resemble Group-4 medulloblastomas, while display 
divergent features from other three subgroups (Swartling et al., 2012). Additional studies 
have suggested that N-myc activation in different cell types gives rise to 
medulloblastomas of different molecular subgroups: while expression of mutationally 
stabilized N-Myc (N- mycT58A) in postnatal (P0) cerebellar stem cells give rise to SHH-
independent medulloblastomas, its activation in embryonic (E16) cerebellar stem cells 
causes medulloblastomas with characteristic components of SHH signaling pathway 
(Swartling et al., 2012). 
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Table 6. Representative mouse models and characterized cell of origin for 
medulloblastoma subgroups. 
Genotype/model Proposed cell of origin Molecular subgroup Reference 
Blbp-Cre+/-; Ctnnb1+/lox(ex3); 
Trp53flox/flox (OR +) 
Lower rhombic lip 
progenitor cells (r2-8) WNT 
(Gibson et 
al., 2010) 
Blbp-Cre; Ctnnb1+/lox(ex3); 
Trp53+/flox; Pik3caE545K 
Lower rhombic lip 
progenitor cells (r2-r8) WNT 
(Robinson 
et al., 
2012) 
Ptch1+/- Cerebellar granule neuron precursors SHH 
(Oliver et 
al., 2005) 
Ptch1+/-; Trp53-/- Not defined. SHH 
(Wetmore 
et al., 
2001) 
Atoh1-Cre; Ptch1flox/flox Cerebellar granule neuron precursors SHH 
(Yang et 
al., 2008) 
hGFAP-Cre; Ptch1flox/flox Ventricular zone neural stem cells SHH 
(Yang et 
al., 2008) 
ND2-SmoA1/+ or 
ND2-SmoA1/SmoA1 
Cerebellar granule neuron 
precursors SHH 
(Hatton et 
al., 2008) 
hGFAP-cre::SmoM2Fl/+ or 
Atoh1-cre::SmoM2Fl/+ 
Cochlear granule neuron 
precursors of the lower 
rhombic lip (r2-r5) 
SHH 
(Grammel 
et al., 
2012) 
Olig1-Cre; Gnasflox/flox Olig1
+ progenitor cells of the 
lower rhombic lip (r2-r4) SHH 
(He et al., 
2014) 
hGFAP-Cre; Gnasflox/flox Neural stem/progenitor cells SHH (He et al., 2014) 
Atoh1-GFP; Trp53-/- CGNPs 
infected with Myc-RFP 
retrovirus 
Cerebellar granule neuron 
precursors Group-3 
(Kawauch
i et al., 
2012) 
prominin1+lineage- cerebellar 
stem cells infected with 
MycT58A and DNp53 
retroviruses 
prominin1+lineage- cerebellar 
stem cells Group-3 
(Pei et al., 
2012) 
prominin1+ cerebellar stem 
cells infected with GFI1 (or 
GFI1B) and MYC retroviruses 
prominin1+ cerebellar stem 
cells Group-3 
(Northcott 
et al., 
2014) 
Glt1-tTA;TRE-N-myc/Luc 
(aka GTML mice) 
Developing posterior 
hindbrain Group-4?  
(Swartling 
et al., 
2010) 
Postnatal cerebellar NSCs 
infected with N-MycT58A Postnatal cerebellar NSCs Group-4? 
(Swartling 
et al., 
2012) 
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Chapter II:  Mutant-p53 driven gliomagenesis is blocked and/or delayed 
by inhibition of Rictor/mTORC2 signaling 
 
 
 
2.1 Introduction 
 
Glioblastoma is the most common malignant neoplasm of the central nervous system in 
adults with an annual incidence of 5 cases per 100,000 people (Furnari et al., 2007; 
Louis, 2006; Wen and Kesari, 2008). The median survival rate remains approximately 
12-15 months in spite of supportive care and intense treatment plans, which includes 
surgery, chemotherapy and radiotherapy (Huse et al., 2013; Stupp et al., 2009). 
Complications associated with tumor debulking, poor drug delivery, and tumor 
heterogeneity are considered to be the main factors that limit the effectiveness of these 
treatment strategies (Sottoriva et al., 2013). The presence of intratumor and intertumor 
heterogeneity, in particular, suggests that molecularly distinct tumors might exhibit 
differences in progression, prognosis, and clinical implications (Phillips et al., 2006; 
Verhaak et al., 2010). In order to better understand this complexity, glioblastomas have 
been extensively studied in terms of their genome-wide DNA copy number events, 
sequence-based mutations, and DNA methylation profiles, and categorized into multiple 
subgroups (Classic, Proneural, Neural, Mesenchymal) based on their gene expression 
profiles (Brennan et al., 2013; Noushmehr et al., 2010; Parsons et al., 2008; Phillips et al., 
2006; Sturm et al., 2012; Verhaak et al., 2010). Nevertheless, it remains a challenge as to 
whether and how the identification of subgroups can improve the current treatment 
options, especially as recent studies have suggested that tumor cells associated with 
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different subgroups or with different molecular characteristics could be found within a 
single tumor mass (Patel et al., 2014; Sottoriva et al., 2013). Furthermore, some tumors 
have shown the ability to switch their profile upon the occurrence of certain molecular 
events such as NF1 loss (Ozawa et al., 2014) or NF-κB activation (Bhat et al., 2013), 
suggesting a tumor evolution.  
 
Even in the presence of generally unpredictable tumor dynamics and molecular 
heterogeneity, a gain of several chr7 copies and a loss of at least one chr10q copy remain 
the most common molecular events in a majority of glioblastoma tumors and tumor cells 
(86% and 90%, respectively) (Ozawa et al., 2014; Patel et al., 2014). These two 
chromosomal abnormalities are specifically associated with the amplification of EGFR 
and PDGFA, and the loss of PTEN, respectively (Ozawa et al., 2014; Verhaak et al., 
2010), consistent with the previous findings that PI3K/RTK pathway is altered in 90% of 
human glioblastomas, leading to highly active AKT signaling (Brennan et al., 2013; 
Cancer Genome Atlas Research, 2008; Furnari et al., 2007). Furthermore, the finding 
showing that frequency of AKT activation significantly correlates with the histologic 
grade of gliomas underlines the important roles of this pathway in disease progression 
(Wang et al., 2004). Hence, the inhibition of PI3K and/or AKT signaling has been of 
particular interest in many cancer studies, including glioblastoma (Altomare and Testa, 
2005; Bellacosa et al., 2005; Cully et al., 2006; Momota et al., 2005; Testa and Bellacosa, 
2001; Wen and Kesari, 2008).  
 
mTORC2 is a major kinase that activates AKT through its phosphorylation at Serine-473 
(Ser473), along with PDK1, which phosphorylates AKT at Threonine-308 (Thr308) (Alessi 
et al., 1997; Guertin et al., 2006; Ikenoue et al., 2008; Sarbassov et al., 2005). It has been 
shown that functional loss of Rictor, a critical subunit of mTORC2, is sufficient to block 
Akt activation and tumor growth in various cancer models (Guertin et al., 2009; Magee et 
al., 2012; Masui et al., 2013). These findings indicate that tumor cells characterized by 
elevated Akt signaling are dependent on this molecule for survival, and are thus 
vulnerable to Akt inhibition (Bellacosa et al., 2005; Koul et al., 2006). Similarly, mouse 
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models containing tissue specific mutations in critical tumor suppressor genes such as 
p53, Pten, Nf1 and Rb, as well as models with combined activation of Ras and Akt in 
neural progenitors, lead to high grade gliomas characterized by elevated PI3K/Akt 
pathway (Chow et al., 2011; Holland et al., 2000; Kwon et al., 2008; Zheng et al., 2008; 
Zhu et al., 2005). It is not well established, however, as to whether these mouse tumors 
undergo the spontaneous genomic events that are frequently observed in human 
glioblastomas. Furthermore, the introduction of multiple genetic modifications, especially 
in key tumor suppressor genes, might change the cascades of genomic alterations 
required for tumor initiation and/or progression. It is, therefore, critical to test whether the 
inhibition of Rictor/mTORC2 has an impact on tumorigenesis using de novo glioma 
models that carry minimal genetic modifications and allow the occurrence of sporadic 
genomic alterations characteristic to human glioblastomas. 
 
Consistent with the fact that p53 signaling is altered in 86% of human glioblastomas 
(Brennan et al., 2013; Cancer Genome Atlas Research, 2008), mouse models with p53-
deficiency alone are capable of giving rise to high-grade gliomas with elevated PI3K/Akt 
signaling (Wang et al., 2009), As this model carried relatively minimal genetic 
modifications, allowing for occurrence of the spontaneous molecular events observed 
during the natural progression of human glioblastomas, it provided us with a unique tool 
to test the therapeutic potential of targeting Rictor/mTORC2 signaling in vivo. More 
specifically, we used genetically engineered mouse (GEM) models to investigate the 
effects of loss of Akt signaling in the development of glioblastomas by deleting 
Rictor/mTORC2. We show that during mutant p53-driven gliomagenesis, loss of chr19 
and chr7, syntenic to human chr10q, spontaneously occurs in many p53-mutant high-
grade gliomas, which is accompanied by loss of Pten and activation of PI3K/Akt 
signaling. Moreover, we show that the inhibition of Rictor/mTORC2, and by extension 
PI3K/Akt signaling pathway, exerts significant tumor suppressive activity, but not 
absolutely required for mutant p53-driven glioma development. These results underline 
the therapeutic potential of Rictor/mTORC2 inhibitors, and also underline the necessity 
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to prescreen and classify glioblastoma patients based on their plausible response to these 
inhibitors. 
 
2.2 Results 
 
2.2.1 p53-mutant GEM gliomas undergo key genomic alterations observed In 
human Glioblastoma 
 
We previously developed three GEM glioma models driven by (1) a conditional in-frame 
deletion of exons 5 and 6 of the p53 gene alone (hGFAP-cre;p53E5-6/E5-6) or (2) in 
combination with a germline heterozygous Nf1 mutation (hGFAP-cre;p53E5-6/E5-6;Nf1+/-), 
and (3) a conditional cis-p53/Nf1 mutation (hGFAP-cre;cis-p53+/-;Nf1+/flox) (Wang et al., 
2009; Zhu et al., 2005). Based on the status of p53 and Nf1 in these gliomas, we hereafter 
referred these three GEM gliomas as p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6Nf1-/- and p53-/-Nf1-/-, 
respectively. These GEM gliomas exhibited critical histopathological characteristics of 
human high-grade gliomas, approximately 40% of which showed necrosis and/or 
microvascular proliferation – the diagnostic features of glioblastoma (Zhu et al., 2005).  
 
We further analyzed these tumors in collaboration with Dr. Roeland G.W. Verhaak and 
Dr. Siyuan Zheng at the University of Texas MD Anderson Cancer Center, Houston, TX. 
Our findings showed that the gene expression profiles of p53- and p53/Nf1-mutant GEM 
gliomas were most similar to the Proneural subgroup of glioblastoma with one exception 
that showed the Classical signature (Figure 1A). Consistent with human Proneural 
glioblastomas, these GEM gliomas exhibited high similarity to the gene expression 
profile of oligodendrocyte precursor cells (OPCs) characterized by high expression of 
Olig2 and Ascl1 (Figures 1B and 1C). However, high levels of Nestin expression 
observed in these GEM gliomas also suggest their similarity to a subset of Type C transit-
amplifying progenitors with Olig2+Ascl1+Nestin+ expression in the subventricular zone 
(SVZ) of the lateral ventricle – the neural stem niche of the adult brain (Figure 1C). 
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Based on our findings that GEM gliomas resemble the G-CIMP(negative) Proneural 
subgroup of human glioblastoma (Figure 1A), and the observations that no Idh1/2 
mutation was identified in these GEM gliomas (data not shown), we propose that the 
p53- and p53/Nf1-mutant GEM gliomas genetically resemble the Proneural subtype of 
primary, but not IDH1-mutated secondary, glioblastoma in humans.   
 
To determine the cooperating oncogenic events following inactivation of p53 or p53 and 
Nf1, we analyzed the copy number alterations (CNA) in these 23 GEM gliomas (p53Δ5-
6/Δ5-6, n = 4; p53Δ5-6/Δ5-6Nf1-/-, n = 4; p53-/-Nf1-/-, n = 15). Although human chr10q is 
distributed in multiple chromosomes in the mouse genome, almost half of the human 
chr10q corresponds to the segments in mouse chr19 and chr7 (Figure 2A). Remarkably, 
we found that chr19 and chr7 underwent simultaneous and independent deletions in many 
of the p53- and p53/Nf1-mutant GEM gliomas (Figures 2B (lower segment) and 2C). 
Especially the deletion of chr19, which harbors the Pten gene, further demonstrates that 
these GEM gliomas recapitulate the critical genetic events during primary glioblastoma 
development in humans (Figure 2D). It is worth noting that the region in mouse chr7 
corresponding to human chr19 was actually amplified in some of the p53-mutant GEM 
gliomas, which harbored the deletion of the chr7 segment syntenic to human chr10q 
(Figures 2B and 2C). These observations not only reveal the specificity of the focal 
deletion event in mouse chr7 that is syntenic to human chr10q during glioblastoma 
development, but also recapitulates the previously reported chr19 amplification in human 
glioblastomas (Brennan et al., 2013). Together, the co-deletion of two different 
chromosome segments in mouse chr19 and chr7, which both are syntenic to human 
chr10q, suggests that the whole chromosomal arm deletion of chr10q is critical to 
primary glioblastoma pathogenesis, but not merely a by-product of PTEN loss in humans. 
Moreover, these results provide the support for the hypothesis that a single genetic event 
of chr10q loss leads to the deletion of multiple tumor suppressor genes (besides PTEN), 
providing a greater growth advantage. In support, we also identified a simultaneous 
deletion of Pten and Dmbt1, a tumor suppressor gene located in mouse chr7 (in human 
	   60	  
10q), of another group of mutant-p53 GEM gliomas (Figures 2E and 2F) (see next 
section for details about these new mouse models).     
 
When a conditional heterozygous Pten mutation with a floxed exon 5 (Pten+/E5) was 
introduced to the p53Δ5-6 model, the resultant p53Δ5-6;Pten+/Δ gliomas exhibited targeted 
loss of exon 5, but untargeted exon 9 was less affected. In contrast, both exons 5 and 9 
were lost in the p53Δ5-6 gliomas, an observation that is consistent with the CNA data - 
loss of the entire chr19 containing Pten (Figure 2E). Similarly, a previous study using 
conditional inactivation of p53 and Pten with or without Rb induced malignant gliomas 
including glioblastomas, which exhibited no loss of chr19 or chr7 (Figure 2B (upper two 
segments)) (Chow et al., 2011). These results suggest that despite the existence of 
additional tumor suppressor genes in mouse chr19 and chr7 (human chr10q), the major 
tumor suppressor gene in chr10q is Pten, as the targeted loss of Pten can circumvent 
chr19/chr7 loss to promote mutant p53-driven gliomagenesis. Therefore, a strategy that 
targets downstream events of PTEN/Pten loss would be effective for primary 
glioblastoma.     
 
2.2.2 RICTOR expression is upregulated in human Glioblastomas with TP53 
mutation 
 
We next sought to further elucidate potential signaling pathways critical to the 
progression of human glioblastomas. PTEN is a negative regulator of the PI3K/AKT 
pathway and its deletion leads to increased phosphorylation of AKT (Li and Sun, 1997; 
Li et al., 1997; Stambolic et al., 1998; Steck et al., 1997) at Thr308 by PDK1 (Alessi et al., 
1997) and at Ser473 by mTORC2 (Sarbassov et al., 2005). Previous studies suggest that 
both phosphorylation events are required in order for AKT to be fully activated (Alessi et 
al., 1996; Foster and Fingar, 2010; Laplante and Sabatini, 2009). Even though PI3K/AKT 
signaling is elevated in majority of the human glioblastomas (Brennan et al., 2013), we 
found that both pAKTT308 and pAKTS473 protein levels varied significantly, as some 
samples had higher expression levels than the others (Figure 3A). This finding suggests 
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that the degree at which the AKT signaling involves in glioma initiation/progression 
might differ between the tumors. As expected, glioblastomas with TP53 mutations had 
higher p53 protein levels, consistent with previous studies (Figure 3A) (Anker et al., 
1993; Brosh and Rotter, 2009; Louis et al., 1993). More interestingly, human 
glioblastomas with a TP53 mutation had significantly higher expression of RICTOR, a 
critical subunit of mTORC2, compared to the tumors without a TP53 mutation (Figure 
3B), suggesting that mTORC2 signaling might have a crucial role especially in TP53-
mutant glioblastomas. Thus, these results suggest that RICTOR expression, and by 
extension mTORC2 activity, is critical for glioblastomas with a TP53 mutation.  
 
2.2.3 Rictor-deficiency reduces forebrain tumor formation while increasing 
hindbrain tumor incidence 
 
Our initial findings showing that p53-mutant GEM gliomas spontaneously undergo key 
genomic alterations (e.g. chr10q/PTEN deletion) typical in human glioblastomas, and that 
mTORC2 signaling may play a key oncogenic role led me to test whether the removal of 
mTORC2 can affect glioma initiation and/or progression. Thus, in addition to utilizing 
the previously established hGFAP-cre; p53flox/flox mice (p53Δ5-6/Δ5-6, hereafter) (Wang et 
al., 2009), I generated hGFAP-cre; p53flox/flox ; Rictorflox/+ (p53Δ5-6/Δ5-6; Rictor+/Δ, 
hereafter) mice, which had an additional heterozygous Rictor mutation, as well as 
hGFAP-cre ; p53flox/flox ; Rictorflox/flox (p53Δ5-6/Δ5-6; RictorΔ/Δ, hereafter) mice, which 
lacked both Rictor alleles (Figure 4A). Cre-mediated recombination occurs at around 
embryonic stage 12.5 (E12.5) and it targets multipotent radial glial cells in the brain. 
Consequently, nearly all neurons, glia and neural stem cells in the dorsal forebrain, as 
well as the majority of the cerebellar population except for the Purkinje cells are targeted 
by this strategy (Wang et al., 2009; Zhuo et al., 2001).  
 
Approximately 70% of the p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ mice and 55% of the 
p53Δ5-6/Δ5-6; RictorΔ/Δ mice were sacrificed due to observable neurological symptoms 
including enlarged head, tremor, seizure, ataxia, or lack of balance indicating the 
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presence of an end-stage brain tumor (Figure 4B). These symptoms were encountered 
between 4-24 months of age, representing a wide time window for tumor formation 
and/or progression (Figure 4D). Remaining mice were sacrificed due to other health 
problems including dermatitis, old age leading to poor health conditions, rectal or penile 
prolapse, GI tract obstruction, rarely observed eye injuries likely due to fighting, spinal 
cord problems including paralysis, hyperplasia in the brain, and enlarged and/or ulcerated 
soft tissue sarcomas outside the central nervous system (CNS) (Figure 4B) due to 
hGFAP-cre expression in cells outside of the CNS. Interestingly, p53Δ5-6/Δ5-6; RictorΔ/Δ 
mice with these non-brain-tumor problems lived significantly longer than both p53Δ5-6/Δ5-6 
and p53Δ5-6/Δ5-6; Rictor+/Δ mice (Figure 4C), implying that Rictor deficiency reduces the 
overall brain tumor formation even when mice are aged. More interestingly, though there 
was no significant survival difference between p53Δ5-6/Δ5-6 (n = 38) and p53Δ5-6/Δ5-6; 
Rictor+/Δ (n = 72) mice with brain tumors, p53Δ5-6/Δ5-6; RictorΔ/Δ (n = 52) mice with brain 
tumors lived significantly longer than both p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ mice 
(median = 254 days, 268 days, 308 days; respectively) (Figure 4D). Furthermore, p53Δ5-
6/Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ mice were characterized by brain tumors positioned 
predominantly in the forebrain (i.e. supratentorial or prosencephalon) while p53Δ5-6/Δ5-6; 
RictorΔ/Δ mice had a lower incidence of this type of tumor (forebrain tumor incidence: 
84%, 72% and 46%, respectively) (Figure 4E). On the other hand, tumor formation in the 
hindbrain (i.e. infratentorial or rhombencephalon), especially in the cerebellum, was 
significantly increased in p53Δ5-6/Δ5-6; RictorΔ/Δ mice compared to p53Δ5-6/Δ5-6 and p53Δ5-
6/Δ5-6; Rictor+/Δ (hindbrain tumor incidence: 16%, 28%, 54%) (Figure 4E). These results 
suggest that Rictor loss extends the survival of the mice with brain tumors, and shifts the 
tumor location from forebrain to hindbrain.  
 
2.2.4 p53-mutant GEM gliomas are inhibited and/or delayed by Rictor/mTORC2 
loss 
 
After characterizing these mouse models based on their brain tumor location, I further 
examined the tumors based on their pathology on the basis of WHO (World Health 
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Organization) criteria with the help of Sandra Dr. Camelo-Piragua, a neuropathologist at 
the University of Michigan Medical School (Louis et al., 2007). Consistent with previous 
studies, the majority of the forebrain tumors and some of the hindbrain tumors in all 
models were high-grade gliomas characterized by a significant number of mitotic figures, 
necrotic tissue, pleomorphic nuclei, multi-nucleated giant tumor cells, abnormal mitoses, 
neuronal satellitosis and microvascularization (Figure 5A). These tumor cells were also 
immunoreactive to GFAP and Olig2, as observed in human glioblastomas (Figures 5B 
and 5C) (Furnari et al., 2007). Notably, Olig2 expression was observed in all GEM 
gliomas, making it a reliable glioma marker, while Pax6 was virtually absent (Figures 5B, 
5C, 9D and 9E). Furthermore, many tumor cells expressed mutant-p53 protein (Figures 
5B, and 5C), as previously reported (Wang et al., 2009) - a phenomenon also observed in 
many other human tumors (Brosh and Rotter, 2009). When quantified, I did not observe a 
significant difference between p53Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ mice in terms of glioma 
penetrance as both models predominantly formed high-grade gliomas and rarely MBs 
(Figure 5D). However, overall glioma formation in p53Δ5-6/Δ5-6; RictorΔ/Δ mice (49%) 
reduced significantly compared to p53Δ5-6/Δ5-6 (95%) and p53Δ5-6/Δ5-6; Rictor+/Δ (81%) 
mice (Figure 5D). Even more strikingly, glioma bearing p53Δ5-6/Δ5-6; RictorΔ/Δ mice lived 
significantly longer than their counterparts in both p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ 
with an up to 48% increase in life span (median = 380 days, 257 days and 284 days, 
respectively) (Figure 5E). These results suggest that mutant-p53 mediated glioma 
formation is inhibited and/or delayed by Rictor loss and Rictor-deficiency provides a 
survival advantage to glioma-bearing mice. 
 
2.2.5 Rictor deficiency impairs mTORC2 and mTORC1 signaling in mutant-p53 
GEM gliomas accompanied by a reduction in tumor cell proliferation 
 
The reduction in glioma penetrance and increase in the overall survival of glioma bearing 
mice upon Rictor deficiency raised the question of how Rictor deletion alone can lead to 
such significant tumor suppression. I first confirmed that end-stage tumors came from the 
recombined cells that had undergone cre-mediated recombination by examining the 
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floxed, wild type, and deleted alleles of p53, Rictor, and cre genes (Figure 6A). In order 
to identify the molecular consequences of Rictor-deficiency, I analyzed the key 
components of the mTORC2 pathway. As expected, all of the p53Δ5-6/Δ5-6; RictorΔ/Δ mice 
had very low levels of pAktS473 compared to p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ 
gliomas, which were characterized by very high levels of pAktS473 (Figure 6B), consistent 
with human glioblastoma samples (Altomare and Testa, 2005; Wang et al., 2004). 
Surprisingly, pAktT308 was also very low in Rictor-deficient gliomas even though this site 
is phosphorylated by PDK1 (Figure 6B), consistent with previous studies suggesting that 
AKT/Akt phosphorylation at Ser473 is required for phosphorylation at Thr308 (Guertin et 
al., 2009; Scheid et al., 2002). Another downstream target of mTORC2, Ndrg1, also 
showed reduced phosphorylation in many p53Δ5-6/Δ5-6; RictorΔ/Δ gliomas even though this 
reduction was not as robust as pAkt (Figure 6B). Consistent with our copy number 
analyses, Pten expression was reduced in gliomas of all three models including p53Δ5-6/Δ5-
6; RictorΔ/Δ tumors, which lack pAktS473 and pAktT308 (Figures 6B and 2E). We did not 
observe any difference between the mouse models in terms of pErk1/2, and pGSK3-β and 
c-Myc levels, which served as readouts for MAPK and Wnt signaling pathways (Figure 
6C). These findings suggest that Rictor is required for an intact mTORC2 activity, 
including the phosphorylation of Akt, and impediment of the mTORC2 signaling may 
cause reduction in glioma formation and/or progression. 
 
Since active Akt positively regulates mTORC1 signaling (Laplante and Sabatini, 2009), I 
determined whether loss of pAkt in Rictor-deficient gliomas had an impact on mTORC1 
activity. TSC2 forms a dimer with TSC1 and upon dimerization, the TSC1/TSC2 
complex functions as a GTPase-activating protein that inactivates mTORC1 by 
hydrolyzing Rheb-GTP. Active Akt, on the other hand, releases this inhibition by directly 
phosphorylating TSC2 and preventing the dimerization (Inoki et al., 2002; Potter et al., 
2002). I first analyzed the two components of the mTORC1 pathway, S6K and 4E-BP1, 
which are phosphorylated by mTORC1 itself (Figure 6D) (Inoki et al., 2002). Our results 
showed that only 1/8 of the p53Δ5-6/Δ5-6; RictorΔ/Δ gliomas had pS6KT389 while 4/4 of the 
p53Δ5-6/Δ5-6 and 6/8 of the p53Δ5-6/Δ5-6; Rictor+/Δ gliomas had prominent levels of pS6KT389 
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(Figure 6D). Similarly, p4E-BP1T37/46 was detected in only half of the p53Δ5-6/Δ5-6; 
Rictor+/Δ and p53Δ5-6/Δ5-6; RictorΔ/Δ gliomas whereas all of the p53Δ5-6/Δ5-6 gliomas were 
positive for this molecule (Figure 6D). I then examined pTSC2T1462 levels in order to 
determine whether the reduction in mTORC1 activity was mediated by TSC1/TSC2 
complex (Figure 6D). The reduced levels of pTSC2T1462 in p53Δ5-6/Δ5-6; RictorΔ/Δ gliomas 
indicated that Rictor loss could modulate mTORC1 activity by releasing the inhibition on 
TSC1/TSC2 complex, which is otherwise phosphorylated and inhibited by the active Akt. 
These results suggest that removal of Rictor can inhibit glioma initiation and/or 
progression by impairing mTORC2 and mTORC1 activity, which are the two important 
signaling pathways in malignant gliomas. 
 
Lastly, I examined the proliferation rate of the end-stage GEM gliomas by quantifying 
the Ki-67+ tumor cells. Interestingly, Rictor-deficient gliomas had significantly lower Ki-
67+ tumor cell percentage compared to both p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ gliomas 
(Figures 6E and 6F). I did not detect a significant difference between p53Δ5-6 vs p53Δ5-
6/Δ5-6; Rictor+/Δ gliomas consistent with their comparable glioma incidence and survival 
rate (Figures 6E and 6F). These results indicate that Rictor deficiency can reduce the 
tumor cell proliferation, which may explain the 48% life span increase in the glioma 
bearing p53Δ5-6/Δ5-6; RictorΔ/Δ mice. 
 
2.2.6 Expansion of the plausible early glioma-forming cells are inhibited by Rictor 
loss 
 
Our previous studies have showed that mutant-p53 expressing (p53+, thereafter) 
precursor-like cells were easily detectable in the vicinity of the subventricular zone 
(SVZ) around 4-7 months of age and were suggested as the early tumor forming cells 
(Wang et al., 2009). These p53+ glioma precursor cells typically form clusters with high 
levels of proliferation in the vicinity of the SVZ areas such as the corpus callosum (CC), 
(RMS), cerebral cortex (Ctx), hippocampus, and olfactory bulb (OB) (Wang et al., 2009). 
Given this finding, I aimed to determine whether and how the early tumor forming cells 
	   66	  
are affected by the Rictor loss. I examined the p53+ cells residing in two main locations: 
inside the germinal zone defined by the cells in the SVZ and rostral migratory stream 
(RMS) and outside the germinal zone, which are all of the remaining p53+ cells scattered 
throughout the brain. p53Δ5-6/Δ5-6; Rictor+/Δ mice were excluded from this investigation 
since end-stage tumor analyses demonstrated a very similar phenotype between p53Δ5-6 
and p53Δ5-6/Δ5-6; Rictor+/Δ mice. Consistent with the previous studies (Wang et al., 2009), I 
detected an expansion of the p53+Olig2+ cells outside the germinal zone in 5/9 of the 
p53Δ5-6/Δ5-6 mice (Figures 7B-7D). These tumor incipient cells were found in various 
places of the brain, including the corpus callosum, hippocampus, olfactory bulb, striatum, 
and the vicinity of the anterior RMS (Figure 7A). Interestingly, only 1/9 of the p53Δ5-6/Δ5-
6; RictorΔ/Δ mice had a similar expansion outside of the germinal zone, while most of the 
mice had p53+ cells restricted in the SVZ/RMS region (Figures 7C and 7D). Furthermore, 
the proliferation of the p53+ cells was also different between these two models: while the 
average proliferation rate of the scattered p53+ cells in p53Δ5-6/Δ5-6 was about 30-35%, the 
same ratio was only 10% in p53Δ5-6/Δ5-6; RictorΔ/Δ brain (Figure 7E). On the other hand, 
the number and the proliferation of the p53+ cells within the germinal zone (i.e. 
SVZ/RMS) were comparable between p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; RictorΔ/Δ mice (Figure 
7F). These results suggest that even though the generation of tumor forming cells within 
the germinal zone is almost identical between p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; RictorΔ/Δ mice, 
their expansion and cluster formation outside the germinal zone requires functional 
Rictor/mTORC2 and, more specifically, an intact Akt pathway, underlining one of the 
mechanisms by which Rictor deficiency reduced gliomagenesis. 
 
2.2.7 Rictor loss has minimal effects in the developing Subventricular zone 
 
Since the expanding p53+ population in p53Δ5-6/Δ5-6 brains reduced dramatically upon 
Rictor loss, I assessed whether the Rictor-deficient developing brain, especially in SVZ, 
had any abnormality in overall structure or major cell populations. In these analyses, I 
used an additional mouse model - hGFAPCre ; p53flox/+ ; Rictorflox/flox (RictorΔ/Δ, hereafter) 
- to better understand the mutant-Rictor phenotype in the absence of complete p53-loss. 
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Based on our previous studies and experience, hGFAPCre ; p53flox/+ mice do not have any 
noticeable abnormalities and they do not form tumors (data not shown), thus the RictorΔ/Δ 
phenotype can be attributed only to  Rictor deficiency. I compared RictorΔ/Δ and p53Δ5-
6/Δ5-6; RictorΔ/Δ mice to wild-type controls and noted that both Rictor-deficient brains 
were significantly smaller and weighed less than controls in various stages of the lifespan 
including P8, P16, P22, and 4-months even though the body weights were very similar 
(Figures 8A-8C). Furthermore, the total number of proliferating Ki-67+ cells in the SVZ 
was comparable between P16 controls and mutants even though there was a slight but 
statistically significant reduction in the Ki-67+/DAPI+ percentage within the mutant SVZ 
population, especially p53Δ5-6/Δ5-6; RictorΔ/Δ (Figures 8D-8F). Similarly, the number of the 
stem cells in the P16 SVZ labeled by GFAP and Nestin did not change significantly 
between controls and Rictor mutants (Figures 8G-8I). I, thus, concluded that Rictor loss 
does not have a dramatic effect on the overall structure of the neonatal brain and the 
developing SVZ in relation to the tumorigenesis, consistent with a recent study showing 
that Rictor deletion has only modest effects on hematopoietic stem cell frequency and 
function (Magee et al., 2012). As the glioma cells are more fragile to the loss of 
Rictor/mTORC2 signaling pathway, these findings are inline with a phenomenon called 
“oncogene addiction”, which describes a dependence of cancer cells on a single 
oncogenic pathway for malignancy, proliferation and/or survival, while the normal cells 
rely on multiple redundant signals and/or molecules (Sharma and Settleman, 2007).  
 
2.3 Discussion 
 
Herein, we demonstrated that mutant-p53 driven high-grade gliomas recapitulate the key 
genomic alterations of human glioblastomas, and that genetic deletion of Rictor has 
significant tumor suppressive activity in these tumors. More specifically, our data suggest 
that Rictor loss reduces gliomagenesis approximately by half, as well as provides a 
substantial survival advantage to the remaining mice with high-grade gliomas. Despite of 
this anti-glioma activity, formation of gliomas in a subset of Rictor-deficient mice 
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accentuates the essential need to reveal the major oncogenic signals in Rictor/mTORC2-
independent gliomagenesis. 
 
2.3.1 p53-mutant GEM gliomas undergo genomic alterations described in human 
glioblastomas 
 
Mouse models provide a unique platform to delineate the complexity of glioblastoma 
formation and perform preclinical studies by designing and applying novel therapies. 
There are, though, some aspects of the disease that have not been well recapitulated in 
genetically engineered models, including its intratumoral cellular and molecular 
heterogeneity (Huse et al., 2013). The introduction of specific genetic modifications into 
these models has the potential to direct tumor cells to acquire only selected oncogenic 
features, rather than representing this diversity. Thus, generating models that allow the 
tumor forming cells to gain sporadic molecular alterations that are heterogenic and - more 
importantly - comparable to human counterparts is essential to achieve both scientific and 
clinical goals. We have, both here and previously, shown that p53 deficiency alone gives 
rise to highly anaplastic cells that are capable of accumulating various oncogenic features 
leading to malignant glioma formation (Wang et al., 2009). Our current study, 
additionally, demonstrates that GEM gliomas carry key genomic alterations frequently 
seen in human glioblastomas. In particular, co-deletion of genomic loci in mouse chr7 
and chr19 corresponding to human chr10q suggested that, in addition to having similar 
gene expression profiles, mouse tumors recapitulate human glioblastomas at the genomic 
level. Several studies have proposed that deletion of multiple tumor suppressor genes 
located in chr10q, including DMBT1, WDR11, and LGI1, was involved in glioma 
initiation and/or progression. (Chernova et al., 2001; Ichimura et al., 1998). Homozygous 
deletion of DMBT1, especially, was associated with unfavorable clinical outcomes 
(Motomura et al., 2012). Thus, the independent but simultaneous deletion of Pten (chr19) 
and Dmbt1 (chr7) in our GEM gliomas was in line with this hypothesis, and suggested an 
additive oncogenic effect for the loss of at least two tumor suppressor genes located in 
human chr10q. However, the absence of such chromosomal deletions, especially deletion 
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of chr7, in mouse models that are prepared by genetic deletion of Pten suggests that the 
major target of chr19 (chr10q in humans) loss in high-grade gliomas is Pten/PTEN gene. 
This observation also implies that additional mutations introduced to mouse models 
might eliminate the necessity to undergo critical genomic alterations observed during the 
natural progression of human glioblastomas. In addition to deletion, we detected 
significant amplification in a different locus of mouse chr7 that corresponds to human 
chr19. Interestingly, this region found to be amplified in human glioblastomas as well, 
and contained several cancer-associated genes, including AKT2, MAP3K10, PLD3, and 
MAP4K1.  
 
2.3.2 Rictor/mTORC2 is important for both the initiation and progression of 
mutant-p53 GEM gliomas 
 
Many human cancers manifest themselves with multiple genomic, epigenetic and 
chromosomal alterations accumulating in a complex sequence of events. Consequently, 
regulation of numerous genes and networks is disrupted, mostly leading to more 
malignant tumors. It is, therefore, remarkable that reversal of only one or a couple altered 
signaling pathways, which promote tumor initiation and growth, can lead to such 
dramatic benefits in terms of controlling the tumor progression, if not totally eliminating 
it (Weinstein and Joe, 2006). Various experimental systems and successful clinical 
investigations, including chronic myelogenous leukemia, melanoma, and non-small-cell 
lung cancer (Huse et al., 2013) provided profound evidences for identifying the 
“Achilles’ heel” of the tumor cells to attack the diseases efficiently (Weinstein, 2002). 
These studies described this phenomenon as ‘oncogene addiction’, which explains the 
dependence of cancer cells on a single oncogenic pathway for their malignancy, 
proliferation and/or survival (Sharma and Settleman, 2007; Weinstein, 2002). 
Accordingly, our study here indicated that Rictor/mTORC2 is a critical molecule for 
high-grade gliomas as its absence significantly reduces glioma penetrance as well as 
extends the survival of glioma-bearing mice. Our early stage analyses suggested that 
functional loss of Rictor does not affect the formation of the tumor incipient cells within 
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the germinal zone but rather blocks the spreading of these cells to surrounding areas. 
Since cellular expansion is a central event for tumor growth, this finding implies that 
intact Rictor, and by extension PI3K/Akt signaling, is essential for glioma initiation. 
Consistently, it has been shown that PTEN loss and EGFR amplification are two driver 
events in human glioblastomas (Brennan et al., 2013; Ozawa et al., 2014). Furthermore, 
we found that Rictor-deficient end-stage GEM gliomas had a lower proliferation 
percentage compared to Rictor wild type or heterozygous models, suggesting that 
Rictor/mTORC2 provides a growth advantage to glioma cells in addition to its impact on 
early tumorigenesis. We, therefore, strongly advocate that combinatory treatment plans 
involving Rictor/mTORC2 inhibition will benefit patients during both the early and late 
stages of glioblastomas (Figure 22). However, the fact that a group of Rictor-deficient 
mice still form mutant-p53 driven gliomas, Rictor/mTORC2 signaling is not absolutely 
required for every glioma case (see next section). 
 
2.3.3 Rictor/mTORC2-independent gliomagenesis underscores the necessity of 
additional molecular stratification of Glioblastomas 
 
Targeted therapies that include novel agents have made only a small impact on the 
clinical outcome of glioblastoma patients. For instance, PI3K/AKT pathway inhibitors, 
including monotherapies and combinatory strategies with other agents and/or radiation, 
produced mostly inconsistent and short-lived responses (Wen et al., 2012). This could be 
partly because of an imperfection in patient selection. Consequently, many glioblastoma 
patients succumb from recurring tumors that acquire resistance to current therapies, a 
phenomenon that has not been well recapitulated and established in mouse models 
(Hambardzumyan et al., 2011). Our study here showed that while Rictor deficiency 
reduced mutant-p53 driven glioma penetrance by half, the remaining mice still 
maintained the deadly tumor, in spite of a 50% increase in their overall survival. This 
finding implies the presence of Rictor-deficient early transforming cells or malignant 
tumor cells that are capable of escaping from “an oncogene addiction” (Sharma and 
Settleman, 2007). More specifically, although Rictor/mTORC2/Akt signaling exerts an 
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essential role in the development of high-grade gliomas, it is not absolutely required for 
every tumor case. It is, therefore, critical to identify the prominent oncogenic pathways in 
Rictor-deficient gliomas, and determine whether these tumors correspond to a novel 
molecular subgroup within human glioblastomas. Subsequent classification of human 
tumors based on their plausible response to the inhibition of Rictor/mTORC2 pathway 
will not only increase the potential of novel Rictor/mTORC2 inhibitors, but also improve 
the success rate of the existing treatment plans utilizing PI3K/AKT inhibitors. 
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Figure 1. High-grade gliomas induced by mutant-p53 (with or without Nf1 mutations) 
resemble proneural subgroup of human glioblastomas. 
(A) Subgroup analysis of genetically engineered mouse (GEM) gliomas based on gene 
expression profiles. Each tumor is compared to Proneural, Neural, Classical and Mesenchymal 
subgroups of human glioblastomas. High similarity is indicated by red, low similarity is 
indicated by blue. G-CIMP signature is also analyzed. Note that none of the GEM gliomas are 
found to be G-CIMP+. 
(B) Gene expression profile of GEM gliomas in comparison with different cell populations. High 
ssGSEA Score (red) indicates strong resemblance; low scores (blue) indicate difference. The 
expression profile of GEM gliomas resemble to that of oligodendrocyte precursors. 
(C) Detailed analyses of the expression levels of Ascl1, Olig2 and Nestin genes in GEM gliomas 
in comparison to normal brain tissue. 
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Figure 2. Mutant-p53 mediated GEM gliomas share key genomic alterations with human 
glioblastomas. 
 
(A) Synteny map illustrating the equivalents of human (Homo sapiens) chr10q in mouse (Mus 
musculus) chr19 and chr7. The location of the PTEN/Pten gene is indicated in both human and 
mouse chromosomes.  
(B) Heatmap representation of the copy number changes (blue for deletion, red for amplification) 
across the entire genome of the GEM gliomas. Upper two segments include the samples from a 
previous study (Chow et. al, 2011) that used conditional inactivation of p53 and Pten with or 
without Rb genes. Lower segment includes our samples from 23 GEM gliomas carrying mutant-
p53 with or without mutant-Nf1 alleles. Mouse chromosomes (chr19 and chr7) corresponding to 
human chr10q and chr19 are indicated. 
(C) Genome plot displaying the frequencies of the copy number gains (red) and copy number 
losses (blue) in the genome of 23 GEM gliomas carrying mutant-p53 with or without mutant-Nf1 
alleles. Two loci in mouse chromosomes (i.e. chr19 and chr7) corresponding to human chr10q 
and chr19 are boxed.  
(D) Deletion analysis of Pten (chr19) and Fgf2 (chr7) genes in GEM gliomas carrying mutant-
p53 with or without mutant-Nf1 alleles. Light blue implicates heterozygous deletions while dark 
blue indicates homozygous deletions. Co-deletions of Pten and Fgf2 genes are pointed with 
asterisks.  
(E) Copy number estimates of the Pten gene in GEM gliomas based on readings on exon-5 and 
exon-9.  
(F) Copy number estimates of Dmbt1 (chr7) gene in comparison with Pten (chr19) gene in GEM 
gliomas.  
Estimates were calculated by RT-PCR using the genomic DNA as template and the readings 
were normalized to β-Actin (mouse chr5), which served as an internal reference gene for each 
sample. The average of readings from wild-type controls was set to “2” and all of the samples 
were calculated accordingly. 
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Figure 3. RICTOR expression and AKT signaling across the human glioblastoma samples. 
 
(A) Protein level analyses of pAKTS473, pAKTT308 and TP53 in relation to PTEN and TP53 status 
in human glioblastoma samples. The level of protein abundance is represented with a color scale 
as depicted. PTEN deletions or TP53 mutations are colored as indicated. 
(B) The expression levels of RICTOR (mRNA), TP53 (protein) and PTEN (protein) among the 
human glioblastoma samples with or without TP53 mutation. The level of abundance is 
represented with a color scale as depicted. 
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Figure 4. Mutant-p53 mediated GEM brain tumors display distinct brain locations based 
on Rictor status.  
 
(A) Schematic representation of the genetic configurations in p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, 
and p53Δ5-6/Δ5-6; RictorΔ/Δ mice. Floxed genes undergo hGFAP-cre-mediated recombination at 
around E12.5, therefore the mice are named after the genotype of the recombined cells.  
(B) Phenotypic classification of the entire cohort of mice used in this study. The mice that 
represented brain tumors at the time of euthanasia are shown in red bars. Other bars show the 
phenotypes of the mice that did not generate brain tumors. These mice without brain tumors 
represented other health-concerning reasons, including large and/or ulcerated soft tissue 
sarcomas, dermatitis, eye problems, prolapse, GI tract obstruction, old age, fighting and poor 
health conditions. 
(C) Kaplan-Meier survival curves of all the mice used in this study including the ones with or 
without brain tumors. Brain tumor cases are entered as uncensored events (i.e. “1”) while others 
are entered as censored events (i.e. “0”). The Mantel-Cox (Log-rank) test was used to compare 
the curves statistically. 
(D) Kaplan-Meier survival curves of the in p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, and p53Δ5-6/Δ5-6; 
RictorΔ/Δ mice euthanized due to end-stage brain tumor(s). 1 year of time is indicated with a 
vertical dashed line on the graph. The Mantel-Cox (Log-rank) test is used to compare the curves 
statistically.  
(E) The brain tumors from in p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, and p53Δ5-6/Δ5-6; RictorΔ/Δ mice 
were grouped based on their location within the brain. Two-tailed Fisher’s exact test is used to 
compare the groups. 
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Figure 5. Mutant-p53 driven GEM gliomas are inhibited and/or delayed by concurrent 
deletion of Rictor gene. 
 
(A) H&E staining of the high-grade gliomas (HGG) in three mouse models. Necrotic areas are 
indicated with “N”. Characteristic features of the GEM gliomas are shown with arrowheads. The 
insets show abnormal mitotic figures (in p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ) and a 
multinucleated giant cell (in p53Δ5-6/Δ5-6; RictorΔ/Δ). 
(B) Histopathology analyses of the GEM gliomas using p53, Olig2, GFAP and Synaptophysin 
antibodies. Insets illustrate the immunoreactivity at higher magnification, as well as some glioma 
features including the mitotic figures (i, iv, and vii), multinucleated giant cells (iii and xii), 
abnormal mitosis (xi) and a giant tumor nucleus (vi).  
 (C) In-depth histopathology analyses of the GEM gliomas. Multipolar or abnormal mitoses (i, iii 
and xii), multinucleated giant cells (ii, iv, vi, vii and xiv), mitotic figures (x and xiii) and vascular 
proliferation (xv) are noted.  
(D) The frequency of the high-grade glioma and medulloblastoma formation in each mouse 
model. Two-tailed Fisher’s exact test is used to compare the groups. 
(E) Kaplan-Meier survival curves of the p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, and p53Δ5-6/Δ5-6; 
RictorΔ/Δ mice euthanized due to end-stage high-grade gliomas. 1 year of time is indicated with a 
vertical dashed line on the graph. The Mantel-Cox (Log-rank) test is used to compare the curves 
statistically. Scale bars, 50 µm (A-B), 25 µm (C). 
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Figure 6. Rictor-deficient GEM gliomas display reduced tumor proliferation accompanied 
by impaired mTORC1 and mTORC2 signaling pathways. 
 
(A) Genotyping of the glioma samples from p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, and p53Δ5-6/Δ5-6; 
RictorΔ/Δ mice. hGFAP-cre; p53flox/+; Rictorflox/+ normal brain tissue is used as a positive control 
(CTR) for p53 and Rictor genes, while cre-negative normal brain tissue is used as a negative 
control (CTR) for Cre band.  
(B-D) Western blotting analyses of the mTORC2 signaling pathway (B), Olig2, Erk, GSK-3β 
and c-Myc signaling (C), and mTORC1 signaling pathway (D) in GEM gliomas. Tissue samples 
include a normal cerebral cortex tissue (CTR) and high-grade gliomas from two p53Δ5-6/Δ5-6; 
Pten+/Δ, four p53Δ5-6/Δ5-6, eight p53Δ5-6/Δ5-6; Rictor+/Δ, and eight p53Δ5-6/Δ5-6; RictorΔ/Δ mice. 
Gliomas from p53Δ5-6/Δ5-6; Pten+/Δ mice are used as positive controls and the details about this 
mouse model is described in detail in the next sections of Chapter III. 
(E-F) Analyses of the cellular proliferation in GEM gliomas based on Ki-67 immunoreactivity 
(E) and the Ki-67+ cell percentage (F), which is calculated by the ratio of Ki-67+ cell number to 
the total cell number in 40X images. The images from each sample are taken from the regions 
that displayed the highest Ki-67 immunoreactivity. The images shown in the figure are picked 
from samples that have approximately average Ki-67+ percentage for each group. Scale bars, 50 
µm. 
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Figure 7. Expansion of the plausible early glioma-forming cells are inhibited by Rictor loss. 
 
(A-F) 6-7 months old control and mutant mice are injected with BrdU (10 mg/kg) five times 
every two hours. All the mice are sacrificed two hours after the last injection. 
(A) Various locations where p53+ cells are detected in the forebrain of 6-7 months old p53Δ5-6/Δ5-6 
and p53Δ5-6/Δ5-6; RictorΔ/Δ mice are listed.  
(B) The cells that might carry tumor-forming ability are detected by p53 and BrdU staining in 6-
7 months old p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; RictorΔ/Δ brains.  
(C-D) p53+ cells expanding outside of the germinal zone in p53Δ5-6/Δ5-6 brains (C) or restricted 
within the germinal zone in p53Δ5-6/Δ5-6; RictorΔ/Δ brains (D) are illustrated by p53, Olig2 and 
BrdU staining in 6-7 months old mice. White line indicates the RMS, yellow line indicates the 
p53+ and Olig2+ proliferating cell clusters. 
(E-F) The number of the total p53+ cells that remain in the germinal zone (i.e. SVZ/RMS) (E) or 
scattered and/or clustered outside the germinal zone (F) are quantified in 6-7 months old p53Δ5-
6/Δ5-6 and p53Δ5-6/Δ5-6; RictorΔ/Δ mice. The proliferation percentages of the p53+ cells (i.e. 
BrdU+p53+ / p53+) are also calculated using the samples that have at least 20 or more p53+ cells 
(scattered and/or clustered group) or at least 10 or more p53+ cells (SVZ/RMS group). Unpaired 
t-test is used to compare the groups. 
All the quantification data are presented as mean ± SD.  
Scale bars 250 µm. Ctx: Cerebral cortex, CC: Corpus callosum, RMS: Rostral migratory stream, 
LV: Lateral ventricle, OB: Olfactory bulb.   
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Figure 8. Rictor loss is mostly tolerated in the developing subventricular zone. 
 
(A) Whole-mount images of the PFA-fixed, 4-months old wild-type control, RictorΔ/Δ and p53Δ5-
6/Δ5-6; RictorΔ/Δ mice. 
(B-C) Brain (B) and body (C) weights of the wild-type control, RictorΔ/Δ and p53Δ5-6/Δ5-6; 
RictorΔ/Δ mice at P8, P16, P22 and 4-months (P120). 
(D) Proliferating cells and the overall structure of the P16 SVZ were compared between the 
control and mutant brains using Ki-67 and Ascl1 antibodies. Insets show higher magnification 
images. 
(E-F) Total Ki-67+ proliferating cells (E) and the Ki-67+/DAPI+ percentage (F) were examined in 
the SVZ of P16 brains.  
(G-I) Stem cells in the SVZ of P16 mice were examined using GFAP and Nestin antibodies (G). 
Total stem cell number (H) and their representation within the SVZ population was also 
measured (I).  
All the quantification data are presented as mean ± SD. Unpaired t-test is used for statistical 
comparison. Scale bars, 1 mm (A) and 100 µm (B and G). CC: Corpus callosum, RMS: Rostral 
migratory stream, LV: Lateral ventricle.  
	   87	  
2.4 References 
 
Alessi, D. R., Andjelkovic, M., Caudwell, B., Cron, P., Morrice, N., Cohen, P. and 
Hemmings, B. A. (1996). Mechanism of activation of protein kinase B by insulin and 
IGF-1. The EMBO journal 15, 6541-6551. 
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B. 
and Cohen, P. (1997). Characterization of a 3-phosphoinositide-dependent protein 
kinase which phosphorylates and activates protein kinase Balpha. Current biology : 
CB 7, 261-269. 
Altomare, D. A. and Testa, J. R. (2005). Perturbations of the AKT signaling pathway in 
human cancer. Oncogene 24, 7455-7464. 
Anker, L., Ohgaki, H., Ludeke, B. I., Herrmann, H. D., Kleihues, P. and Westphal, 
M. (1993). p53 protein accumulation and gene mutations in human glioma cell lines. 
International journal of cancer. Journal international du cancer 55, 982-987. 
Bellacosa, A., Kumar, C. C., Di Cristofano, A. and Testa, J. R. (2005). Activation of 
AKT kinases in cancer: implications for therapeutic targeting. Advances in cancer 
research 94, 29-86. 
Bhat, K. P., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., 
Hollingsworth, F., Wani, K., Heathcock, L., James, J. D., Goodman, L. D., et al. 
(2013). Mesenchymal differentiation mediated by NF-kappaB promotes radiation 
resistance in glioblastoma. Cancer cell 24, 331-346. 
Brennan, C. W., Verhaak, R. G., McKenna, A., Campos, B., Noushmehr, H., 
Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. 
(2013). The somatic genomic landscape of glioblastoma. Cell 155, 462-477. 
Brosh, R. and Rotter, V. (2009). When mutants gain new powers: news from the mutant 
p53 field. Nature reviews. Cancer 9, 701-713. 
Cancer Genome Atlas Research, N. (2008). Comprehensive genomic characterization 
defines human glioblastoma genes and core pathways. Nature 455, 1061-1068. 
Chernova, O. B., Hunyadi, A., Malaj, E., Pan, H., Crooks, C., Roe, B. and Cowell, J. 
K. (2001). A novel member of the WD-repeat gene family, WDR11, maps to the 
10q26 region and is disrupted by a chromosome translocation in human glioblastoma 
cells. Oncogene 20, 5378-5392. 
Chow, L. M., Endersby, R., Zhu, X., Rankin, S., Qu, C., Zhang, J., Broniscer, A., 
Ellison, D. W. and Baker, S. J. (2011). Cooperativity within and among Pten, p53, 
and Rb pathways induces high-grade astrocytoma in adult brain. Cancer cell 19, 305-
316. 
Cully, M., You, H., Levine, A. J. and Mak, T. W. (2006). Beyond PTEN mutations: the 
PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nature 
reviews. Cancer 6, 184-192. 
Foster, K. G. and Fingar, D. C. (2010). Mammalian target of rapamycin (mTOR): 
conducting the cellular signaling symphony. The Journal of biological chemistry 285, 
14071-14077. 
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., 
Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007). Malignant 
	   88	  
astrocytic glioma: genetics, biology, and paths to treatment. Genes & development 21, 
2683-2710. 
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J. H., 
Mullholland, D. J., Magnuson, M. A., Wu, H. and Sabatini, D. M. (2009). mTOR 
complex 2 is required for the development of prostate cancer induced by Pten loss in 
mice. Cancer cell 15, 148-159. 
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, 
J., Brown, M., Fitzgerald, K. J. and Sabatini, D. M. (2006). Ablation in mice of 
the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required 
for signaling to Akt-FOXO and PKCalpha, but not S6K1. Developmental cell 11, 
859-871. 
Hambardzumyan, D., Parada, L. F., Holland, E. C. and Charest, A. (2011). Genetic 
modeling of gliomas in mice: new tools to tackle old problems. Glia 59, 1155-1168. 
Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E. and Fuller, G. N. 
(2000). Combined activation of Ras and Akt in neural progenitors induces 
glioblastoma formation in mice. Nature genetics 25, 55-57. 
Huse, J. T., Holland, E. and DeAngelis, L. M. (2013). Glioblastoma: molecular 
analysis and clinical implications. Annual review of medicine 64, 59-70. 
Ichimura, K., Schmidt, E. E., Miyakawa, A., Goike, H. M. and Collins, V. P. (1998). 
Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor 
suppressor genes in the development of astrocytic gliomas of different malignancy 
grades. Genes, chromosomes & cancer 22, 9-15. 
Ikenoue, T., Inoki, K., Yang, Q., Zhou, X. and Guan, K. L. (2008). Essential function 
of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. 
The EMBO journal 27, 1919-1931. 
Inoki, K., Li, Y., Zhu, T., Wu, J. and Guan, K. L. (2002). TSC2 is phosphorylated and 
inhibited by Akt and suppresses mTOR signalling. Nature cell biology 4, 648-657. 
Koul, D., Shen, R., Bergh, S., Sheng, X., Shishodia, S., Lafortune, T. A., Lu, Y., de 
Groot, J. F., Mills, G. B. and Yung, W. K. (2006). Inhibition of Akt survival 
pathway by a small-molecule inhibitor in human glioblastoma. Molecular cancer 
therapeutics 5, 637-644. 
Kwon, C. H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D. K., Mason, R. P., 
Lee, E. Y., Wu, H. and Parada, L. F. (2008). Pten haploinsufficiency accelerates 
formation of high-grade astrocytomas. Cancer research 68, 3286-3294. 
Laplante, M. and Sabatini, D. M. (2009). mTOR signaling at a glance. Journal of cell 
science 122, 3589-3594. 
Li, D. M. and Sun, H. (1997). TEP1, encoded by a candidate tumor suppressor locus, is 
a novel protein tyrosine phosphatase regulated by transforming growth factor beta. 
Cancer research 57, 2124-2129. 
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, 
C., Rodgers, L., McCombie, R., et al. (1997). PTEN, a putative protein tyrosine 
phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 
1943-1947. 
Louis, D. N. (2006). Molecular pathology of malignant gliomas. Annual review of 
pathology 1, 97-117. 
	   89	  
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., 
Scheithauer, B. W. and Kleihues, P. (2007). The 2007 WHO classification of 
tumours of the central nervous system. Acta neuropathologica 114, 97-109. 
Louis, D. N., von Deimling, A., Chung, R. Y., Rubio, M. P., Whaley, J. M., Eibl, R. 
H., Ohgaki, H., Wiestler, O. D., Thor, A. D. and Seizinger, B. R. (1993). 
Comparative study of p53 gene and protein alterations in human astrocytic tumors. 
Journal of neuropathology and experimental neurology 52, 31-38. 
Magee, J. A., Ikenoue, T., Nakada, D., Lee, J. Y., Guan, K. L. and Morrison, S. J. 
(2012). Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem 
cell self-renewal and leukemia suppression. Cell stem cell 11, 415-428. 
Masui, K., Tanaka, K., Akhavan, D., Babic, I., Gini, B., Matsutani, T., Iwanami, A., 
Liu, F., Villa, G. R., Gu, Y., et al. (2013). mTOR complex 2 controls glycolytic 
metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. 
Cell metabolism 18, 726-739. 
Momota, H., Nerio, E. and Holland, E. C. (2005). Perifosine inhibits multiple signaling 
pathways in glial progenitors and cooperates with temozolomide to arrest cell 
proliferation in gliomas in vivo. Cancer research 65, 7429-7435. 
Motomura, K., Mittelbronn, M., Paulus, W., Brokinkel, B., Keyvani, K., Sure, U., 
Wrede, K., Nakazato, Y., Tanaka, Y., Pierscianek, D., et al. (2012). DMBT1 
homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical 
outcome. Journal of neuropathology and experimental neurology 71, 702-707. 
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, 
B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010). 
Identification of a CpG island methylator phenotype that defines a distinct subgroup 
of glioma. Cancer cell 17, 510-522. 
Ozawa, T., Riester, M., Cheng, Y. K., Huse, J. T., Squatrito, M., Helmy, K., Charles, 
N., Michor, F. and Holland, E. C. (2014). Most human non-GCIMP glioblastoma 
subtypes evolve from a common proneural-like precursor glioma. Cancer cell 26, 
288-300. 
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., 
Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L., et al. (2008). An integrated 
genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812. 
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, 
H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014). Single-
cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 
344, 1396-1401. 
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., 
Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006). Molecular 
subclasses of high-grade glioma predict prognosis, delineate a pattern of disease 
progression, and resemble stages in neurogenesis. Cancer cell 9, 157-173. 
Potter, C. J., Pedraza, L. G. and Xu, T. (2002). Akt regulates growth by directly 
phosphorylating Tsc2. Nature cell biology 4, 658-665. 
Sarbassov, D. D., Guertin, D. A., Ali, S. M. and Sabatini, D. M. (2005). 
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 
307, 1098-1101. 
	   90	  
Scheid, M. P., Marignani, P. A. and Woodgett, J. R. (2002). Multiple phosphoinositide 
3-kinase-dependent steps in activation of protein kinase B. Molecular and cellular 
biology 22, 6247-6260. 
Sharma, S. V. and Settleman, J. (2007). Oncogene addiction: setting the stage for 
molecularly targeted cancer therapy. Genes & development 21, 3214-3231. 
Sottoriva, A., Spiteri, I., Piccirillo, S. G., Touloumis, A., Collins, V. P., Marioni, J. 
C., Curtis, C., Watts, C. and Tavare, S. (2013). Intratumor heterogeneity in human 
glioblastoma reflects cancer evolutionary dynamics. Proceedings of the National 
Academy of Sciences of the United States of America 110, 4009-4014. 
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, 
T., Ruland, J., Penninger, J. M., Siderovski, D. P. and Mak, T. W. (1998). 
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor 
PTEN. Cell 95, 29-39. 
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., 
Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997). 
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 
10q23.3 that is mutated in multiple advanced cancers. Nature genetics 15, 356-362. 
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, 
R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009). Effects of 
radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone 
on survival in glioblastoma in a randomised phase III study: 5-year analysis of the 
EORTC-NCIC trial. The Lancet. Oncology 10, 459-466. 
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D. A., Jones, D. T., Konermann, 
C., Pfaff, E., Tonjes, M., Sill, M., Bender, S., et al. (2012). Hotspot mutations in 
H3F3A and IDH1 define distinct epigenetic and biological subgroups of 
glioblastoma. Cancer cell 22, 425-437. 
Testa, J. R. and Bellacosa, A. (2001). AKT plays a central role in tumorigenesis. 
Proceedings of the National Academy of Sciences of the United States of America 98, 
10983-10985. 
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., 
Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010). Integrated genomic 
analysis identifies clinically relevant subtypes of glioblastoma characterized by 
abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 17, 98-110. 
Wang, H., Wang, H., Zhang, W., Huang, H. J., Liao, W. S. and Fuller, G. N. (2004). 
Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse 
gliomas. Laboratory investigation; a journal of technical methods and pathology 84, 
941-951. 
Wang, Y., Yang, J., Zheng, H., Tomasek, G. J., Zhang, P., McKeever, P. E., Lee, E. 
Y. and Zhu, Y. (2009). Expression of mutant p53 proteins implicates a lineage 
relationship between neural stem cells and malignant astrocytic glioma in a murine 
model. Cancer cell 15, 514-526. 
Weinstein, I. B. (2002). Cancer. Addiction to oncogenes--the Achilles heal of cancer. 
Science 297, 63-64. 
	   91	  
Weinstein, I. B. and Joe, A. K. (2006). Mechanisms of disease: Oncogene addiction--a 
rationale for molecular targeting in cancer therapy. Nature clinical practice. 
Oncology 3, 448-457. 
Wen, P. Y. and Kesari, S. (2008). Malignant gliomas in adults. The New England 
journal of medicine 359, 492-507. 
Wen, P. Y., Lee, E. Q., Reardon, D. A., Ligon, K. L. and Alfred Yung, W. K. (2012). 
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-
oncology 14, 819-829. 
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A. J., Perry, S. 
R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008). p53 and Pten control neural and 
glioma stem/progenitor cell renewal and differentiation. Nature 455, 1129-1133. 
Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D. K., Mason, R. P., Messing, A. 
and Parada, L. F. (2005). Early inactivation of p53 tumor suppressor gene 
cooperating with NF1 loss induces malignant astrocytoma. Cancer cell 8, 119-130. 
Zhuo, L., Theis, M., Alvarez-Maya, I., Brenner, M., Willecke, K. and Messing, A. 
(2001). hGFAP-cre transgenic mice for manipulation of glial and neuronal function in 
vivo. Genesis 31, 85-94. 
 
	   92	  
 
 
Chapter III: Rictor/mTORC2 deficiency facilitates mutant-p53 
mediated medulloblastoma formation 
 
 
 
3.1 Introduction 
 
In contrast to glioblastoma, which mainly occurs in adulthood, medulloblastoma is 
largely a childhood malignancy, as it predominantly occurs in infants (≤ 3 years old) and 
children (4-17 years old). Despite the increased survival rates, a significant portion of the 
treated patients suffers from long-term adverse sequelae, including neurological, 
neuroendocrine and psychosocial deficits, as well as various problems in fertility, 
cardiopulmonary fitness, hearing, and physical performance (Gajjar and Robinson, 2014; 
Northcott et al., 2012a). Similar to glioblastomas, molecular stratification of 
medulloblastomas is critical in the comprehension of the disease and implementation of 
targeted therapies based on the genetic makeup that defines individual cases (Northcott et 
al., 2012a; Taylor et al., 2012). The current consensus of molecular classification predicts 
four subgroups with specific mutations and genetic alterations, each of which are 
associated with different survival rates (Jones et al., 2012; Northcott et al., 2011; 
Northcott et al., 2012b; Pugh et al., 2012; Robinson et al., 2012; Thompson et al., 2006). 
WNT medulloblastomas (10%) have the best outcome with 5-year overall survival (OS) 
of 95% followed by SHH (30%) and Group-4 (35%) medulloblastomas with 
approximately 75% OS. The worst outcome was seen in Group-3 or MYC (25%) patients 
with approximately 50% OS (Gajjar and Robinson, 2014; Kool et al., 2012; Northcott et 
al., 2012a). 
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The role of PI3K/AKT signaling in medulloblastoma formation, however, is relatively 
less understood. Previous research has revealed that mutations and copy number 
alterations in key pathway components, including PTEN, PIK3CA, IGF1R and IRS2 are 
mostly enriched in SHH medulloblastomas (Northcott et al., 2012a; Northcott et al., 
2012b; Robinson et al., 2012). Nevertheless, these alterations are still rare compared to 
glioblastomas, as only 10% of the SHH medulloblastomas have copy number changes 
associated with PI3K/RTK signaling (Northcott et al., 2012b). Especially SHH 
medulloblastomas in children between the ages of 3-18 (childhood SHH 
medulloblastomas, thereafter) exhibited a virtually absence of mutations in PIK3CA, 
PTEN and PIK3C2G genes, making these alterations restricted to adults (≥ 18 years old) 
and infants (< 3 years old) (Kool et al., 2014). Consistently, only less than 10% of the 
childhood SHH medulloblastomas are found to be immunoreactive to pAKTS473, while 
majority of the positive cases are found in the adult tumors (Kool et al., 2014). These 
findings underline the essential roles of AKT signaling in adult tumors (e.g. 
glioblastoma), while raise questions about its roles in pediatric tumors.  
 
Interestingly, almost 50% of the childhood SHH medulloblastomas had TP53 alterations 
in contrast to their relatively normal PI3K/AKT signaling. Similar alterations in TP53 
gene are virtually absent in the remaining SHH medulloblastoma patients, as well as 
Group-3 and Group-4 tumors (Kool et al., 2014; Zhukova et al., 2013). This finding has 
particular clinical importance, as TP53-mutated medulloblastomas observed specifically 
in SHH children have an early recurrence and extremely poor outcome, making TP53 
status the most decisive adverse prognostic factor (Tabori et al., 2010; Zhukova et al., 
2013). Subsequent studies have revealed that TP53-mutant SHH medulloblastomas 
undergo a chromosomal phenomenon called “chromothripsis”, which results in 
catastrophic DNA rearrangements (Jones and Jallepalli, 2012; Rausch et al., 2012; 
Stephens et al., 2011), as well as amplifications in GLI2 and N-MYC genes (Jones and 
Jallepalli, 2012; Rausch et al., 2012). These genomic events have also been associated 
with poor clinical outcome and resistance to SMO-inhibitors (Kool et al., 2014; Northcott 
et al., 2012a; Northcott et al., 2012b; Pfister et al., 2009).  
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In the present study, I aimed to understand the role of TP53 alterations in the context of 
PI3K/AKT signaling during the medulloblastoma formation. To this end, I utilized the 
same mouse models that are described in Chapter II. As discussed earlier, genetic 
deletion of Rictor, leading to an alleviated PI3K/Akt signaling, was sufficient to inhibit 
and/or delay mutant-p53 driven gliomagenesis. However, removal of this well-known 
oncogenic signal at embryonic stages significantly increased medulloblastoma frequency, 
suggesting that Rictor/mTORC2, and thus PI3K/Akt signaling, has opposite roles in 
glioblastoma and medulloblastoma formation. Our further analyses in this chapter have 
revealed that Rictor loss increases a pool of cerebellar granule neuron precursor cells 
with a longer susceptible window, leading to an increased incidence of mutant-p53 driven 
medulloblastoma formation. Subsequently, we showed that these medulloblastomas were 
characterized by their unique genomic and chromosomal alterations that resemble a 
subgroup of human medulloblastomas with poor clinical outcome. This study, combined 
with the previous chapter, underscores the differential functions of an important signaling 
pathway in adult and pediatric brain tumors, emphasizing the context-dependent roles of 
molecular alterations. 
 
3.2 Results 
 
3.2.1 Mutant-p53 mediated medulloblastoma formation is increased upon Rictor loss 
 
As described in Chapter II, Rictor loss had a robust suppressive effect on mutant-p53 
driven gliomagenesis. However, more than half of the p53Δ5-6/Δ5-6; RictorΔ/Δ mice still 
succumbed to death due to severe medulloblastomas as there was a significant increase in 
the medulloblastoma formation from 8% and 23% observed in p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-
6; Rictor+/Δ mice to 53% in p53Δ5-6/Δ5-6; RictorΔ/Δ (Figures 5D and 5E). Though the 
survival rate of medulloblastoma-bearing p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; Rictor+/Δ mice were 
similar, there was a marginal increase in p53Δ5-6/Δ5-6; RictorΔ/Δ mice (Figure 9A). Almost 
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all of the p53Δ5-6/Δ5-6; RictorΔ/Δ medulloblastomas had either large cell/anaplastic or 
classic pathology characterized by a high density of tumor cells with dark nuclei making 
them look like “blue tumors”, nuclear moldings, pseudo-palisading tumor cells, Rosette 
structures, small round or ellipsoid cells, carrot-shaped nuclei, and apoptotic cells 
(Figures 9B and 9C) (Gilbertson and Ellison, 2008; Louis et al., 2007). These tumors 
were sometimes immunoreactive to Synaptophysin, indicative of their neuronal 
differentiation, and sometimes to GFAP, indicating glial differentiation (Figures 9B and 
9C). Similar to high-grade gliomas, GEM medulloblastomas were also characterized by 
the overexpression of the mutant-p53 protein (Figures 9B and 9C). More interestingly, as 
opposed to gliomas, all of the medulloblastomas notably expressed Pax6, while Olig2 
expression was either absent or very minimal  (Figures 9D-9F). Thus, Pax6 and Olig2 
expression in brain tumors were mutually exclusive and Pax6 specifically labeled 
medulloblastomas while Olig2 was a distinguishing marker for high-grade gliomas 
regardless of their localization within the brain (Figures 9E and 9F).  
 
My further analyses of p53Δ5-6/Δ5-6; RictorΔ/Δ medulloblastomas revealed a minor 
population of Sox2+ cells within the tumor mass, which were recently described as tumor 
propagating cells and are resistant to current treatments (Figures 10A-10C) (Vanner et al., 
2014). While some of the Sox2+ cells coexpressed Pax6 protein at high levels, some of 
them had lower or no Pax6 expression (i.e. Sox2+Pax6high and Sox2+Pax6low or 
Sox2+Pax6-), suggesting heterogeneity and possibly a complex hierarchy within a single 
tumor (Figures 10A and 10D). Indicative of their quiescent nature, Sox2+ cells were 
comparatively less proliferative and they rarely expressed mutant-p53 proteins (Figures 
10B-10D). Interestingly, I detected a significant correlation between mutant-p53 
expression and the proliferation in medulloblastomas. More specifically, the mutant-p53 
expressing Sox2+ cell percentage (Sox2+p53+ / Sox2+) was significantly correlated with 
the proliferating Sox2+ cell percentage (Sox2+Ki-67+ / Sox2+) within the whole Sox2+ cell 
population (Figure 10E). One possible explanation is that quiescent Sox2+ cells trigger 
p53-signaling pathway upon induction of cellular proliferation mechanisms. These results 
overall suggest that even though Rictor deficiency plays an anti-glioma role in adulthood, 
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its loss at the embryonic stages may facilitate the formation of the mutant-p53 driven 
medulloblastoma with distinctive histopathologic and clinical characteristics. 
 
3.2.2 Pten mutation cooperates with Rictor-deficiency in facilitating mutant-p53 
induced medulloblastoma formation 
 
Next, I wanted to further test my findings utilizing additional mouse models where I 
introduced a heterozygous Pten mutation into each p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, and 
p53Δ5-6/Δ5-6; RictorΔ/Δ mouse model, and the new mouse models were called p53Δ5-6/Δ5-6; 
Pten+/Δ, p53Δ5-6/Δ5-6; Pten+/Δ; Rictor+/Δ, and p53Δ5-6/Δ5-6; Pten+/Δ; RictorΔ/Δ, respectively 
(Figure 11A). All three new models with brain tumors showed comparable survival rates 
(Figure 11B), though they did live significantly shorter than their counterparts lacking the 
heterozygous Pten mutation (compare with Figure 4D). This finding suggests that the 
heterozygous Pten mutation itself may be an oncogenic signal, regardless of the Rictor or 
Akt status. Similar to p53Δ5-6/Δ5-6 mice, p53Δ5-6/Δ5-6; Pten+/Δ tumors were primarily high-
grade gliomas (83%), even though there was a slight increase in the hindbrain 
tumorigenesis (Figures 11C and 11D, compare with Figures 4E and 5D). Interestingly, 
p53Δ5-6/Δ5-6; Pten+/Δ tumors were enriched in the hindbrain, and medulloblastoma 
incidence increased up to 50%, which is slightly different than our observations in p53Δ5-
6/Δ5-6; Rictor+/Δ mice (Figures 11C, 11D, compare with Figures 4E and 5D). Remarkably, 
and consistent with the differential role of Rictor-deficiency in brain tumorigenesis, 
p53Δ5-6/Δ5-6; Pten+/Δ; RictorΔ/Δ mice predominantly formed hindbrain tumors that were 
mostly medulloblastomas (86% and 79%, respectively), and only 26% of the mice 
formed high-grade gliomas (Figures 11C and 11D). Similar to the first group of mice that 
we studied, all of the p53Δ5-6/Δ5-6; Pten+/Δ, p53Δ5-6/Δ5-6; Pten+/Δ; Rictor+/Δ, and p53Δ5-6/Δ5-6; 
Pten+/Δ; RictorΔ/Δ GEM gliomas exhibited distinctive histology, including multinucleated 
tumor cells, increased mitotic activity, nuclear atypia, horseshoe-like structures and 
immunoreactivity to Olig2, GFAP and p53 (Figure 11E). medulloblastomas displayed 
classic or L/A type features including dense nuclei, nuclear molding, Rosette structure, 
apoptotic cells, carrot-shaped nuclei and immunoreactivity to Synaptophysin and p53 
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(Figure 11E). While these tumors were mainly Olig2-, GFAP immunoreactivity was 
observed occasionally (Figure 11E). As expected, Akt signaling was elevated in both 
p53Δ5-6/Δ5-6; Pten+/Δ and p53Δ5-6/Δ5-6; Pten+/Δ; Rictor+/Δ, however virtually inhibited in 
p53Δ5-6/Δ5-6; Pten+/Δ; RictorΔ/Δ gliomas. Pten expression was significantly reduced in all 
glioma models (Figure 11F). These results confirm my previous findings and suggest that 
Pten mutation is a key oncogenic event for both gliomas and medulloblastomas, however 
additional Rictor deficiency can inhibit/delay high-grade glioma formation while 
facilitating the medulloblastoma formation. 
 
3.2.3 Proliferating granule neuron precursors are maintained in Rictor-deficient 
cerebella 
 
Oncogenic activation, but not inhibition, of mTORC2 signaling has been previously 
associated with many cancer types including glioblastoma, prostate cancer, and leukemia, 
therefore, it was surprising to see that deletion of Rictor gene facilitated medulloblastoma 
formation. Thus, I investigated potential mechanisms by which Rictor loss promotes 
medulloblastoma development. Given that medulloblastoma arises from the developing 
cerebellum, I determined the consequences of Rictor loss during the cerebellar 
development. At postnatal day 16 (P16), granule neuron precursors (GNPs) in the 
external granular layer (EGL) – a cell-of-origin of medulloblastoma, ceased proliferation, 
became differentiated and migrated out of the EGL in all but two folia of the control 
cerebellum (Folium-6 and -10, F6 and F10) (Figure 12A) (White and Sillitoe, 2013). 
Remarkably, in addition to the actively proliferating BrdU+ cells seen in control F6 and 
F10, both RictorΔ/Δ and p53Δ5-6 Δ5-6; RictorΔ/Δ mutants had ectopically proliferating BrdU+ 
cells at the superficial surface of the EGL in virtually all of the cerebellar folia (Figures 
12A and 12B). Overall, we observed a 2-fold increase in the total number of BrdU+ cells 
and 3-fold increase in the number per unit area in Rictor mutants compared to the control 
cerebella (Figures 12D and 12E). Ectopically proliferating BrdU+ cells were also 
observed in p53Δ5-6 cerebella, despite that both the total number and the number per unit 
area were not as high as the Rictor-deficient cerebella (Figures 12A, 12B, 12D and 12E). 
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Thus, I concluded that the increase in the p53Δ5-6/Δ5-6RictorΔ/Δ cerebellum was mainly 
caused by Rictor loss. Of note, compared to control and p53Δ5-6/Δ5-6 cerebella, Rictor-
deficient cerebella, including both RictorΔ/Δ and p53Δ5-6/Δ5-6; RictorΔ/Δ, were significantly 
smaller accompanied by a reduction in brain weight by Rictor loss during the postnatal 
stages (Figures 12C, 8A and 8B). In all of the mutant cerebella, the ectopically 
proliferating cells expressed high levels of neural lineage marker Pax6 (Engelkamp et al., 
1999; Yamasaki et al., 2001), suggesting that these cells are GNPs that failed to exit cell 
cycle and, remained in the EGL (Figure 12A).  
 
Subsequently, I analyzed three individual folia (F-5/6, F-9/10a and F-10b) in order to 
confirm my findings. I found that EGL-associated Pax6+ cell number was notably 
increased in all three folia of both RictorΔ/Δ and p53Δ5-6/Δ5-6; RictorΔ/Δ cerebella compared 
to wild type controls. Though, p53Δ5-6/Δ5-6; RictorΔ/Δ cerebella had slightly higher Pax6+ 
cells especially in F-9/10a and F-10b than RictorΔ/Δ cerebella (Figures 13A-13D). Similar 
increase was also observed in p53Δ5-6/Δ5-6 cerebella, although it was mostly pronounced in 
F-10b (Figure 13D). I also detected proliferating Pax6+BrdU+ cells in all three folia of 
both Rictor-deficient cerebella, while there was already a reduction in F-5/6 of p53Δ5-6/Δ5-
6 cerebellum (Figures 13A-13D). Together, these results suggest that Rictor deficiency 
alone can lead to the formation of ectopically proliferating GNPs when control cells have 
already differentiated.  
 
3.2.4 A minor population of GNPs requires intact mTORC2 signaling for proper 
differentiation 
 
In order to better understand how Rictor deficiency led to ectopically proliferating GNPs 
in the cerebellum, I performed a BrdU pulse-chase experiment where mice were injected 
with BrdU at P15 and sacrificed at P17. I then determined whether the proliferating cells 
at P15 (i.e. BrdU+) exited  (BrdU+Ki-67-) or remained in (BrdU+Ki-67+) cell cycle after 
two days (Figure 14A). As I aimed to specifically determine the role of Rictor deficiency 
in ectopic GNPs, I excluded p53Δ5-6/Δ5-6 mice from this analysis. At P17, there were 
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almost no proliferating cells (Ki67+) in the control cerebellum except in the most 
posterior folium (F-10b), whereas a considerable number of proliferating cells were 
observed in Rictor-deficient cerebella regardless of the presence or absence of p53 
(Figure 14B). Moreover, many of the proliferating cells in Rictor-deficient cerebella were 
labeled by BrdU, indicating that the proliferating GNPs in Rictor-deficient cerebella at 
P15 failed to exit the cell cycle two days later at P17, as did the wild type control GNPs 
(Figure 14C). Consistently, the ratio of the cells exiting the cell cycle to the cells 
remaining in the cell cycle was significantly reduced in RictorΔ/Δ cerebella and also 
noticeably smaller in the p53Δ5-6 Δ5-6; RictorΔ/Δ compared to controls (Figure 14D). These 
results suggest that Rictor is required for a subset of GNPs to undergo timely cell-cycle 
exit and become differentiated during postnatal cerebellar development.  
 
Consistent with the role of Rictor/mTORC2 in the normal differentiation of GNPs, 
pAktS473 levels were largely absent in the highly proliferative EGL at P8, and reached a 
very high level in newly differentiated neurons located in the Molecular Layer (ML) 
(Figures 14E and 14G). Once these neurons were fully differentiated and migrated to the 
IGL, pAktS473 levels were kept at an intermediate level (Figures 14E and 14G). In 
contrast, Pten had an opposite expression pattern: while it had an intermediate level in the 
ML, it reached a very high level in the IGL (Figures 14E and 14G). As expected, pAktS473 
levels in the RictorΔ/Δ was not detectable in any part of the cerebellum except for the 
Purkinje cells, which were not targeted by the cre-flox system (Figures S5E and S5F) 
(Zhuo et al., 2001). These results suggest that Rictor/mTORC2-dependent Akt activation 
is required for a subset of GCPs to undergo timely cell-cycle exit and become 
differentiated in the postnatal developing cerebellum. 
 
3.2.5 Ectopically proliferating GNPs transform into early-tumor forming cells in the 
absence of Rictor/mTORC2 and p53 
 
I next analyzed cerebella at later stages to determine whether the ectopically proliferating 
cells in the EGL provided any indication of early tumor initiation process. I first 
	   100	  
examined the mice at P22 when the wild type control cerebellum was completely formed, 
and there were virtually no proliferating cells in the EGL (Figures 15A-15D) (White and 
Sillitoe, 2013). Remarkably, p53Δ5-6/Δ5-6; RictorΔ/Δ mice were the only mutants that still 
had BrdU+Pax6+ proliferating cells in all three analyzed folia, while only half of the 
p53Δ5-6/Δ5-6 mice had a similar population and they were restricted to F-10b (Figures 15A-
15D). I also observed BrdU+Pax6+ cells in the RictorΔ/Δ cerebella, however the total 
number was noticeably smaller than the p53Δ5-6/Δ5-6; RictorΔ/Δ cerebella (Figures 15A-
15D). Importantly, Pax6+ cells were abnormally accumulated in the EGL and ML of both 
Rictor-deficient cerebella, of which the p53Δ5-6/Δ5-6RictorΔ/Δ cerebellum exhibited a 
greater increase (Figures 15D and 15E). Given no abnormal accumulation of Pax6+ cells 
in the EGL and ML of the p53Δ5-6/Δ5-6 cerebellum, these results are most consistent with a 
model wherein Rictor loss delayed the timely differentiation of a subset of GNPs, 
triggering a p53-dependent cell-cycle arrest/differentiation response that leads to 
accumulation of differentiated Pax6+ cells in the EGL and ML of the RictorΔ/Δ 
cerebellum. However, upon loss of both Rictor and p53, a subset of proliferating 
BrdU+Pax6+ cells were maintained in the EGL and ML of the p53Δ5-6/Δ5-6RictorΔ/Δ 
cerebellum. It is worth noting that even in the p53Δ5-6/Δ5-6; RictorΔ/Δ mice, the total 
number of the proliferating cells reduced dramatically from P16 to P22, indicating the 
presence of p53-independent pathways that induce cell cycle exit/differentiation response 
in p53Δ5-6/Δ5-6; RictorΔ/Δ cerebella (Figure 16F).  
 
To provide additional support for this model, I examined the expression of mutant p53 
protein that was shown to accumulate at a high level upon oncogenic stress (Wang et al., 
2009). I analyzed P16, P22 and P60 cerebella, and did not detect p53 expression in the 
control and RictorΔ/Δ cerebella, as none of these mice formed brain tumors throughout 
their life (Figure 16D). However, p53+ GNPs were readily detected in p53Δ5-6/Δ5-6 and 
p53Δ5-6/Δ5-6RictorΔ/Δ cerebella as early as P16 (Figures 16A and 16E). Remarkably, with 
the maturation of the cerebellum from P16 to P22, 4/5 of the p53Δ5-6/Δ5-6RictorΔ/Δ mice 
maintained a significant number of p53+ cells in their cerebella, however these cells 
disappeared in 3/4 of the p53Δ5-6/Δ5-6 cerebella (Figures 16B, 16C and 16E) (images are 
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provided for only p53Δ5-6/Δ5-6RictorΔ/Δ cerebella). Importantly, when the mice reached 
P60, I still detected p53+ cells in 4/7 p53Δ5-6/Δ5-6RictorΔ/Δ mice (Figures 16D and 16E). As 
most of the p53+ cells already disappeared in P22 p53Δ5-6/Δ5-6 cerebella, I did not further 
analyze p53Δ5-6/Δ5-6 mice at P60. These results were, interestingly, in contrast to my 
earlier findings where p53Δ5-6/Δ5-6 mice were characterized with the p53+ cells scattered 
around various places of the forebrain, while only one p53Δ5-6/Δ5-6RictorΔ/Δ mouse 
displayed a comparable phenotype, underlining the opposite roles of Rictor in glioma 
forming cells versus medulloblastoma forming cells (Figure 7A).  
 
While the proliferating BrdU+ cells in the EGL of the p53Δ5-6/Δ5-6; RictorΔ/Δ mice reduced 
over time (Figure 16F), the percentage of p53+ cells within this population increased to 
90%, suggesting that there was a clonal expansion of the p53+ cells from P16 to P60, 
while the remaining proliferating cells disappeared through various mechanisms such as 
differentiation (Figure 16G). It is worth noting that 4/7 of the p53Δ5-6/Δ5-6; RictorΔ/Δ mice 
maintained p53+ cells in the EGL - a ratio similar to the medulloblastoma penetrance 
observed in this mouse model (Figures 16G and 5D). Together, these results suggest that 
the delay in timely differentiation of GNPs caused by Rictor loss increases a pool of 
targeted cells with a longer susceptible window, leading to an increased incidence of 
mutant-p53 driven medulloblastoma development (Figure 17). 
 
As described above, distinct regulation of the tumor-initiating cell pools by 
Rictor/mTORC2 signaling elucidates the opposing effects of Rictor on gliomagenesis 
versus medulloblastoma formation. We found that Rictor/mTORC2 deficiency reduces 
the number and proliferation of the glioma-initiating progenitor cells in the forebrain, 
while it prolongs the ectopic presence of the proliferating progenitor cells in the 
cerebellum. Thus, our study here demonstrates a recently identified correlation between 
the total number of divisions in various stem cell pools and the lifetime risk of cancers in 
respective organs (Tomasetti and Vogelstein, 2015). 
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3.2.6 Mutant-p53 induced medulloblastomas share molecular events with Ptch1+/- 
tumors 
 
Having shown that Rictor/mTORC2 deficiency can facilitate mutant-p53 induced 
medulloblastoma formation, I then aimed to characterize the molecular signatures of the 
tumors in this novel model. Since TP53 mutation has been mostly associated with the 
Sonic Hedgehog-group medulloblastomas (SHH medulloblastomas) (Jones et al., 2012; 
Kool et al., 2014; Zhukova et al., 2013), I included Ptch1+/- medulloblastoma samples 
(i.e. Ptch1+/-, p53Δ5-6/Δ5-6; Ptch1+/-, and p53Δ5-6/R172P; Ptch1+/-) into my analyses. My 
laboratory colleague Daniel M. Triesman generously provided these Ptch1+/- 
medulloblastoma samples. As predicted, all of the p53Δ5-6/Δ5-6; RictorΔ/Δ 
medulloblastomas lacked pAktS473 and also pAktT308 (Figure 18A). As opposed to GEM 
high-grade gliomas, pAkt levels were very low in the majority of the p53Δ5-6/Δ5-6 and 
p53Δ5-6/Δ5-6; Rictor+/Δ medulloblastomas, and more importantly, all of the Ptch1+/- 
medulloblastomas (Figure 18A). This finding is particularly interesting because neither 
p53Δ5-6/Δ5-6 nor Ptch1+/- medulloblastomas had any reduction in Rictor expression, and 
p53Δ5-6/Δ5-6; Rictor+/Δ medulloblastomas had only about 50% decrease (Figure 18A). 
These results support the model that low levels of Akt activity promote medulloblastoma 
development.  
 
While Olig2 expression was uniformly absent in medulloblastoma samples as we noted 
earlier (Figures 9C-9F), Gli1 expression was easily detectable in many samples (Figure 
18A). I, therefore, extended my analyses to other genes associated with Shh-signaling, 
and found that all of the medulloblastoma samples had significant Gli1, Gli2, N-Myc and 
Atoh1 expression - very similar to the Ptch1+/- samples (Figure 18B). Surprisingly, Ptch1 
expression was elevated in many p53Δ5-6/Δ5-6; RictorΔ/Δ medulloblastomas raising the 
question of whether they carried loss-of-function mutations in this gene (Figure 18C). Of 
note, c-Myc expression in the p53Δ5-6/Δ5-6RictorΔ/Δ medulloblastomas was not as 
consistently high as Ptch1+/- medulloblastomas, though both groups exhibited elevated 
levels of Ezh2 expression. I did not observe a consistent pattern across the 
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medulloblastoma samples in terms of pErk1/2 levels, however its expression was mostly 
lower than the glioma samples (Figure 18D). Together, these results suggest that mutant-
p53 induced medulloblastomas are characterized by Shh-signature gene expression 
similar to the Ptch1+/- tumors, and that the absence of pAkt is a characteristic feature of 
this group of tumors regardless of the Rictor and p53 status. 
 
3.2.7 Rictor deficiency facilitates mutant-p53 mediated medulloblastomas that 
resemble human SHH medulloblastomas  
 
Previous studies identified distinct molecular variants of medulloblastomas named after 
the important signaling pathways associated with them and current consensus categorizes 
the medulloblastomas into four: WNT, SHH, Group C (or MYC) and Group D (Kool et 
al., 2008; Northcott et al., 2011; Taylor et al., 2012; Thompson et al., 2006). Expression 
of the Shh-related genes in mutant-p53 mediated medulloblastomas raised the question of 
whether these tumors belonged to the SHH medulloblastomas. In order to answer this 
question, we analyzed the gene expression prolife of our samples in comparison with 
previously determined mouse SHH medulloblastomas, Group C medulloblastomas, 
GNPs, and normal brain tissue. This part of the project was carried out as collaboration 
with the scientists at the German Cancer Research Center (DKFZ), Heidelberg, Germany. 
More specifically, I collaborated with Dr. Stefan M. Pfister, Dr. Marcel Kool, Dr. 
Sebastian Stark and Susanne Gröbner. 
 
Our results showed that 16/22 of the analyzed medulloblastoma samples were strongly 
associated with SHH medulloblastomas, and also shared similarity with the GNP 
expression profile (Figure 19A), consistent with the previous findings showing that SHH-
medulloblastomas arise from neural lineage committed GNPs (Gibson et al., 2010; 
Schuller et al., 2008; Yang et al., 2008). We did not observe such significant resemblance 
between our samples and the Group C tumors, and the normal tissue samples had a 
significantly distinct profile. (Figure 19A). The remaining 6/22 of our medulloblastoma 
samples shared similarity with the normal tissues, yet were still characterized by the 
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expression of Shh-specific genes including Otx1, Pdlim3, Boc, Atoh1, Sfrp1 and Gli1, 
suggesting that these samples may have been contaminated with the normal tissue during 
the dissection procedures (Figures 19A and 19B). When we focused on the expression of 
Gli1, Gli2, Atoh1 and Sfrp1 - four of the most characteristic genes in SHH 
medulloblastomas -, we found that all of our samples were intermixed with the previously 
identified SHH medulloblastomas with significant expression of these Shh-marker genes 
(Figure 19C). Of note, there was no difference between the mutant-p53 mediated 
medulloblastomas in terms of Rictor status, as they all had similar levels of Shh-signature 
gene expression (Figures 19A and 19D). These results overall suggest that Rictor loss 
facilitates mutant-p53 driven medulloblastomas that are most similar to SHH 
medulloblastomas in humans. 
 
3.2.8 Rictor-deficient medulloblastomas are characterized by distinctive genomic 
and chromosomal abnormalities associated with poor clinical outcomes 
 
Approximately 21% of the human SHH medulloblastomas carry TP53 mutations, and 
almost all of these patients are children between the ages of 5 and 18 years (Zhukova et 
al., 2013). It has been reported that childhood medulloblastomas with TP53 mutations 
also harbored N-MYC and/or GLI2 amplifications rendering them resistant to 
Smoothened inhibitors (Kool et al., 2014). A recent study also underlined the combined 
effects of TP53 mutation and N-MYC amplification in relapse medulloblastomas that 
correlated with rapid disease progression (Hill et al., 2015). I, therefore, tested whether 
our GEM medulloblastomas carried such genomic abnormalities. I first performed a 
series of RT-PCR experiments using tumor genomic DNA as template. I calculated the 
copy numbers of N-Myc and Gli2 genes in comparison to two internal reference genes (β-
Actin in chr5 and Gapdh in chr7), and I included Ptch1+/- mediated medulloblastoma 
samples into my analyses. My results showed that the copy number readings based on the 
two reference genes are significantly similar to each other, supporting the accuracy of my 
copy number estimates (Figures 20A and 20B).  Remarkably, 7/9 of the p53Δ5-6/Δ5-6; 
RictorΔ/Δ tumors had notable N-Myc amplifications, while only 1/7 of the Ptch1+/-, and 
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none of the p53Δ5-6 (n = 2) and p53Δ5-6/Δ5-6; Rictor+/Δ (n = 3) medulloblastomas had a 
similar amplification (Figure 20C). The N-Myc amplification clearly distinguished p53Δ5-
6/Δ5-6; RictorΔ/Δ medulloblastomas from the rest of the mutant-p53 mediated 
medulloblastomas. In terms of the Gli2 gene, I observed that 3/9 of the p53Δ5-6/Δ5-6; 
RictorΔ/Δ, 2/7 of the Ptch1+/-, and 1/3 of the p53Δ5-6/Δ5-6; Rictor+/Δ tumors had slight to 
intermediate level of amplifications (Figure 20C). We confirmed these results with a low-
coverage copy number analysis using another set of tumor samples. We detected similar 
amplifications in Gli1, Gli2 and N-Myc genes, though Gli2 amplification was much 
noticeable in this set of samples (Figure 20D). Interestingly, we also noticed chr13/Ptch1 
deletions in 10/15 samples (Figure 20D), suggesting that multiple alterations occurring 
simultaneously contribute to the Shh-signatures observed in these mutant-p53 driven 
medulloblastomas 
 
One critical genomic abnormality that has been strongly linked to SHH 
medulloblastomas with p53 mutations is tetraploidy - harboring four times the haploid 
number of chromosomes (Jones et al., 2012). Having shown that p53Δ5-6/Δ5-6; RictorΔ/Δ 
tumors are SHH medulloblastomas with important gene amplifications, I aimed to test 
whether there were any chromosomal aneuploidies within these tumors that might also be 
relevant to the observed gene alterations. For this purpose, I established primary tumor 
cell lines using fresh tumor tissue samples, and examined the structure and number of the 
chromosomes at very early passages (passages 0-2). I detected characteristic 
chromosomal abnormalities including head-to-head and head-to-tail chromosome fusions, 
breaks, translocations, centromere losses and double minute chromosomes in p53Δ5-6/Δ5-6; 
RictorΔ/Δ cell lines (Figures 21A, 21C and data not shown). 1/1 of the p53Δ5-6/Δ5-6; 
Rictor+/Δ and 6/9 of the p53Δ5-6/Δ5-6; RictorΔ/Δ medulloblastoma cell lines had increased 
number of the chromosomes ranging between 45-85 reminiscent of triploidy or 
tetraploidy (Figure 21B). Interestingly, 2/5 of the p53Δ5-6/Δ5-6; RictorΔ/Δ cell lines gained 
aneuploidy, and 1/5 had increased its chromosome number at later passages (passages ≥ 
3), suggesting that passaging might introduce further abnormalities or allow the 
expansion of particular clones (Figures 21C and 21D). These distinctive genomic and 
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chromosomal events, which mimic childhood medulloblastomas with TP53 mutations, 
led us to investigate whether RICTOR/mTORC2 signaling is altered in human tumors 
too. We interestingly found that childhood medulloblastomas with TP53 mutations had 
notably lower RICTOR expression compared to the tumors with wt-TP53 (Figure 21E). 
As previously noted, we observed somewhat the opposite results in human GBMs (Figure 
3B), where RICTOR expression was higher in tumors with TP53 mutation compared to 
tumors with wt-TP53, underlining the opposite roles of RICTOR/Rictor in adult and 
pediatric brain tumors. Overall, these results suggest that Rictor deficiency facilitates the 
formation of medulloblastomas that undergo specific genomic and chromosomal 
abnormalities that have been associated with resistance to current treatments and poor 
clinical outcomes in childhood SHH medulloblastomas. 
 
3.3 Discussion 
 
In combination with the previous chapter, here we demonstrated that Rictor/mTORC2 
signaling has opposite roles in gliomagenesis and medulloblastoma formation. Our data 
suggest that despite the significant tumor suppressive activity of Rictor loss in glioma 
development, its embryonic deletion increases the frequency of medulloblastoma 
formation.  This phenomenon occurs mainly through a temporary delay in differentiation 
of a subset of p53-deficient cerebellar granule neuron precursors (Figure 22). This study, 
therefore, identifies a molecular signaling pathway - Rictor/mTORC2 - with distinct 
functions in adult and pediatric brain tumors.  
 
3.3.1 Abnormal presence of a cerebellar progenitor cell population in Rictor-
deficient brains underlies increased medulloblastoma formation 
 
Li-Fraumeni syndrome patients carrying germline TP53 mutations have increased risks of 
developing malignant gliomas and medulloblastoma, however medulloblastoma 
formation in these patients is still a rare event. Similarly, medulloblastoma development 
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in mutant-p53 mice is also a rare event (5-10%), as shown here and previously (Wang et 
al., 2009). One likely explanation for this fact is that the rapid stem/progenitor cell 
depletion in the cerebellum leads to a relatively quiescent organ that prevents the 
emergence and/or accumulation of the mutant-p53 induced sporadic molecular 
alterations. Furthermore, this biological phenomenon may be responsible for the largely 
pediatric nature of medulloblastoma. Here, we have shown that alterations in a critical 
molecular pathway, such as Rictor/mTORC2 and possibly PI3K/Akt, can interfere with 
the natural differentiation of the cerebellar progenitor cells, providing a short but 
essential window for the mutant-p53 cells to undergo sufficient molecular abnormalities 
required for medulloblastoma formation. More specifically, Rictor loss increases a pool 
of GNPs with a longer period of predisposition, causing an increased frequency of 
mutant-p53 driven medulloblastoma formation (Figure 17).  
 
It is worth noting that Rictor-deficiency alone is not capable of initiating 
medulloblastoma formation, which suggests that p53 mutation is the main driver of the 
tumorigenesis, while Rictor-deficiency is a facilitator of this process. It also indicates that 
abnormally proliferating Rictor-deficient GNPs exit cell cycle and differentiate into 
mature cells by p53-dependent mechanisms. Consistent with these findings, we found 
that pAktS473 was virtually absent in actively proliferating GNPs, while the newly 
differentiating cells in ML and mature neurons in IGL had prominent Akt activation. 
Therefore, PI3K/Akt signaling functions as an essential pathway that regulates the 
lineage progress from cerebellar progenitor cells to fully differentiated neurons. As 
RictorΔ/Δ GNPs eventually differentiate into mature neurons, there might be other 
redundant pathways that allow this transition. Lastly, we cannot dispute the possibility 
that other downstream components of Rictor/mTORC2 signaling (e.g. PKC-α and SGK1) 
are responsible for the phenotypes that we observed. 
 
3.3.2 Rictor loss facilitates the formation of mutant-p53 driven medulloblastomas 
with SHH signature 
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The comprehensive analyses performed in our laboratory and also in collaboration with 
scientists in DKFZ indicated that all of our mutant-p53 driven medulloblastoma samples 
had Shh gene expression profile. Accordingly, these tumors were categorized along with 
the previously generated GEM models of SHH medulloblastoma. It is worth noting that 
we did not detect a difference among our mutant-p53 driven medulloblastomas with 
regards to Rictor status, as they all had similar histopathologic features and Shh 
activation. Therefore, the major role of Rictor loss in medulloblastoma formation seems 
to prolong the time of susceptibility of cerebellar progenitor cells to transform into tumor 
cells by mechanisms described in previous section.  
 
Almost all of the previous SHH medulloblastoma mouse models were generated by 
introducing a mutation in Ptch1 or Smo gene, which results in elevated Shh signaling 
(Northcott et al., 2012a). Our mutant-p53 models, however, represented a spontaneous 
activation of Shh signaling pathway that drives tumorigenesis from cerebellar progenitor 
cells. Of note, same p53 mutation in the forebrain led to glioma formation accompanied 
by Akt activation. Thus, the same gene mutation allowed different stem/progenitor cell 
populations to acquire distinct oncogenic pathways for the development of different 
tumors.  
 
3.3.3 Rictor-deficient medulloblastomas display unique genomic and chromosomal 
alterations 
 
Aberrant activation of Shh signaling in medulloblastomas, often due to inactivating 
mutations in PTCH1, led researchers to develop drugs that target this oncogenic pathway 
(Ng and Curran, 2011). Virtually all of the current Shh antagonists target the 
transmembrane protein Smoothened (SMO) itself with promising results seen in both 
mouse model studies (Berman et al., 2002; Romer et al., 2004) and clinical trials 
(Amakye et al., 2013). However, inhibiting the Shh pathway in medulloblastomas is more 
challenging and complicated than it seems, as several strategies for pathway activation 
have been identified (Amakye et al., 2013). Consistently, only 50% of medulloblastoma 
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cases with Shh activation are associated with mutations in PTCH1, SUFU or SMO (Ng 
and Curran, 2011), implying the presence of other molecular alterations, including the 
downstream components, leading to pathway activation. Furthermore, acquired drug 
resistance plays an important role in disease complexity, as evidenced by a case study 
reporting the emergence of a novel mutation in SMO gene, resulting in irresponsiveness 
to SMO-inhibitors (Rudin et al., 2009; Yauch et al., 2009). Similarly, amplifications in 
key Shh downstream target genes such as GLI1, GLI2 and N-MYC, detected especially in 
patients with TP53 mutations, are thought to render the tumors inherently resistant to 
SMO-inhibitors (Gajjar and Robinson, 2014; Northcott et al., 2012a). It is, therefore, 
critical to 1) distinguish between SMO-dependent and SMO-independent pathway 
activation (Amakye et al., 2013), 2) identify unique genetic alterations, and subsequently 
tailor precise treatment plans for each patient, 3) develop novel drugs that are able to 
target Shh pathway downstream components (Hyman et al., 2009; Kool et al., 2014), and 
finally 4) generate mouse models that recapitulate various genomic alterations observed 
in human medulloblastomas to test these newly designed drugs and study drug resistance. 
Although insightful, the majority of the current mouse models for SHH medulloblastoma 
do not represent the complete genetic diversity observed in human tumors (Ng and 
Curran, 2011), especially those that have a natural resistance to SMO-inhibitors. This 
might be partly because many models are engineered to have a Ptch1 mutation, making 
them inherently vulnerable to SMO-inhibitors. Mutant-p53-Rictor medulloblastomas, 
then, are unique in that they are easily distinguished from other models by their 
prominent amplifications in N-Myc and Gli2 genes, as well as increased chromosome 
numbers reminiscent of tetraploidy. These tumors resemble the childhood SHH 
medulloblastomas, which show a limited or no response to SMO-inhibitors (Kool et al., 
2014) and associated with poor prognosis (Northcott et al., 2012b). Thus, we strongly 
advocate the utilization of Rictor-deficient medulloblastomas, with or without a Pten 
mutation, as unique tools to test novel drugs targeting Shh pathway downstream 
components such as Gli1, Gli2, and N-Myc (Figure 22).  
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Figure 9. Rictor-deficient medulloblastomas have distinctive histopathologic features. 
 
(A) Kaplan-Meier survival curves of p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, and p53Δ5-6/Δ5-6; RictorΔ/Δ 
mice that developed end-stage medulloblastoma. The Mantel-Cox (Log-rank) test is used to 
compare the curves statistically. 
(B) Histopathologic features of the p53Δ5-6/Δ5-6; RictorΔ/Δ medulloblastomas. H&E staining 
illustrates the dense tumor (i) with carrot-shaped nuclei, apoptotic cells and nuclear moldings 
(ii). Tumors were immunoreactive to p53 (iii) and Synaptophysin (iv). Some areas of the tumors 
are GFAP+ (vi) while others were GFAP- (v). Insets show the immunoreactivity to each antibody 
at a higher magnification.  
(C) In-depth analyses of the histopathologic features of the medulloblastomas in p53Δ5-6/Δ5-6; 
RictorΔ/Δ mice. Tumors were characterized by dense nuclei with nuclear moldings (illustrated in 
H&E staining), p53 immunoreactivity, occasional Synaptophysin and GFAP staining, and very 
minimal Olig2+ cells. 
(D) Western blotting analysis of the p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, and p53Δ5-6/Δ5-6; RictorΔ/Δ 
medulloblastoma samples along with the various Ptch1+/- (i.e. Ptch1+/-, p53Δ5-6/Δ5-6; Ptch1+/-, and 
p53Δ5-6/R172P; Ptch1+/-) SHH medulloblastoma models. Wild type cerebellar tissue is used as a 
control (CTR), and two glioma samples from p53Δ5-6/Δ5-6; Rictor+/Δ and p53Δ5-6/Δ5-6; Pten+/Δ (last 
two lanes) are also included into the analysis. Expression levels of glioma marker Olig2 and 
medulloblastoma marker Pax6 are analyzed along with mTOR and Rictor.  
(E) Immunohistochemical analysis of Pax6 and Olig2 in and p53Δ5-6/Δ5-6; RictorΔ/Δ 
medulloblastoma and p53Δ5-6/Δ5-6 cerebellar high-grade glioma. Note the mutually exclusive 
staining of the Pax6 and Olig2 in both medulloblastoma and glioma.  
(F) Pax6 and Olig2 staining in two consecutive sections of a p53Δ5-6/Δ5-6; RictorΔ/Δ brain with a 
forebrain glioma and a cerebellar medulloblastoma. Note the Pax6-Olig2+ glioma and the 
Pax6+Olig2- medulloblastoma. 
Scale bars, 50 µm (B and C), 1 mm (E and F). 
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Figure 10. A minor population of Sox2+ stem-like cells is detected within Rictor-deficient 
medulloblastomas. 
 
(A-C) Expression patterns of Sox2 in relation to Pax6 (A), Ki-67 (B) and p53 (C) in p53Δ5-6/Δ5-6; 
RictorΔ/Δ medulloblastomas are examined. Arrows show the colocalized expressions.  
(D) Pax6 expression, proliferation rate and mutant-p53 expression of Sox2+ cells in p53Δ5-6/Δ5-6; 
RictorΔ/Δ medulloblastomas are quantified. Three different populations of Sox2+ cells in relation 
to Pax6 expression levels are identified: Sox2+Pax6high (marked with Ψ), Sox2+Pax6low (marked 
with Φ) and Sox2+Pax6- (marked with Ω). Proliferation rate of Sox2+ cells is calculated by the 
ratio of the total number of Sox2+Ki-67+ cells to the total number of the Sox2+ cells. Percentage 
of the mutant-p53 expressing Sox2+ cells is calculated by the total number of Sox2+p53+ cells to 
the total number of the Sox2+ cells. Quantifications are done using 40X images of the two 
different regions in each tumor and the average percentage of the two are taken for each sample 
(n = 10). The data are presented as mean ± SEM. 
Scale bars, 25 µm. 
(E) The correlation between the mutant-p53 expression (Sox2+p53+) and the proliferation 
(Sox2+Ki-67+) within the Sox2+ cells is determined by a linear regression analysis. Goodness of 
fit (R2), and the significance of the slope are calculated (p-value). Note the significant correlation 
between the mutant-p53 expression and the increased proliferation within the Sox2+ cell 
population in mutant-p53 mediated medulloblastomas. 
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Figure 11. Pten mutation cooperates with Rictor-deficiency in facilitating mutant-p53 
induced medulloblastoma formation. 
 
 (A) Schematic representation of the genetic configurations in p53Δ5-6/Δ5-6; Pten+/Δ, p53Δ5-6/Δ5-6; 
Pten+/Δ; Rictor+/Δ, and p53Δ5-6/Δ5-6; Pten+/Δ; RictorΔ/Δ mice. Floxed genes undergo hGFAP-cre-
mediated recombination at around E12.5, therefore the mice are named after the genotype of the 
recombined cells.  
(B) Kaplan-Meier survival curves of the p53Δ5-6/Δ5-6; Pten+/Δ, p53Δ5-6/Δ5-6; Pten+/Δ; Rictor+/Δ, and 
p53Δ5-6/Δ5-6; Pten+/Δ; RictorΔ/Δ mice sacrificed due to end-stage brain tumor(s). The Mantel-Cox 
(Log-rank) test is used to compare the curves statistically.  
(C) The tumors from p53Δ5-6/Δ5-6; Pten+/Δ, p53Δ5-6/Δ5-6; Pten+/Δ; Rictor+/Δ, and p53Δ5-6/Δ5-6; Pten+/Δ; 
RictorΔ/Δ are grouped based on their location within the brain. Two-tailed Fisher’s exact test is 
used to compare the groups. 
(D) Pie-chart representation of the high-grade glioma and medulloblastoma frequency in each 
mouse model. Two-tailed Fisher’s exact test is used to compare the groups. 
(E) Histopathologic analyses of the high-grade gliomas from p53Δ5-6/Δ5-6; Pten+/Δ and p53Δ5-6/Δ5-6; 
Pten+/Δ; Rictor+/Δ mice, and medulloblastomas from p53Δ5-6/Δ5-6; Pten+/Δ; Rictor+/Δ, and p53Δ5-6/Δ5-
6; Pten+/Δ; RictorΔ/Δ mice. High-grade gliomas were relatively less dense with more cytoplasmic 
material making them appear as “pink” tumors in H&E staining while medulloblastomas had 
very crowded nuclei with minimal amount of cytoplasm making them “blue” tumors. Note the 
differential Olig2 immunoreactivity between the gliomas and medulloblastomas.  
 (F) Western blotting analyses of the tissue samples from two p53Δ5-6/Δ5-6; Pten+/Δ, four p53Δ5-6/Δ5-
6; Pten+/Δ; Rictor+/Δ, five p53Δ5-6/Δ5-6; Pten+/Δ; RictorΔ/Δ medulloblastomas along with the various 
Ptch1+/- (i.e. Ptch1+/-, p53Δ5-6/Δ5-6; Ptch1+/-, and p53Δ5-6/R172P; Ptch1+/-) SHH medulloblastoma 
models. Analysis also includes a normal cerebral cortex tissue (CTR), and two glioma control 
samples from p53Δ5-6/Δ5-6; Rictor+/Δ and p53Δ5-6/Δ5-6; Pten+/Δ mice (last two lanes). 
Scale bars, 50 µm.  
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Figure 12. Rictor-deficient cerebella are characterized by ectopically proliferating granule 
neuron precursors (part-I). 
 
(A-D) The control and mutant mice at P16 are injected with BrdU (10 mg/kg) twice every two 
hours. All the mice are sacrificed two hours after the last injection, followed by analyses of 
cellular proliferation. 
(A) The overall cerebellar structure along with the Pax6+ neural lineage cells and BrdU+ 
proliferating cells are examined in P16 mice. Each folium is labeled with Roman numbers. 
Yellow frames indicate the three areas that are further analyzed. 
(B) H&E staining showing Folium 9/10a (F-9/10a) of the cerebella from P16 control and mutant 
mice.  
(C-D) The cerebellar surface area (mm2) (C), total number of the BrdU+ cells in the whole 
cerebella (D), and the total number of the cerebellar BrdU+ proliferating cells per unit area (mm2) 
(E) is calculated.  
The data are presented as mean ± SD. Unpaired t-test is used to compare the groups statistically. 
Scale bars, 1 mm (A) and 100 µm (B). ML: Molecular layer, EGL: External granular layer. 
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Figure 13. Rictor-deficient cerebella are characterized by ectopically proliferating granule 
neuron precursors (part-II). 
 
(A-D) The control and mutant mice at P16 were injected with BrdU (10 mg/kg) twice every two 
hours. All the mice were sacrificed two hours after the last injection, followed by analyses of 
cellular proliferation. 
(A-C) High magnification images of F-9/10a (A), F-5/6 (B) and F-10b (C) of P16 wild type 
control and mutant cerebella illustrating the BrdU+ proliferating cells and Pax6+ cells.  
(D) EGL-associated Pax6+ cells are quantified in relation to their BrdU content in F-5/6, F-9/10a 
and F-10b of the control and mutant cerebella.  
All the quantification data are presented as mean ± SEM. Scale bars, 100 µm. IGL: Internal 
granular layer, ML: Molecular layer, EGL: External granular layer. 
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Figure 14. A minor population of GNPs requires intact mTORC2/Akt signaling for proper 
differentiation. 
 
(A-D) Cell cycle analysis is performed by injecting the mice with BrdU (10 mg/kg) once at P15 
and analyzing at P17.  
(A) The cells proliferating at P15 are labeled with BrdU (green), proliferating at P17 were 
labeled with Ki-67 (red), the cells that are in the cell cycle at both time points are BrdU+Ki-67+ 
(yellow). Fully differentiated neurons are labeled with NeuN (red). BrdU+NeuN+ cells indicate 
the mature neurons that are generated from progenitor cells proliferating between P15-P17. 
Insets show higher magnification view of the EGL cells. Images are taken from F-9/10a. 
(B-C) Quantification of the cells from the experiment described above. Total Ki-67+ cells (B) 
and BrdU+Ki-67+ cells (C) are counted.  
(D) The cell cycle exit index is calculated by the ratio of BrdU+Ki-67-/BrdU+Ki-67+.  
(E-F) Immunohistochemistry analysis of pAktS473 and Pten expression in P8 control (E) and 
RictorΔ/Δ (F) cerebella. Boxed regions in the whole cerebella are depicted at higher 
magnification. Insets show higher magnification at ML (ii and iii) or EGL (v and vi). 
(G) Illustration of the differential expression of pAktS473 and Pten in the P8 control and RictorΔ/Δ 
cerebella. Pten expression is shown in green and pAktS473 is shown in pink. The thickness of the 
bars depicts the relative expression levels. 
The data are presented as mean ± SD. Unpaired t-test is used to compare the groups statistically. 
IGL: Internal granular layer, ML: Molecular layer, EGL: External granular layer. Scale bars, 100 
µm. 
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Figure 15. Ectopically proliferating GNPs are maintained in postnatal Rictor-deficient 
cerebella. 
 
(A-D) The control and mutant mice at P22 are injected with BrdU (10 mg/kg) twice every two 
hours. All the mice are sacrificed two hours after the last injection. 
(A-C) Pax6+ cells and BrdU+ proliferating cells are examined in P22 mice. The representative 
images are from F-9/10a (A), F-5/6 (B) and F-10b (C). 
(D) EGL-associated Pax6+ cells are quantified in relation to their BrdU content in F-5/6, F-9/10a 
and F-10b of the control and mutant cerebella.  
(E) Total Pax6+ cells located in ML are quantified in F-5/6, F-9/10a and F-10b of the control and 
mutant cerebella.  
All the quantification data are presented as mean ± SEM. Scale bars, 100 µm. IGL: Internal 
granular layer, ML: Molecular layer, EGL: External granular layer. Arrows in (A) point the EGL 
layers. 
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Figure 16. Rictor-deficient ectopically proliferating GNPs transform into early-tumor 
forming cells in the absence of p53. 
 
(A-G) The control and mutant mice at P16 and P22 are injected with BrdU (10 mg/kg) twice, 
while P60 mice are injected three times every two hours. All the mice are sacrificed two hours 
after the last injection, followed by analyses of cellular proliferation. 
(A, B and D) Proliferating p53+ cells in p53Δ5-6/Δ5-6; RictorΔ/Δ cerebella are examined at P16 (A), 
P22 (B) and P60 (D) using p53 and BrdU antibodies. Neuronal populations (NeuN+) are also 
shown for P22 brains in (B). Boxed areas indicate the regions where higher magnification 
images are taken.  
(C) The total number of the p53+ cells in F-5/6, F-9/10a, and F-10b of P22 control and mutant 
cerebella is quantified.  
(E-G) Quantification of the cells from the experiments described above.  
The number of the p53+ cells (E) and BrdU+ cells (F) in p53Δ5-6/Δ5-6 and p53Δ5-6/Δ5-6; RictorΔ/Δ 
cerebella is calculated over three time points – P16, P22 and P60. The frequency of the 
proliferating p53+ cells among the entire proliferating population is calculated by the ratio of 
BrdU+p53+/BrdU+ (G). 
Scale bars, 50 µm. IGL: Internal granular layer, ML: Molecular layer, EGL: External granular 
layer. Arrows point the EGL layers. 
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Figure 17. Schematic representation of the different cell populations in wild type control 
and mutant cerebella during the development. 
 
Wild type control cerebellum completes its maturation around P16, and virtually lacks 
proliferating GNPs after then. p53+/Δ; RictorΔ/Δ cerebellum, on the other hand, temporarily 
maintains a subpopulation of proliferating GNPs past P16. Despite of a delay, these cells 
abnormally differentiate in different regions of the cerebellum, including the ML, by possibly 
p53-dependent mechanisms. Evidenced by their mutant-p53 expression, a subset of ectopically 
proliferating GNPs acquires cellular stress and possibly transform into early tumor-forming cells 
in the absence of p53 (e.g. p53Δ/Δ; RictorΔ/Δ). 
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Figure 18. Mutant-p53-Rictor induced medulloblastomas share molecular events with 
Ptch1+/- tumors. 
 
(A and D) Western blotting analysis of the p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, and p53Δ5-6/Δ5-6; 
RictorΔ/Δ medulloblastoma samples along with the various Ptch1+/- (i.e. Ptch1+/-, p53Δ5-6/Δ5-6; 
Ptch1+/-, and p53Δ5-6/R172P; Ptch1+/-) models. Wild type cerebellar tissue is used as a control 
(CTR), and two glioma samples from p53Δ5-6/Δ5-6; Rictor+/Δ and p53Δ5-6/Δ5-6; Pten+/Δ (last two 
lanes) are also included into the analysis.  
(B-C) RT-PCR experiments were performed using cDNAs from the mutant-p53 
medulloblastomas in comparison with the Ptch1+/- models.  
The average expression levels of each Gli1, Gli2, N-Myc and Atoh1 (B) and Ptch1 (C) genes for 
the Ptch1+/- tumors are set to 100 and all of the samples are calculated accordingly. Two glioma 
samples and a P13 normal cerebellar tissue are used as negative controls.  
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Figure 19. Rictor deficiency facilitates mutant-p53 driven medulloblastomas that resemble 
human SHH medulloblastomas.  
 
(A-B) Heatmap representation of the microarray analysis illustrating the gene expression prolife 
of the mutant-p53 medulloblastomas in comparison with the previously established SHH GEM 
medulloblastomas.  
The expression profiles of the Group C medulloblastomas, GNPs and normal tissues are also 
included into the array. An area containing the genes that are specifically upregulated in the SHH 
tumors is highlighted with a dashed white box (A). The genes that are found in the white-dashed 
area are listed, and the important ones are highlighted in yellow (B).  
Samples used in this analysis: three p53-/-, two p53Δ5-6/Δ5-6; Rictor+/Δ, five p53Δ5-6/Δ5-6; RictorΔ/Δ, 
three p53Δ5-6/Δ5-6; Pten+/Δ, six p53Δ5-6/Δ5-6; Pten+/Δ; Rictor+/Δ (three of which had germline Rictor 
mutation) and three p53Δ5-6/Δ5-6; Pten+/Δ; RictorΔ/Δ. 
(C) Detailed gene expression analyses of Gli1, Gli2, Atoh1, and Sfrp1 (SHH medulloblastoma 
signature genes).  
(D) Microarray gene expression levels of Gli1, Gli2, Atoh1 and Sfrp1 are examined in relation to 
Rictor status of mutant-p53 mediated GEM medulloblastomas. 
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Figure 20. Rictor-deficient medulloblastomas are distinguished from other SHH GEM 
medulloblastomas by their gene amplification events. 
 
 (A-B) Copy number estimates of each N-Myc (A) and Gli2 (B) genes based on two different 
reference genes (β-Actin on chr5 and Gapdh on chr7) are compared. The readings of both N-Myc 
and Gli2 in relation to β-Actin showed highly similar results to those in relation to Gapdh, 
indicating the accuracy of the analysis. 
(C) Copy number estimates of the N-Myc and Gli2 genes in p53Δ5-6/Δ5-6, p53Δ5-6/Δ5-6; Rictor+/Δ, 
and p53Δ5-6/Δ5-6; RictorΔ/Δ medulloblastomas in comparison to Ptch1+/- tumors. Copy numbers 
were calculated by a series of RT-PCR experiments using the tumor genomic DNA as template. 
β-Actin in chr5 and Gapdh in chr7 were used as internal reference genes for each sample. Wild-
type controls were set to “2” and all of the samples were calculated accordingly. 
(D) Low-coverage copy number analysis of chr13/Ptch1, Gli1, Gli2 and N-Myc was performed 
using various mutant-p53 mediated medulloblastomas. All the tumors had mutant p53 genes, and 
the status of Rictor and Pten is indicated.  
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Figure 21. Chromosomal abnormalities are readily detectable in Rictor-deficient 
medulloblastomas. 
 
(A) Chromosome metaphase assay is performed in order to examine the structure and number of 
the chromosomes in p53Δ5-6/Δ5-6; RictorΔ/Δ early-passage (passage number ≤ 2) cell lines. Head-
to-head fusions (i, ii, iv, v and vi), head-to-tail fusions or translocations (iv) and centrosome loss 
(iii), double minute chromosomes (vii), and centrosome pieces (viii) are pointed with red arrows. 
(B) The chromosome numbers were quantified in nine p53Δ5-6/Δ5-6; RictorΔ/Δ and one p53Δ5-6/Δ5-6; 
Rictor+/Δ early passage cell lines. The cells with clear aneuploidy are shown with red dots while 
others are black. 
(C) Chromosomes from late-passage (passage number ≥ 3) p53Δ5-6/Δ5-6; RictorΔ/Δ cell lines are 
examined. Chromosome break (i) and chromosome fusion (i and ii) are pointed with red arrows. 
(D) The chromosome numbers are quantified in late-passage (passage number ≥ 3) p53Δ5-6/Δ5-6; 
RictorΔ/Δ cell lines. Mean value is indicated.  
(E) RICTOR expression within SHH childhood medulloblastomas with or without TP53 
mutation. Samples in blue frames have expression levels ≤ 600, samples in red frames have 
expression levels > 600. 
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Figure 22. Schematic representation of the brain tumorigenesis distinctively regulated by 
Rictor/mTORC2 signaling pathway. 
 
(A) Early glioma cells or glioma-forming cells (orange cells) in an adult p53Δ/Δ forebrain 
require intact Rictor/mTORC2 signaling in order to expand outside the germinal zones, and 
invade the surrounding tissue. These cells may migrate several remote locations of the brain to 
form clusters (red cells) leading to glioma development. p53-mutant cerebellum, on the other 
hand, mostly develops properly, and becomes a quiescent organ throughout the organism’s life 
span. Only in rare cases mutations in p53 gene can lead to medulloblastoma development.  
(B) Rictor deficiency inhibits the initial expansion of the early glioma cells or glioma-forming 
cells (orange cells) in an adult p53Δ/Δ; RictorΔ/Δ forebrain. These cells remain restricted to the 
germinal zones, and do not display an expansion to the surrounding areas. It should be noted that 
some of those cells may eventually escape from this restriction and form high-grade gliomas at 
very late stages. Rictor-deficient neonatal cerebellum is characterized by the ectopically 
proliferating cerebellar progenitor cells (light blue cells or lines), some of which might have 
already acquired tumorigenic potential driven by p53 mutation (dark blue cells). Rictor 
deficiency facilitates the formation of mutant-p53 driven medulloblastomas that carry gene 
amplifications in downstream components of the Shh signaling pathway. 
Based on these two major findings, inhibition of Rictor/mTORC2 signaling in malignant gliomas 
may have therapeutic potential in a group of adult patients, but not pediatric cases. 
Medulloblastomas that are driven by mutant-p53 and carry gene amplifications in Shh signaling 
pathway components will likely need novel therapies, including Gli1, Gli2 and N-Myc 
inhibitors.
	   137	  
3.4 References 
 
Amakye, D., Jagani, Z. and Dorsch, M. (2013). Unraveling the therapeutic potential of 
the Hedgehog pathway in cancer. Nature medicine 19, 1410-1422. 
Berman, D. M., Karhadkar, S. S., Hallahan, A. R., Pritchard, J. I., Eberhart, C. G., 
Watkins, D. N., Chen, J. K., Cooper, M. K., Taipale, J., Olson, J. M., et al. 
(2002). Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 
297, 1559-1561. 
Engelkamp, D., Rashbass, P., Seawright, A. and van Heyningen, V. (1999). Role of 
Pax6 in development of the cerebellar system. Development 126, 3585-3596. 
Gajjar, A. J. and Robinson, G. W. (2014). Medulloblastoma-translating discoveries 
from the bench to the bedside. Nature reviews. Clinical oncology 11, 714-722. 
Gibson, P., Tong, Y., Robinson, G., Thompson, M. C., Currle, D. S., Eden, C., 
Kranenburg, T. A., Hogg, T., Poppleton, H., Martin, J., et al. (2010). Subtypes of 
medulloblastoma have distinct developmental origins. Nature 468, 1095-1099. 
Gilbertson, R. J. and Ellison, D. W. (2008). The origins of medulloblastoma subtypes. 
Annual review of pathology 3, 341-365. 
Hill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., 
Boult, J. K., Williamson, D., Ahmad, Z., Hallsworth, A., et al. (2015). Combined 
MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly 
Progressive, Therapeutically Targetable Disease. Cancer cell 27, 72-84. 
Hyman, J. M., Firestone, A. J., Heine, V. M., Zhao, Y., Ocasio, C. A., Han, K., Sun, 
M., Rack, P. G., Sinha, S., Wu, J. J., et al. (2009). Small-molecule inhibitors reveal 
multiple strategies for Hedgehog pathway blockade. Proceedings of the National 
Academy of Sciences of the United States of America 106, 14132-14137. 
Jones, D. T., Jager, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y. J., 
Pugh, T. J., Hovestadt, V., Stutz, A. M., et al. (2012). Dissecting the genomic 
complexity underlying medulloblastoma. Nature 488, 100-105. 
Jones, M. J. and Jallepalli, P. V. (2012). Chromothripsis: chromosomes in crisis. 
Developmental cell 23, 908-917. 
Kool, M., Jones, D. T., Jager, N., Northcott, P. A., Pugh, T. J., Hovestadt, V., Piro, 
R. M., Esparza, L. A., Markant, S. L., Remke, M., et al. (2014). Genome 
sequencing of SHH medulloblastoma predicts genotype-related response to 
smoothened inhibition. Cancer cell 25, 393-405. 
Kool, M., Korshunov, A., Remke, M., Jones, D. T., Schlanstein, M., Northcott, P. A., 
Cho, Y. J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., et al. (2012). 
Molecular subgroups of medulloblastoma: an international meta-analysis of 
transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and 
Group 4 medulloblastomas. Acta neuropathologica 123, 473-484. 
Kool, M., Koster, J., Bunt, J., Hasselt, N. E., Lakeman, A., van Sluis, P., Troost, D., 
Meeteren, N. S., Caron, H. N., Cloos, J., et al. (2008). Integrated genomics 
identifies five medulloblastoma subtypes with distinct genetic profiles, pathway 
signatures and clinicopathological features. PloS one 3, e3088.
	   138	  
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., 
Scheithauer, B. W. and Kleihues, P. (2007). The 2007 WHO classification of 
tumours of the central nervous system. Acta neuropathologica 114, 97-109. 
Ng, J. M. and Curran, T. (2011). The Hedgehog's tale: developing strategies for 
targeting cancer. Nature reviews. Cancer 11, 493-501. 
Northcott, P. A., Jones, D. T., Kool, M., Robinson, G. W., Gilbertson, R. J., Cho, Y. 
J., Pomeroy, S. L., Korshunov, A., Lichter, P., Taylor, M. D., et al. (2012a). 
Medulloblastomics: the end of the beginning. Nature reviews. Cancer 12, 818-834. 
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., 
Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., et al. (2011). 
Medulloblastoma comprises four distinct molecular variants. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 29, 1408-
1414. 
Northcott, P. A., Shih, D. J., Peacock, J., Garzia, L., Morrissy, A. S., Zichner, T., 
Stutz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012b). 
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. 
Nature 488, 49-56. 
Pfister, S., Remke, M., Benner, A., Mendrzyk, F., Toedt, G., Felsberg, J., Wittmann, 
A., Devens, F., Gerber, N. U., Joos, S., et al. (2009). Outcome prediction in 
pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 
6q and 17q and the MYC and MYCN loci. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 27, 1627-1636. 
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, 
D., Bochicchio, J., Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et 
al. (2012). Medulloblastoma exome sequencing uncovers subtype-specific somatic 
mutations. Nature 488, 106-110. 
Rausch, T., Jones, D. T., Zapatka, M., Stutz, A. M., Zichner, T., Weischenfeldt, J., 
Jager, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012). Genome sequencing 
of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 
mutations. Cell 148, 59-71. 
Robinson, G., Parker, M., Kranenburg, T. A., Lu, C., Chen, X., Ding, L., Phoenix, 
T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012). Novel mutations target distinct 
subgroups of medulloblastoma. Nature 488, 43-48. 
Romer, J. T., Kimura, H., Magdaleno, S., Sasai, K., Fuller, C., Baines, H., Connelly, 
M., Stewart, C. F., Gould, S., Rubin, L. L., et al. (2004). Suppression of the Shh 
pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-
)p53(-/-) mice. Cancer cell 6, 229-240. 
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., 
Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009). Treatment of 
medulloblastoma with hedgehog pathway inhibitor GDC-0449. The New England 
journal of medicine 361, 1173-1178. 
Schuller, U., Heine, V. M., Mao, J., Kho, A. T., Dillon, A. K., Han, Y. G., Huillard, 
E., Sun, T., Ligon, A. H., Qian, Y., et al. (2008). Acquisition of granule neuron 
precursor identity is a critical determinant of progenitor cell competence to form Shh-
induced medulloblastoma. Cancer cell 14, 123-134. 
	   139	  
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., 
Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011). Massive 
genomic rearrangement acquired in a single catastrophic event during cancer 
development. Cell 144, 27-40. 
Tabori, U., Baskin, B., Shago, M., Alon, N., Taylor, M. D., Ray, P. N., Bouffet, E., 
Malkin, D. and Hawkins, C. (2010). Universal poor survival in children with 
medulloblastoma harboring somatic TP53 mutations. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 28, 1345-1350. 
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y. J., Clifford, S. 
C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012). 
Molecular subgroups of medulloblastoma: the current consensus. Acta 
neuropathologica 123, 465-472. 
Thompson, M. C., Fuller, C., Hogg, T. L., Dalton, J., Finkelstein, D., Lau, C. C., 
Chintagumpala, M., Adesina, A., Ashley, D. M., Kellie, S. J., et al. (2006). 
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic 
alterations. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 24, 1924-1931. 
Tomasetti, C. and Vogelstein, B. (2015). Cancer etiology. Variation in cancer risk 
among tissues can be explained by the number of stem cell divisions. Science 347, 
78-81. 
Vanner, R. J., Remke, M., Gallo, M., Selvadurai, H. J., Coutinho, F., Lee, L., 
Kushida, M., Head, R., Morrissy, S., Zhu, X., et al. (2014). Quiescent sox2(+) cells 
drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. 
Cancer cell 26, 33-47. 
Wang, Y., Yang, J., Zheng, H., Tomasek, G. J., Zhang, P., McKeever, P. E., Lee, E. 
Y. and Zhu, Y. (2009). Expression of mutant p53 proteins implicates a lineage 
relationship between neural stem cells and malignant astrocytic glioma in a murine 
model. Cancer cell 15, 514-526. 
White, J. J. and Sillitoe, R. V. (2013). Development of the cerebellum: from gene 
expression patterns to circuit maps. Wiley interdisciplinary reviews. Developmental 
biology 2, 149-164. 
Yamasaki, T., Kawaji, K., Ono, K., Bito, H., Hirano, T., Osumi, N. and Kengaku, M. 
(2001). Pax6 regulates granule cell polarization during parallel fiber formation in the 
developing cerebellum. Development 128, 3133-3144. 
Yang, Z. J., Ellis, T., Markant, S. L., Read, T. A., Kessler, J. D., Bourboulas, M., 
Schuller, U., Machold, R., Fishell, G., Rowitch, D. H., et al. (2008). 
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted 
progenitors or stem cells. Cancer cell 14, 135-145. 
Yauch, R. L., Dijkgraaf, G. J., Alicke, B., Januario, T., Ahn, C. P., Holcomb, T., 
Pujara, K., Stinson, J., Callahan, C. A., Tang, T., et al. (2009). Smoothened 
mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. 
Science 326, 572-574. 
Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D. J., Martin, D. C., 
Castelo-Branco, P., Baskin, B., Ray, P. N., Bouffet, E., et al. (2013). Subgroup-
specific prognostic implications of TP53 mutation in medulloblastoma. Journal of 
	   140	  
clinical oncology : official journal of the American Society of Clinical Oncology 31, 
2927-2935. 
Zhuo, L., Theis, M., Alvarez-Maya, I., Brenner, M., Willecke, K. and Messing, A. 
(2001). hGFAP-cre transgenic mice for manipulation of glial and neuronal function in 
vivo. Genesis 31, 85-94. 
 
	   141	  
 
 
 
Chapter IV: Pten and mTORC2 signaling pathways orchestrate cortical 
neurons and neuronal layering during the embryonic development 
 
 
 
4.1 Introduction 
 
4.1.1 Neuroepithelium and radial glial cells are the earliest stem cells in the 
developing brain 
 
Neuroepithelium of ectodermal origin constitutes the earliest stem cells during the 
embryonic brain development. These neuroepithelial cells divide extensively in a 
symmetric manner to populate the pseudo-lining of the early cerebral ventricles - the 
ventricular zone (VZ). Upon this hyperproliferation of the neuroepithelia, VZ becomes a 
thick and dense layer of stem cells, which remain tightly anchored to the pial and 
ventricular surfaces. Even though it is thought that neuroepithelial cells might directly 
give rise to mature neurons, cortical neurogenesis in mouse brain does not start until 
approximately E10 (Gotz and Huttner, 2005; Kriegstein and Alvarez-Buylla, 2009). One 
of the key events that initiate the cortical neurogenesis, however, is the transformation of 
neuroepithelium to radial glial cells (RGCs), which serve as the major neural stem cells 
(NSCs) in an embryonic brain (Martynoga et al., 2012).  
 
Different from neuroepithelial cells, RGCs elongate and extend their radial filament to 
the meninges at the basal surface of the cortex while remain attached to the ventricle at 
the apical surface (Kriegstein and Alvarez-Buylla, 2009; Mori et al., 2005). This tight 
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apico-basal network of fibers accompanies the gradual thickening of the cortex, and they 
convert to comparatively looser and shorter processes only after birth. RGCs are also 
attached to each other, and together with their apico-basal polarity, these tight junctions 
maintain the delicate architecture of VZ. Several studies have shown that mutations that 
disrupt these firm connections and basal contact of RGCs lead to disorganized cortical 
layering and severely altered cortical structure (Kriegstein and Alvarez-Buylla, 2009). In 
addition to morphologic changes during the transition from the epithelium, RGCs also 
starts expressing intermediate filament proteins, including nestin, glial fibrillary acidic 
protein (GFAP), and vimentin, and astrocyte-specific proteins, including L-glutamate/L-
aspartate transporter (GLAST), brain lipid-binding protein (BLBP) and the β subunit of 
calcium-binding protein S100 (S100β) (Hartfuss et al., 2001; Mori et al., 2005). Self-
renewal and lineage progression of RGCs occurs through asymmetric cell divisions, 
where the daughter cells can be a neuron, an intermediate progenitor cell (IPC) or a new 
RGC.  It is important to note that, IPCs form a second layer called subventricular zone 
(SVZ) basal to the VZ at around E13.5, and they further divide to generate neurons (from 
nIPC) or oligodendrocytes (from oIGC). As the RGC progeny is continuously generated 
during the development, they migrate tangentially or radially into the mantel, causing an 
increase in cortical thickness. As a response, RGCs elongate further, and their fibers can 
extend to the apical surface as long as a millimeter in mammalian cortices (Kriegstein 
and Alvarez-Buylla, 2009; Rakic, 2009).  At the end of the embryonic development, a 
portion of RGCs starts detaching from the VZ surface and converts into mature 
astrocytes. The remaining RGC population, on the other hand, maintains its tight 
attachment with the VZ, serving as NSCs that continue to generate neurons, 
oligodendrocytes (through specific IPCs), and ependymal cells lining the ventricle. In 
later stages after birth, VZ shrinks to a single layer of ependymal cells, and RGCs convert 
into type B cells, which function as a central NSC pool in adult brains thereafter (Doetsch 
et al., 1999; Noctor et al., 2007).   
 
4.1.2 Cortical neurogenesis and pyramidal projection neurons 
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The majority of the cortical neurogenesis takes place between E12-E17 (Hartfuss et al., 
2001), and neurons can be produced in three different ways based on their origin 1) In 
early development, asymmetric divisions of neuroepithelial cells and RGCs can generate 
mature neurons (direct neurogenesis, aka radial unit hypothesis). This type of 
neurogenesis mostly takes place in VZ.  2) More restricted nIPCs that are generated from 
RGCs can divide symmetrically and produce two neurons (indirect neurogenesis aka 
intermediate progenitor hypothesis). 3) Additionally, nIPCs can undergo extra rounds of 
symmetric cell divisions giving rise to new IPCs, and subsequently produce mature 
neurons (indirect neurogenesis) (Kriegstein et al., 2006; Molyneaux et al., 2007; Noctor 
et al., 2008). The latter two events occur mainly in SVZ and recent studies have 
suggested that SVZ is actually the major site for cortical neurogenesis. As opposed to 
neuroepithelia and RGCs, nIPCs do not form tight connections with pial or ventricular 
surfaces. (Noctor et al., 2007).  
 
Once the cortical neurogenesis is completed, pyramidal neurons, which are glutamatergic 
projection neurons, are arranged into morphologically distinguishable six layers (I-VI) in 
a postnatal mouse brain. Except for layer-I neurons, which are located at the most 
superficial portion of the cortex, all layers are formed in an inside-out manner. 
Accordingly, formation of initial deeper layers is followed by subsequent addition of 
more superficial layers, which migrate through preformed neuronal layers (deep layers 
first, upper layers last gradient) (Britanova et al., 2006; Tarabykin et al., 2001). Late-born 
superficial cortical layers (II-IV) constitute “upper layer neurons” (ULNs), and early-
born more apical layers (V-VI) consist of  “deeper layer neurons” (DLNs). Upper layer 
neurons are mostly corticocortical projection neurons, which form a complex connection 
between different cortical areas in an ipsilateral and contralateral manner. While deeper 
layer-IV neurons provide the major neuronal input, the majority of the deeper layer-V 
and –VI neurons send their axons to more distant areas, including spinal cord, pons, 
tectum, and thalamus. Therefore, the majority of the DLNs are considered as subcortical 
projections neurons (Britanova et al., 2008; Leone et al., 2008). Cux1 and Cux2 are 
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expressed in all ULNs, while Ctip2 and Fezf5 are used as a DLN marker (Leone et al., 
2008; Nieto et al., 2004).  
 
4.1.3 Embryonic neurogenesis is regulated by various signaling pathways, including 
PTEN signaling 
 
A complex interaction of several signaling pathways regulates the cortical neurogenesis, 
starting with the early transition of neuroepithelium to RGCs, and ending with the 
completion of cortical development (reviewed in (Martynoga et al., 2012)).  Notch, ErB 
and Fgfr2 signals facilitate the transformation of neuroepithelial cells into RGCs at 
around E10. Meanwhile, Wnt and Myc signaling pathways promote the self-renewal of 
RGCs. While Wnt, Bmp, Pax6, and Prc signaling pathways control the direct 
neurogenesis, a complex network of Ezh2, Tbr2, N-Myc, Foxg1 and Wnt signals provide 
indirect neurogenesis by inducing the IPC generation from RGCs (Martynoga et al., 
2012). These signaling pathways are essential for accurate lineage progression from 
multipotent stem cells to fully differentiated and functional neurons, and by extension, for 
proper neural network. Therefore, abnormalities in any of the signaling pathways may be 
pathological, as evidenced by cognitive problems resulting from an absence of 
connectivity in callosal projection neurons (CPN), which are enriched in cortical layers II 
and III, and to a lesser extent in V and VI. Unfortunately, the patients suffering from 
CPN dysgenesis exhibit autism spectrum disorders (ASD), defects in abstract reasoning, 
problem solving and generalization (Fame et al., 2011; Paul et al., 2007). Similarly, 
germline mutations in PTEN gene can lead to several autosomal dominant syndromes that 
manifest themselves with neurological and cognitive deficits. These disorders altogether 
are called “PTEN hamartoma tumor syndromes (PHTS)”, which include Cowden 
syndrome, Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease and Proteus 
and Proteus-like syndromes (Salmena et al., 2008; Sulis and Parsons, 2003). Numerous 
studies have identified strong correlation between germline PTEN mutations and ASD, 
developmental delay, and mental retardation. These patients, in general, are characterized 
by impaired cognitive functioning, low IQ, deficits in adaptive behaviors, compromised 
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social, emotional and verbal skills, and unusually large head (macrocephaly). 
Remarkably, virtually all of the patients with germline PTEN mutations exhibited 
macrocephaly, and approximately 20-50% of those patients were diagnosed with ASD 
(Butler et al., 2005; Lynch et al., 2009; McBride et al., 2010; Orrico et al., 2009; Varga et 
al., 2009).  
 
4.1.4 PTEN deficiency leads to aberrations in neural stem cells, mature neurons and 
glia  
 
Since the identification of PTEN gene in 1997 (Li and Sun, 1997; Li et al., 1997; Steck et 
al., 1997), several studies have made a significant effort to understand the essential 
functions of PTEN and downstream AKT signaling pathway at the cellular, tissue, and 
organ level. The initial findings suggested that Pten has essential roles in cell cycle 
progress and cell survival, as Pten-deficient embryonic stem cells exhibited rapid entry to 
S-phase, accompanied by increased growth and proliferation (Sun et al., 1999). 
Consistently, tissue specific deletion of Pten in CNS stem/progenitor cells in vivo 
resulted in increased cellular proliferation, decreased cell death, and enlarged cell size, all 
of which contributed significantly to enlarged cranium and neonatal lethality (Groszer et 
al., 2001). It was then reported that Pten deletion promotes self-renewal of neural 
stem/progenitor cells without changing their multipotential differentiation ability, as 
opposed to the wild type stem/progenitor cells which have a limited self-renewal capacity 
and gradually lose their ability to generate subsequent progeny, including neurons 
(Groszer et al., 2006).  Less restricted deletion of Pten in cerebellar and dentate gyrus 
granule neurons caused seizures, ataxia and increased soma size in neurons, reminiscent 
of Lhermitte-Duclos disease (Backman et al., 2001; Kwon et al., 2001). Subsequent 
studies have identified the deregulated signaling pathways that lead to the observed 
phenotypes upon Pten deletion. Akt and mTOR signaling, particularly, have been shown 
to be hyperactivated in Pten-deficient mice, and inhibition of mTOR decreases the 
seizure frequency, lethality, and neuronal hypertrophy (Kwon et al., 2003). Functions of 
Pten in glial populations have been also studied. Similar to the phenotypes in neural 
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stem/progenitor cells and neurons, increased proliferation and hypertrophy was observed 
in Pten-deficient astrocytes, which was thought underlie the enlarged brains in mutant 
mice (Fraser et al., 2004). More importantly, Pten deficiency in Bergmann glia of 
cerebellum caused premature differentiation and abnormal anchorage of glia leading to a 
failure in granule neuron migration. Consequently, Pten-mutant cerebellum exhibited 
severely disorganized foliation and lamination (Yue et al., 2005).  
 
The successful studies summarized above documented the major molecular and cellular 
consequences of Pten mutations that may underlie the deformities in brain tissue and 
architecture. However, more definitive findings reflecting the neurological dysfunctions 
represented by PTEN syndrome patients only came with the behavioral studies and more 
comprehensive neural network analyses. Accordingly, deletion of mouse Pten gene 
specifically in cortical neurons, and in a subpopulation of hippocampal neurons caused 
notable phenotypes similar to ASD, including macrocephaly, abnormal social behaviors, 
and exaggerated responses to sensory stimuli (Kwon et al., 2006). More rigorous studies 
have uncovered that Pten-deficient neurons exhibit abnormal neuronal structure, 
including enlarged caliber of neuronal projections and increased dendritic spine density. 
Pten deletion also led to defects in synaptic structures as evidenced by weakened synaptic 
transmission and synaptic plasticity in pyramidal neurons of hippocampus. Lastly, mutant 
brains displayed severe myelination defects, including thickening and unraveling of the 
myelin sheath surrounding the hypertrophic axons in the corpus callosum (Fraser et al., 
2008).  
 
4.1.5 Neuronal diversity and PTEN signaling 
 
It should be considered that mammalian cerebral cortex accommodates several types of 
neurons with different functions, morphology and origin. It is, however, still not well 
known about how different neuronal populations respond to PTEN mutations in the 
cortex, which functions as the main cognition site. Therefore, identifying the major cell 
types that are severely affected by PTEN mutations will contribute significantly to my 
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understanding of mechanisms leading to the observed disease manifestations. In the 
present study, I specifically analyzed pyramidal neurons, including corticocortical upper 
layer neurons and subcortical deeper layer neurons in Pten-mutant mice. My results 
showed that these two types of projection neurons are affected in distinctive ways in the 
absence of Pten gene. More specifically, 1) Even though I did not detect any defects in 
the production of upper layer neurons, they failed to migrate radially to more superficial 
cortical layers. Instead, they remained in the lower layers (V and VI) mixed with deeper 
layer neurons. Glial collapse seemed to be the major mechanisms that caused their 
ectopic localization. 2) On the other hand, deeper layer neurons were properly located, 
however their number was significantly reduced, suggesting a defect in their production 
or maintenance.  This study, therefore, uncovers the distinct roles of Pten in different 
neuronal subpopulations of cerebral cortex, and further stresses the necessity to clarify 
the cellular defects in neurodevelopmental and cognitive disorders.  
 
4.2 Results 
 
4.2.1 Pten deficiency leads to neonatal lethality that can be rescued by Rictor loss  
 
In order to understand the functions of Pten and Rictor genes in cortical neurogenesis 
during the embryonic stages, I generated three types of mutant mice. Upon cre-mediated 
recombination under the control of hGFAP promoter at around E12.5 (Wang et al., 
2009), the genotypes of the mutant mice that I utilized were 
PtenΔ/Δ; Rictor+/Δ (Pten-deficient), Pten+/Δ; RictorΔ/Δ (Rictor-deficient), and 
PtenΔ/Δ; RictorΔ/Δ (Pten-Rictor double-deficient) (Figure 23A). It is worth nothing that 
PtenΔ/Δ; Rictor+/Δ and  Pten+/Δ; RictorΔ/Δ brains were indistinguishable from 
PtenΔ/Δ and RictorΔ/Δ brains, respectively (data not shown), suggesting that Rictor-
heterozygosity in Pten-deficient mice or Pten-heterozygosity in Rictor-deficient mice is 
inconsequential.  
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When I examined the overall phenotypes of the mutant mice, I noted that Rictor-deficient 
mice were indistinguishable from their wild type littermates in many aspects, including 
survival, social behaviors, breeding, body weight and health conditions (data not shown 
and Figure 23B). All of the Pten-deficient mice, however, had severely enlarged cranium 
and significantly reduced body weight. These mice were lethargic, scruffy and presented 
secondary abnormalities such as GI track obstruction. Since they were not even able to 
feed themselves after a certain stage, I humanely euthanized them within approximately 
2-weeks of age based on the established protocols (data not shown and Figure 23B). 
Interestingly, most of the double-deficient mice had markedly improved health 
conditions, including increased body weight, ability to feed, and socializing behaviors 
with the littermates (data not shown). The median survival rate also increased from 15 
days seen in Pten-deficient mice to 53 days in double-deficient mice. Furthermore, 20% 
of the double-deficient mice survived beyond 4-months (Figure 23B), though there was 
still a noticeable cranial enlargement (Figure 23C). 
 
4.2.2 Brain enlargement and tissue degeneration caused by Pten deficiency is 
alleviated by concurrent Rictor loss 
 
In order to identify the abnormalities that might led to early lethality in Pten-deficient 
mice, I analyzed the mutant brains in comparison to their littermate or aged-matched 
controls at birth (P0.5). I observed approximately 30% increase in brain weight compared 
to the wild type controls (Figures 23C and 23D), consistent with the previous findings 
(Groszer et al., 2001). Curiously, Pten-deficient brains also displayed red spots with 
varying sizes enriched at their pial surface of the cortices (Figure 23C). These spots were 
reminiscent of necrotic and bloody areas frequently observed in brain tumors. 
Remarkably, none of these red spots were detected upon concurrent Rictor-loss in 
double-deficient brains. Even though the brain weight of the double-deficient brains was 
15-17% more than that of control brains, it was still significantly reduced compared to 
Pten-deficient brains (Figures 23C and 23D. Rictor-deficient brains, on the contrary, 
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were smaller and weighed marginally but significantly less than the controls (Figures 23C 
and 23D). 
 
I then aimed to characterize whether there was a cellular damage in Pten-deficient brains, 
especially at the red blood-spots on the dorsal cortices. To this end, I analyzed the 
expression of an apoptotic marker, cleaved caspase-3, in parallel with Pten (Figure 23E). 
While control brains did not exhibit any signs of cell death indicated by the absence of 
cleaved caspase-3, I detected large apoptotic areas, which are accompanied by tissue 
degeneration in Pten-deficient brains. These areas of “dead-tissue” displayed diminished 
tissue integrity and enrichment of cells with small rounded apoptotic nuclei. On the other 
hand, I did not detect an obvious cell death in double-deficient brains, even though Pten 
expression was completely lost (Figure 23E). These results, altogether, suggest that Pten 
deficiency causes brain enlargement accompanied by cortical bleeding, apoptosis and 
tissue degeneration, which are significantly reversed by simultaneous Rictor loss.  
 
4.2.3 Pten deficiency causes cortical layering defects 
 
I further analyzed the dorsal neocortices of the mutant brains with regards to neural 
populations, more specifically, cortical pyramidal projection neurons to determine 
whether brain enlargement or tissue degeneration has any effects on specific cells. 
Among these neurons, Cux1 (Cutl1) is expressed by all upper layer neurons (ULNs), 
while Ctip2 is a deeper layer neuron (DLN) marker (Leone et al., 2008; Nieto et al., 
2004). I firstly analyzed Pten-deficient brains in comparison to littermate controls to 
determine how/whether the extensive tissue degeneration and cellular death affect these 
cortical neurons. Control P0.5 brains displayed organized layering of ULNs at the upper 
parts of the cortex, and another layer of DLNs below this region (Figures 24A-24C). 
Between DLNs and the subventricular zone (SVZ), a well-defined intermediate 
progenitor cell (IPC) layer, which is also Cux1+, was observed. Pten-deficient brains, 
however, were characterized by three easily noticeable layering defects: 1) As opposed to 
their normal location at the upper cortex close to pia matter, majority of the upper layer 
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neurons were found right above the IPC layer, and below or mixed with the deeper layer 
neurons (Figures 24A-24C). Since this area normally contains newly generated and 
radially migrating ULNs, I termed these cells as “migrating Cux1+” cells. While 
approximately 42% of the total Cux1+ cells were in a migrating position in control brains, 
this ratio increased up to 72% in Pten-deficient cortices (Figures 23D-23F). 
Consequently, there was a reduction in the percentage of ULNs properly located at the 
more superficial parts of the cortex (58% in control versus 28% in Pten-deficient brains). 
Total number of the Cux1+ cells, however, changed only slightly between Pten-deficient 
versus control brains. 2) Deeper layer neurons were abnormally located on top of or 
mixed with the upper layer neurons as a result of this layering defect observed in ULNs 
(Figures 24A-24C). 3) There was a substantial (~70%) loss in deeper layer neuron 
number in the neocortices of Pten-deficient brains (Figure 24G). This might have 
partially happened due to the extensive apoptosis that I observed in Pten-deficient brains. 
Despite of this reduction in DLN, cortical thickness of the Pten-deficient brains was 
significantly increased, consistent with my previous findings and other studies showing 
that Pten loss causes an increase in brain size and brain weight (Figures 24A, 24C, 23C, 
23D) (Backman et al., 2001; Groszer et al., 2001; Kwon et al., 2001).  
 
My additional analyses using double-deficient brains have indicated that some, but not 
all, of these abnormalities can be reversed by simultaneous Rictor loss. More specifically, 
the percentage of the migrating Cux1+ cells reduced to 50%, and the percentage of the 
Cux1+ ULNs properly located at the upper cortex increased to 50% from 28% seen in 
Pten-deficient brains (Figures 24D-24F). This reduction in migrating Cux1+ cells and 
improvement in the proper ULN localization resulted in a better layering of the cortical 
neurons (Figures 24B and 24C). However, the total number of the Cux1+ cells, 
surprisingly, reduced by approximately 30% compared to control brains (Figure 24F). I 
also observed an increase in DLN number compared to Pten-deficient brains, however it 
was still less than the wild type control brains (Figure 24G). Increased cortical thickness 
was also alleviated, as I observed a thinner cortex in double-deficient brains compared to 
Pten-deficient brains (Figure 24C). Rictor-deficient brains, on the other hand, were 
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mostly normal except for a decrease in the cortical thickness, and a reduction in the total 
number of ULN (Figures 24B, 24C and 24F). These results altogether suggest that Pten 
loss causes major neuronal layering defects in the cortices, which are mainly contributed 
by misplaced ULNs, and that DLNs require functional Pten gene to form and/or survive. 
Additional Rictor loss, however, can partially alleviate brain abnormalities associated 
with the Pten-deficiency. 
 
4.2.4 Pten deficiency causes a collapse in glial fibers in the cortex 
 
My findings presenting the neuronal layering defects observed in Pten-deficient cortex 
necessitated the understanding of the cellular mechanisms leading to this noteworthy 
phenotype. Upon their formation, Cux1+ cells climb up against the glial fibers, pass 
through the already formed DLNs, and ultimately terminate their migration at the dorsal 
side of the cortex (Britanova et al., 2006; Tarabykin et al., 2001). As the Pten-deficient 
Cux1+ cells seem to accumulate below the DLNs, I hypothesized that there was a failure 
in proper migration leading to misplacement of the ULNs. I, therefore, examined the glial 
fibers labeled with Nestin. Control brains were characterized with a network of thin glial 
fibers stretching from the lateral ventricle (LV) to the very dorsal surface of the cortex, 
and forming a tight passage between the apical and basal surface of the cortex (Figure 
25A). Many newly generated and migrating Cux1+ cells were attached to or at the close 
proximity these fibers, suggesting that there is a physical interaction between the 
migrating neurons and the glial fibers facilitating the cellular movement. In stark contrast, 
this delicate network was severely damaged in Pten-deficient cortex, as the glial fibers 
were but short protrusions from the LV, which were disconnected from the rest of the 
cortex (Figure 25A). Interestingly, Cux1+ cell accumulation was mostly observed right at 
the cortical end of the short glial fibers, suggesting that these cells could migrate only 
until the region where the defective glial tracks extend (Figure 25A). As evidenced by the 
altered glial fibers around the corpus callosum, the regional disconnections in Pten-
deficient brains might not be limited to the cortex, but may even extend to the two 
hemispheres (Figure 25B). Since double-deficient brains had comparatively better ULN 
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migration, I asked whether the glial fibers were more intact compared to Pten-deficient 
cortices. I indeed observed an improvement in the formation of glial tracks, which were 
now able to better extend from the LV to the apical surface of the cortex (Figure 25A). 
These results suggest that an interruption in glial fibers as a result of Pten loss causes a 
disconnection between the LV, where many neurons are generated, and the superficial 
regions of the cortex, where the ULNs are ultimately located. As a result, the newly 
generated ULNs fail to migrate to their terminal destination, which can be partially 
rescued by simultaneous Rictor deficiency.  
 
4.2.5 Intact Pten signaling is required for the generation and/or maintenance of 
deeper layer neurons 
 
Having shown that migration defects, as a result of collapsed glial fibers, cause misplaced 
ULNs and layering abnormalities, I wanted to investigate the mechanisms leading to the 
significant loss in DLN population. hGFAP-cre is activated mainly at the dorsal regions 
of the brain, and only the cells located in or generated from this area undergo cre-
mediated recombination (Wang et al., 2012). As a result, virtually entire ventral brain is 
wild type, whereas dorsal regions are mutant in a cre-positive mouse (Figure 26C). I 
initially tested this system in immunohistochemistry analyses, and showed that Pten was 
expressed in almost every part of the wild type brain, however its expression was indeed 
limited to the ventral parts of the Pten-deficient brains (Figure 26A). As a consequence of 
Pten deletion in the dorsal regions, including the neocortex, pAktS473 level was 
significantly elevated in Pten-deficient cortices, which was reversed upon simultaneous 
Rictor loss in double-deficient brains (Figure 26A).  
 
I subsequently examined an area where cre-positive and cre-negative regions are adjacent 
to each other in order to test whether DLN loss was due to an intrinsic mechanism rather 
than a secondary phenotype of other abnormalities, including enlarged brain, cortical 
bleeding, and layering defects, (Figure 26C). In control brains, these two regions are not 
distinguishable, as both sides are wild type. In Pten-deficient brains, however, Pten 
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expression clearly delineates two different regions, as dorsal region (mutant) lacks Pten 
expression while the neighboring ventral part (wild type) has intact Pten expression 
(Figure 26B). Remarkably, DLNs were significantly reduced at the dorsal region of the 
Pten-deficient brains, where Pten was virtually absent (Figure 26B). On the contrary, 
ULNs of the ventral part in the same Pten-deficient brain was as normal as a control 
brain, since Pten expression was still intact at this region. Interestingly, both dorsal and 
ventral region of the double-deficient brains exhibited a normal layering of DLNs, even 
though only ventral region had intact Pten while the dorsal region lacked Pten expression 
(Figure 26B). These results suggest that Pten has critical roles for the generation and/or 
maintenance of DLNs, and that DLN loss was not due to a simple tissue degeneration I 
observed in Pten-deficient brains. Furthermore, even though Akt signaling is the major 
pathway that is regulated by Pten, other downstream components might have roles in the 
altered neuronal processes, underlining the findings that concurrent Rictor loss could 
rescue a portion of the Pten deficiency driven abnormalities, but not all. 
 
4.2.6 Pten deficiency causes increased gliogenesis and cellular proliferation  
 
The lethargic phenotypes that are gradually increasing in Pten-deficient mice led us to 
investigate how the brain abnormalities change over time. Due to the short life span of 
Pten-deficient mice, the latest time point that I could analyze was P16. However, as there 
was only one Pten-deficient mouse survived up to this period, I included P9 mutant mice 
into my analyses in comparison with the littermate or aged-matched wild type controls. 
Pten-deficient brain at P16 displayed significant enlargement in both dorsoventral and 
anteroposterior axes, though cerebellum was notably smaller than the controls (Figures 
27A and 27B). Accordingly, cortical thickness was also drastically increased (Figure 
27C). As these mice were perfused with 4% PFA, the red blood spots that we observed at 
Pten-deficient P0.5 cortices disappeared at P9 and P16. I then examined the glial 
populations to see whether they contributed to the increased brain size. Remarkably, both 
P9 and P16 Pten-deficient brains were occupied with GFAP+ reactive astrocytes that 
spread to many areas in cortex and corpus callosum (Figures 28A and 28D). These cells 
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were also highly proliferative, indicative of their aggressive expansion (Figures 28B and 
28C). Double-deficient brains and cortices, on the other hand, were markedly smaller 
than that of Pten-deficient brains, and more importantly, reactive astrocyte expansion was 
mostly limited to corpus callosum (Figure 28A and 28D). The total and the proliferating 
GFAP+ reactive astrocytes were also reduced in double-deficient brains compared to 
Pten-deficient brain (Figures 28B and 28C). Even though some regions exhibited 
enrichment of Olig2+ cells, I did not observe a consistent abnormality in Olig2+ 
population in both Pten-deficient and double-deficient brains, even though further 
analyses are still required (Figures 28B and 28D). Interestingly, Rictor-deficient brains 
had a slight reduction in GFAP+ population, consistent with the finding that these mutant 
brains are smaller than the control littermates (Figures 28C, 23C, 23D, 27A and 27B). 
These results indicate that Pten deficiency driven abnormal gliogenesis contribute 
significantly to enlarged cortex. Though, there might be other mechanisms leading to this 
enlargement, as double-deficient brains were still bigger that the wild type brains despite 
the alleviated gliogenesis.  
 
4.2.7 Neuronal layering defects in Pten-deficient brains persist during the postnatal 
stages  
 
Similar to my findings at P0.5, Pten-deficient brains had severe neuronal layering defects 
at P9 and P16 (Figures 29A and 29B). More specifically, the majority of the Pten-
deficient Cux1+ cells were accumulated and mixed with the Ctip2+ DLN population right 
above the LV, causing an absence of neuronal delineation.  Consequently, there was a 
significant reduction in ULN population properly located at the upper surface of the Pten-
deficient cortex (Figures 29A and 29B). The persistent loss in DLN population displayed 
a regional variation, as some areas were more severe that the others. In double-deficient 
cortices, I observed an improved neuronal layering, as the ULN and DLN populations 
were more distinctly separated, though some double-deficient brains still exhibited the 
presence of ectopic ULNs below the DLN populations (Figure 29B). Furthermore, there 
was still a reduction in superficially located ULN and overall DLN populations in some 
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double-deficient brains (Figures 29A and 29B). These results suggest that, neuronal 
layering defects and reduction in DLN population persist in postnatal stages of Pten-
deficient brains. Concurrent Rictor loss can only partially rescue these neuronal defects 
with an additional improvement in glial phenotype. Lastly, Akt-independent functions of 
Pten might also be involved in cortical deficits that I reported.  
 
4.2.8 Pten regulates the formation of cerebellum via its Akt-dependent and –
independent functions 
 
Previous studies have shown that Pten is essential for the glial scaffold formation and 
granule neuron migration during the laminar formation in the cerebellum (Yue et al., 
2005). Consistently, Pten-deficient cerebellum exhibited a failure in structural integrity 
with the absence of proper foliation. I, thus, aimed to test whether Rictor loss could 
reverse these phenotypes by inhibiting abnormally elevated Akt signaling. I first 
confirmed Pten-deficient cerebellum phenotype by examining the P9 cerebella (Figure 
30A). While wild type control cerebellum had ten lobes with clear foliation patterns, the 
architecture of the Pten-deficient cerebellum was severely altered, as the foliation and 
lobular delineation was virtually absent. Cerebellar granule cell precursors and mature 
granule neurons were mostly randomly located, and failed to form distinct EGL and IGL, 
respectively. Cerebellar size was also reduced compared to the control (Figure 30A). 
Having established that Pten deficiency causes severe malformations in the cerebellum, I 
analyzed aged matched double-deficient mice. My preliminary results showed that there 
was only a slight improvement in the overall structure of the double-deficient cerebellum. 
Even though distinct cerebellar folia started to appear, the laminar formation was still 
drastically damaged (Figure 30A). I then decided to analyze the cerebella of the double-
deficient mice that survived significantly longer than the Pten-deficient mice. I evaluated 
the cerebellar improvement by several criteria, including 1) Presence of an enhancement 
in overall architecture or structural integrity 2) Increased cerebellar size 3) Formation of 
IGL-like granule neuron clusters 4) Presence of distinct lamination 5) Absence/reduction 
of cell clusters in ML. Based on these criteria, only 2/8 double-deficient cerebella 
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displayed notable improvement, while another 2/8 had partial improvement, which 
mostly included an increase in granule neurons or granule neuron precursors. The 
remaining 4/8 double-deficient cerebella did not show a noteworthy change compared to 
the Pten-deficient cerebella (Figure 30B). I, therefore, concluded that both Akt-dependent 
and -independent functions of Pten regulate the cellular processes in a developing 
cerebellum, leading to a proper glial scaffold formation, granule neuron migration and 
ultimately cerebellar lamination. 
 
4.3 Discussion 
 
Herein I described the roles of Pten and Rictor in embryonic cortical development. 
Biallelic deletion of Pten in neural stem/progenitor cells during the early development of 
a mouse brain leads to previously characterized abnormalities, including enlarged brain, 
severe cerebellar malformations, and ultimately neonatal lethality. Additionally, I have 
uncovered novel and essential functions of Pten in cortical neuronal layering, 
maintenance of glial fibers facilitating the neural migration, and generation/maintenance 
of a population of cortical neurons. I further demonstrated that simultaneous deletion of 
Rictor reversed some, but not all, of the detected Pten deficiency phenotypes, suggesting 
that both Akt-dependent and -independent functions of Pten regulate the important stages 
of cortical neurogenesis. 
 
4.3.1 Cortical tissue degeneration accompanies Pten-deficiency-associated 
macrocephaly  
 
Megalencephaly is clinically categorized in “malformations of cortical development” 
(MCD), and it is a disorder of brain size. More specifically, megalencephaly refers to an 
abnormally large brain that is above the mean of the corresponding age and gender by 2 
(or 3 in practice) standard deviations (SD). It is further classified as megalencephaly with 
normal cortex by imaging, megalencephaly with polymicrogyria, and dysplastic 
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megalencephaly  (including hemimegalencephaly). These severe brain defects can all 
result from abnormalities in several components of PI3K/AKT signaling pathway, 
including PTEN, PIK3R2, PIK3CA, MTOR, AKT, TSC1/2, and FGFR3 (Guerrini and 
Dobyns, 2014). Macrocephaly, a representation of megalencephaly, is the most common 
abnormality in PTEN syndrome patients (PHTS patients), 20-50% of whom are also 
diagnosed with ASD (Lynch et al., 2009; Varga et al., 2009). As previously shown, Pten-
deficiency in mice causes enlarged cranium and bigger brain, suggestive of macrocephaly 
(Groszer et al., 2001). I additionally noted that Pten-deficient brains had “bleeding red 
spots” on their cortices, which subsequently correlated with extensive apoptotic regions 
and tissue degeneration. My following analyses suggested that a significant increase in 
the reactive astrocyte number occurs concomitantly with the progressive enlargement of 
the postnatal Pten-deficient brains. It is, therefore, possible that an initial enlargement in 
brain size due to Pten deficiency leads to an increased intracranial pressure. This stress 
may consequently initiate tissue bleeding in the cortex, which in turn triggers the 
expansion of reactive astrocytes. Thus, it is important to determine whether the brains of 
megalencephaly patients undergo this cascade of abnormalities leading to severe 
structural defects. Importantly, these abnormalities were significantly alleviated by 
simultaneous Rictor loss in double-deficient mouse brains, which exhibited a notable 
reduction in brain size, disappearance of cortical bleeding and improvement in glial 
response, as detected by a decline in reactive astrocytes. Given that PI3K/AKT signaling 
is one of the most altered pathways in megalencephaly syndromes in general, clinical 
strategies that target Rictor/mTORC2 signaling can benefit patients with megalencephaly. 
 
4.3.2 Intact Pten signaling is essential for migration of upper layer neurons and 
neuronal lamination in cerebral cortex  
 
Pyramidal neurons of the cerebral cortex form a six-layer structure in an inside out 
manner. According to this system, late-born neurons migrate and pass through the early-
born neurons to be localized at more superficial levels. At the end of the cortical 
development, ULNs occupy upper layers (II-IV) below the pia mater, while deeper layer 
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neurons are located in lower layers (V-VI) despite that they are generated earlier than 
ULNs (Britanova et al., 2006). In order for this cellular process to work properly, an 
intact network of glial fibers stretching from the apical surface of the LV to the pial 
surface at the meninges is required. These long processes serve as a migratory scaffold 
and guide newborn neurons to their ultimate destinations in the cortical plate (Molyneaux 
et al., 2007). In Pten-deficient cortices, however, the majority of the ULNs were located 
right above the VZ/SVZ. Some of these ULNs were mixed with the DLNs, while some of 
them were even below the DLN layer. Consequently, neuronal layering was severely 
damaged, and I did not detect a proper neuronal lamination with distinct layers, even 
though total ULN number did not change. My later analyses underlined the essential roles 
of intact glial fibers, as Pten-deficient brains lacked an intact fibrous structure guiding the 
migrating neurons. Interestingly, ULNs could migrate only until a point where defective 
fibers were extending. It is, then, worth noting that one of the outcomes of MCD patients 
is a defect in cortical layer formation, which can occur when a large number of neurons 
do not reach the cortex, or to their proper position (Guerrini and Dobyns, 2014). My 
findings, therefore, uncover one of the cellular and molecular mechanisms triggering 
cortical layering defects. Extrapolations from this study to the human brains with 
abnormal neuronal migration (e.g. lissencephaly, pachygyria, cobblestone cortex) will 
help us better understand the underlying cause of cortical malformations.  
 
4.3.3 Deeper layer neurons require Pten signaling to form and/or survive 
 
During the embryonic development, neurons are generated by both direct and indirect 
modes of neurogenesis. While RGCs (and possibly neuroepithelia) can directly give rise 
to mature neurons through asymmetric divisions, neurogenesis from symmetric divisions 
of more restricted IPCs is considered as an indirect path (Kriegstein et al., 2006; 
Molyneaux et al., 2007; Noctor et al., 2008). Especially early-born neurons, such as 
DLNs, can be formed by both direct and indirect neurogenesis. My findings showed that, 
despite their proper localization right above the VZ/SVZ, DLN populations were severely 
reduced in Pten-deficient brains. This phenomenon was somewhat opposite of my 
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findings with regards to ULN populations, which were fully generated, however 
ectopically localized. These findings altogether suggest that pyramidal neurons of the 
cerebral cortex respond differently to Pten deficiency, and that it is critical to determine 
the specific neuronal defects in each PHTS patient before applying a broad-spectrum 
treatment plans. Furthermore, as concurrent Rictor loss rescues only a portion of DLNs, 
both Akt-dependent and -independent signals regulate the generation and/or maintenance 
of this neural population.  
 
Future directions of this study will include identification of the specific roles of Pten in 
preserving the glial fibers and generating and/or maintaining the DLN populations. 
Furthermore, behavioral analyses will pinpoint the cognition-associated consequences of 
neuronal layering defects induced by Pten loss (future directions are discussed in detail in 
Chapter VI).  
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Figure 23. Pten deficiency leads to various brain abnormalities and neonatal lethality that 
can be alleviated by Rictor loss.  
 
(A) Schematic representation of the genetic configurations in 
PtenΔ/Δ; Rictor+/Δ (Pten-deficient),  Pten+/Δ; RictorΔ/Δ (Rictor-deficient), and  PtenΔ/Δ; 
RictorΔ/Δ (Pten-Rictor double-deficient) mice. Floxed genes undergo hGFAP-cre-mediated 
recombination at around E12.5. 
(B) Kaplan-Meier survival curves of the mutant mice. The Mantel-Cox (Log-rank) test is used to 
compare the curves statistically.  
(C) Whole-mount images of 4% PFA-fixed P0.5 brains from wild type control and mutant 
brains.  
(D) Normalized brain weights of the P0.5 wild type control and mutant mice. The average brain 
weight of the control mice is set to 100, and each sample is calculated accordingly.  
(E) Apoptotic marker (cleaved caspase-3) and Pten expression is detected using IHC techniques 
on P0.5 brains. Dashed areas indicate the apoptotic regions in PtenΔ/Δ; RictorΔ/+ brain. Insets 
are higher magnification images from the spots indicated by asterisks.  
Scale bars, 200 µm. 
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Figure 24. Pten deficiency causes defects in cortical neuronal layering. 
 
(A-C) Upper layer neurons (ULNs) and deeper layer neurons (DLNs) of P0.5 wild type control, 
Pten-deficient, Rictor-deficient and double-deficient brains are labeled with Cux1 and Ctip2 
antibodies, respectively. NeuN antibody is used as a general neuron marker.  
Wild type control brain is shown on the left, Pten-deficient brain is shown on the right. White 
rectangles on the coronal brain sections indicate the areas that are shown in higher 
magnifications (A). 
(D-G) Quantification of Cux1+ cells (basal (D), migrating (E) and total (F)) and total Ctip2+ cells 
(G)  
Unpaired t-test is used to compare the groups. ULN: Upper layer neurons, DLN: Deeper layer 
neurons, LV: Lateral ventricle. Scale bars, 100 µm (except for the coronal whole brain image, 
which is 500 µm). 
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Figure 25. Pten deficiency causes a collapse in the radial glial fibers of the cerebral cortex. 
 
(A) Cux1+ cells and Nestin+ glial fibers are labeled in P0.5 wild type control brains along with 
the three mutants.  
(B) A coronal view of the wild type control and Pten-deficient brain illustrating the glial 
abnormalities around the corpus callosum. White boxes indicate where the higher magnification 
images are taken. 
LV: lateral ventricle. Scale bars, 100 µm (A), 500 µm (B). 
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Figure 26. Intact Pten signaling is required for the generation and/or maintenance of the 
deeper layer neurons. 
 
(A) Pten and pAktS473 expression is detected in P0.5 wild type control, Pten-deficient and 
double-deficient brains. Note the hGFAP-cre-mediated loss of Pten expression in the dorsal parts 
of the Pten-deficient and double deficient brains.  
(B) Ctip2+ DLNs and Pten expression is examined at a cross section that consists of adjacent cre-
positive (dorsal) and cre-negative (ventral) parts. White dashed lines indicate the mutant regions 
that lack Pten expression.  
(C) Cartoon representation of regional cre-activation in the brain. Dorsal brain undergoes cre-
mediated recombination in a mutant brain, while ventral brain remains wild type.  
Scale bars, 1 mm (A), 200 µm (B). 
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Figure 27. Pten deficiency associated abnormalities persist in postnatal brains. 
 
(A) Whole-mount images of 4% PFA-fixed P16 brains from wild type control and mutant brains. 
(B) Weights (mg) of the 4% PFA-fixed brains. Note that only one Pten-deficient brain is used in 
this analysis, as only one mouse from this mutant group survived until P16. 
(C) H&E staining of P16 wild type control and mutant brains. The thickness of the cortices is 
indicated. Lower portion of the hippocampus is taken as reference point.  
Scale bars, 200 µm (A), 500 µm (C). 
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Figure 28. Pten deficiency causes increased gliogenesis and cellular proliferation. 
  
(A) Glial cells in P16 brains are labeled with GFAP (astrocytes) and Olig2 (oligodendrocytes).  
(B) Proliferation ability of the GFAP+ cells is tested with BrdU labeling. P16 mice are injected 
with BrdU twice. Two hours after the last injection, brains are collected, followed by analyses of 
cellular proliferation. White insets show the higher magnification.  
(C) GFAP+ and GFAP- proliferating cells are quantified in P16 brains. Note that only one Pten-
deficient brain is used in this analysis, as only one mouse from this mutant group survived until 
P16. 
(D) Glial cells in P9 brains are labeled with GFAP and Olig2. DAPI labels the cell nuclei. 
Images scan the cortex from the basal surface to the lateral ventricle.  
Scale bars, 500 µm (A), 200 µm (B and D). 
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Figure 29. Neuronal layering defects in Pten-deficient brains persist during the postnatal 
stages.  
 
(A-B) ULNs and DLNs of wild type control, Pten-deficient, Rictor-deficient and double-
deficient brains are labeled with Cux1 and Ctip2 antibodies, respectively.  
P16 brains are shown in (A), and P9 brains are shown in (B). White rectangles in (A) indicate the 
area where the higher magnification images are taken from. Images from P9 brains scan the 
cortex from the basal surface to the lateral ventricle. 
Scale bars, 500 µm (A), 200 µm (B).  
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Figure 30. Pten regulates the formation of cerebellum via its Akt-dependent and -
independent functions. 
 
(A) H&E images of P9 cerebella from wild type control and mutant mice. Note the well-
established structure in the control cerebellum. Rictor-deficient cerebellum is smaller than the 
control, but otherwise mostly normal. Pten-deficient cerebella are characterized by severe 
structural deformities. Double-deficiency has only slight improvement compared to the Pten-
deficient cerebella. 
(B) H&E images of double-deficient cerebella from eight mice with various ages. Structural 
improvement is evaluated by five criteria: 1) Presence of an enhancement in overall architecture 
or structural integrity 2) Increased cerebellar size 3) Formation of IGL-like granule neuron 
clusters 4) Presence of distinct lamination 5) Absence/reduction of cell clusters in ML.  
Scale bars, 1 mm.  
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Chapter V: Experimental procedures, materials and methods 
 
 
5.1 Control and mutant mice 
 
The mutant mice used in this study had various genotypic configurations. For brain tumor 
formation hGFAP-cre; p53flox/flox, hGFAP-cre; p53flox/flox; Rictorflox/+, hGFAP-cre; 
p53flox/flox; Rictorflox/flox were used. A second group of mice as a validation cohort carried 
additional Pten mutation as follows: hGFAP-cre; p53flox/flox; Ptenflox/+, hGFAP-cre; 
p53flox/flox; Ptenflox/+; Rictorflox/+ (or RictorKO/+), hGFAP-cre; p53flox/flox; Ptenflox/+; 
Rictorflox/flox. For developmental biology studies, we utilized a non-tumorigenic mutant 
mouse model with genotype of hGFAP-cre; p53flox/+;Rictorflox/flox. The control group was 
a collection of hGFAP-cre(negative) mice that were phenotypically indistinguishable and 
completely healthy. In addition, brain tumors from a group of Ptch1+/- mice (Treisman et 
al., unpublished data) with the genotype of hGFAP-cre; Ptch1+/-, hGFAP-cre; Ptch1+/-; 
p53flox/flox, hGFAP-cre; Ptch1+/-; p53flox/R172P were used as SHH medulloblastoma 
controls. All the mice were maintained in the mixed backgrounds of C57Bl6, 129Svj, and 
FVB, which improve overall health and life span of the mice. Age and littermate-matched 
control and mutant mice were used for the developmental analyses to minimize the 
impact of modifier genes. Brain tumor mice were either littermates or close relatives 
collected over approximately 5 years. All mice in this study were cared for according to 
the guidelines that were approved by the Animal Care and Use Committees of the 
University of Michigan at Ann Arbor and Children’s National Medical Center, 
Washington, DC. 
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5.2 Genotyping and PCR 
 
Taq 2X MeanGreen Master Mix (Empirical Bioscience) was used in PCR experiments 
along with the following primer sets for tail and tumor tissue genotyping: 
p53  
X6.5: 5’ ACAGCGTGGTGGTACCTTAT 3’ 
e7: 5’ CATGCAGGAGCTATTACACA 3’ 
e4: 5’ TGGGACAGCCAAGTCTGTTA 3’ 
Rictor (flox)  
F1: 5’ CAAGCATCATGCAGCTCTTC 3’ 
F3: 5’ TGCCTCATAGCATCTCCTCA 3’ 
R3: 5’ AAGCATGGTAACATGGTATCAAAA 3’ 
Rictor (KO)  
C1: 5’ AGATAGCCAGAAGTGGGCATCGGACCC 3’ 
C2: 5’ CATCTAGGACTTCTCTCTGCAACAGATGCAGATCAC 3’ 
C3: 5’ TGGGGTTCGTGTCCTACAACACACACTCC 3’ 
Pten  
A: 5’ GTCACCAGGATGCTTCTGAC 3’ 
C: 5’ CTCCTCTACTCCATTCTTCCC 3’ 
E: 5’ ACTATTGAACAGAATCAACCC 3’ 
Cre  
ICres: 5’ CCGTTTGCCGGTCGTGGG-3’ 
ICreas: 5’ CGTATATCCTGGCAGCGATC 3’ 
Rosa-26 LacZ (R26R)  
R26R-1: 5’ AAAGTCGCTCTGAGTTGTTAT 3’        
R26R-2: 5’ GCGAAGAGTTTGTCCTCAACC 3’ 
 R26R-3: 5’ GGAGCGGGAGAAATGGATATG 3’ 
 
5.3 Tissue preparations, histopathology and tumor diagnosis 
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Approximately 70% of the mice were sacrificed due to observable neurological 
symptoms including enlarged head, tremor, seizure, ataxia, or lack of balance indicating 
the presence of an end-stage brain tumor. One set of these mice were perfused using 4% 
paraformaldehyde (PFA), brains were collected and kept in 4% PFA for at least one day. 
The second set of mice sacrificed based on cervical dislocation procedure after anesthesia 
with 3.5 % Tribromoethanol (Avertin). The brains were collected in cold environment, 
soaked in cold PBS and cut sagittally along the midline. One half of the brain was kept in 
4% PFA while the other half was used for SNAP-frozen tissue collection in liquid 
nitrogen and cell culture preparation. Processed and paraffin embedded brain samples 
were sectioned sagittally at 5 µm and collected on Superfrost Plus microscope slides 
(Fisher Scientific). Hematoxylin and eosin (H&E) staining was performed approximately 
every 10 slides and adjacent sections were subjected to immunohistochemical analysis 
using the antibodies for p53, Olig2, GFAP, Synaptophysin and Pax6. Samples were 
analyzed under a light microscope by two investigators (SCP and SA) based upon the 
World Health Organization (WHO) criteria of the classification of tumors in the CNS 
(Louis et al., 2007). Final diagnoses were reached as a consensus of H&E staining 
findings and immunohistochemical analyses. 
 
High-grade gliomas included anaplastic astrocytoma, glioblastoma, anaplastic 
oligoastrocytoma and anaplastic oligodendrioglioma. The multinucleated and/or 
horseshoe-shaped giant cells and atypical pleomorphic tumor nuclei, including elongated, 
bent and dark stained nuclei characterizing neoplastic cells were noted in the malignant 
tumors. The anaplastic tumor cells had increased mitotic activity with abnormal mitotic 
spindle and coarse nuclear chromatin. The malignant tumors exhibited aggressive growth 
patterns and some of them displayed secondary structures of Scherer, including 
perineuronal satellitosis, perivascular growth and subpial aggregates. The dome tumor 
had a more nodular and relatively sharp demarcated growth with the surrounding 
parenchyma. Microvascular proliferation and/or necrosis (pseudo-palisading, geographic 
or coagulation necrosis) were required for a GBM diagnosis. Oligodendrioglioma cells 
had round nuclei and clear cytoplasm (“fried egg” appearance). Regardless of their 
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location and type, majority of the glioma cells had nuclear p53 and Olig2 staining while 
Pax6 immunoreactivity was very low or none. GFAP staining around the irregularly 
shaped nuclei labeled the tumor cells, though, many reactive astrocytes were GFAP+ as 
well. Synaptophysin staining was absent within the tumor cells and highlighted the 
entrapped neuropil.  
 
Medulloblastomas had a higher nuclear/cytoplasm ratio with scant cytoplasm. Classic 
medulloblastomas had dark small nuclei while large cell/anaplastic tumors were 
characterized by the carrot-shaped nuclei with nuclear molding or cellular wrapping. 
Both types of medulloblastomas were mitotically very active and occasionally displayed 
subarachnoid spread. Homer-Wright rosette (neurofibrillary rosette) and the apoptotic 
cells were observed in several samples. On the contrary of the high-grade gliomas, 
medulloblastomas had a very prominent Pax6 immunoreactivity while Olig2 staining was 
minimal. Synaptophysin was usually weak and granular in tumor cells, though, isolated 
cases had easily noticeable Synaptophysin staining. Of note, a subset of the 
medulloblastomas showed a proportion of tumor cells with GFAP immunoreactivity, 
suggestive of glial differentiation. Nuclear p53 staining was easily detected in many 
tumor cells. 
 
Final diagnoses were reached as a consensus of H&E staining findings and 
immunohistochemical analyses. In rare cases where a clear diagnosis was hard to reach, 
Olig2 and Pax6 staining were taken as conclusive criteria as Olig2 was very characteristic 
to high-grade gliomas while Pax6 labeled the medulloblastomas distinctively.   
 
5.4 Immunohistochemistry and immunofluorescence 
 
Histological and molecular experiments were performed as described before (Wang et al., 
2009). Adjacent paraffin sections were used in immunohistochemistry and 
immunofluorescence analyses. Slides were first deparaffinized through a series of 
Xylene, Ethanol and PBS treatments, boiled in Retrieve-All antigen unmasking system 
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(Covance), permeabilized in 0.3% Triton X-100 (Sigma-Aldrich) and blocked with 5% 
normal goat serum or normal donkey serum prior to overnight primary antibody 
incubation in cold room. The visualization of the primary antibodies in 
immunohistochemistry was performed with the avidin/biotin-based peroxidase system 
(Vectastain Elite ABC System, Vector Laboratories), except for pAktS473 and Pten, for 
which SignalStain Boost IHC Detection Reagent HRP-rabbit (Cell Signaling) was used. 
The dilutions of the primary antibodies used on paraffin sections in 
immunohistochemistry study were: p53 (1:500, rabbit, Leica), Olig2 (1:2,000, rabbit, 
Millipore), GFAP (1:1,000, rabbit, Dako), Synaptophysin (1:200, rabbit, Covance), Pax6 
(1:500, rabbit, Covance), Ki-67 (1:500, rabbit, Abcam), pAktS473 (1:200, rabbit, Cell 
Signaling) and Pten (1:400, rabbit, Cell Signaling). In addition to aforementioned 
antibodies, Cleaved caspase-3 antibody (1:500, rabbit, Cell Signaling) is used in 
immunohistochemistry study of the brain development project. Sections were examined 
under a light microscope (Olympus BX51 or BX53). The visualization of the primary 
antibodies in immunofluorescence was performed with the use of the Alexa488, 
Alexa555 and Alexa647 conjugated secondary antibodies (1:400, Invitrogen, Life 
Technologies). The dilutions of the primary antibodies used on paraffin sections in 
immunofluorescence study were: p53 (1:500, rabbit, Leica), BrdU (1:500, rat, Abcam), 
Olig2 (1:2,000, rabbit, Millipore), Ki-67 (1:500, rabbit, Abcam), Ascl1 (1:100-1:200, 
mouse, BD PharMingen), GFAP (1:1,000-1:2,000, rabbit, Dako), Nestin (1:100, mouse, 
Millipore), Sox2 (1:250, goat, Santa Cruz Biotech), Pax6 (1:500, rabbit, Covance) and 
NeuN (1:500, mouse, Millipore). DAPI was used to label individual cell nucleus. In 
addition to aforementioned antibodies, following antibodies are used in 
immunofluorescence study of the brain development project: Ctip2 (1:500, rat, Abcam), 
Cux1 (CDP) (1:100, rabbit, Santa Cruz), and Pten (1:400, rabbit, Cell Signaling). 
Sections were examined under a fluorescent microscope (Olympus BX53).  
 
5.5 BrdU assay for the analyses of proliferation and differentiation 
 
For the proliferation assay, mice were injected with 50 µg/g (gram, body weight) of BrdU 
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every two hours. Embryonic and newborn mice received only one, pups and neonatal 
mice up to 30 days old received two, mice around two months old received three and 
adult mice older than two months old received five injections every two hour-intervals. 
All of the mice were perfused with 4% PFA two hours after the last pulse. For the 
differentiation assay, P15 mice were injected with 50 µg/g (gram, body weight) of BrdU 
only once and perfused with 4% PFA 48 hours later. In both assays, brains were dissected 
and processed for either paraffin-embedded or cryostat sections. BrdU 
immunofluorescence was performed as described previously (Wang et al., 2009). 
 
5.6 Western blotting 
 
Snap-frozen tissue samples from wild-type control brains and tumors were homogenized 
in Pierce RIPA Buffer (Thermo Scientific) (10 µl buffer/1 mg tissue), mixed 1:1 with 
Laemmli Sample Buffer (BioRad) and boiled at 100°C for 8 minutes.  Samples were then 
subjected to SDS-PAGE using the Criterion TGX Precast gels (BioRad) and transferred 
onto PVDF membranes (Millipore). The membranes were blocked in 5% non-fat milk 
prepared in TBST and incubated with primary antibodies at 4°C overnight. Next day, the 
membranes were washed with TBST and incubated in horseradish peroxidase (HRP)-
conjugated secondary antibodies at room temperature for 1 hour. The membranes were 
then exposed to Pierce ECL western blotting substrate (Thermo Scientific) for 3 minutes 
and the signals were detected by film development in dark room. The primary antibodies 
used in this study were as follows: pAktS473 (1:1,000, rabbit, Cell Signaling), pAktT308 
(1:1,000, rabbit, Cell Signaling), Akt (1:1,000, rabbit, Cell Signaling), pNDRG1T346 
(1:1,000, rabbit, Cell Signaling), Pten (1:1,000, rabbit, Cell Signaling), Rictor (1:500, 
rabbit, D. Fingar), mTOR (1:1,000, rabbit, Cell Signaling), β-Actin (1:5,000-10,000, 
mouse, Sigma-Aldrich), pS6KT389 (1:1,000, rabbit, Cell Signaling), p4E-BP1T37/46 
(1:1,000, rabbit, Cell Signaling), pTSC2T1462 (1:1,000, rabbit, Cell Signaling), pS6S240/244 
(1:2,000, rabbit, Cell Signaling), S6 (1:2,000, rabbit, Cell Signaling), Olig2 (1:4,000, 
rabbit, Millipore), cMyc (1:1,000, rabbit, Cell Signaling), pErk1/2T202/Ty204 (1:1,000, 
rabbit, Cell Signaling), Erk1/2 (1:1,000, rabbit, Cell Signaling), pGSK-3βS9 (1:2,000, 
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rabbit, Cell Signaling), P120 (1:1000, mouse, BD Biosciences), Pax6 (1:1,000, rabbit, 
Covance), Gli1 (1:500, rabbit, Cell Signaling) and Ezh2 (1:1,000-1:2,000, rabbit, Cell 
Signaling). HRP-conjugated secondary antibodies were anti-mouse (1:5,000-1:10,000, 
goat, BioRad) and anti-rabbit (1:5,000-1:10,000, goat, BioRad).  
 
5.7 Tumor-sphere cell culture and chromosome assay 
 
End-stage tumors were dissected in cold environment and the tissues were transferred 
into DMEM medium, followed by enzymatic cell dissociation using Accutase 
(Innovative Cell Technologies). Cell cultures were then prepared in self-renewal medium 
based on a previously published protocol (Molofsky et al., 2003). Cell density was 
quantified on a cell-counter plate and approximately 20,000-100,000 cells/well were 
plated into 6-well ultra-low attachment surface polystyrene plates (Corning) for primary 
tumor-sphere cultures. The medium was changed every 3-5 days and the cultured cells 
were passaged into two new 6-well plates after 1-2 weeks based on the growth rate and 
passage number. The first plate was used to propagate the cell line while the second one, 
containing approximately 1-2 million cells, was used for chromosome analyses based on 
a Metaphase preparation protocol from Dr. David Ferguson’s laboratory (Ferguson et al., 
2000). According to this protocol, cells were grown for 24 hours, treated with 100 ng/ml 
KaryoMax Colcemid solution (Gibco, Life Technologies) for 1 hour to arrest 
proliferation at metaphase. Cells were then treated with 0.4% KCl at 37°C, fixed in ice 
cold Methanol:Glacial acetic acid (3:1) solution overnight and dropped on Superfrost 
Plus microscope slides (Fisher Scientific). The chromosomes were stained with DAPI for 
visualization. Passage 1 and passage 2 were considered as “early passage” and the 
subsequent passages were considered as “late passage”.  
 
5.8 RT-PCR for copy number analyses 
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Total genomic DNAs were extracted from wild-type control brain tissue, high-grade 
gliomas and medulloblastomas by using AllPrep DNA/RNA Mini Kit (Qiagen). 
Depending on the sample concentration, various amounts of template DNA (average 100 
ng/reaction) along with the SYBR Select Master Mix (Applied Biosystems) and the 
following primers were used in RT-PCR: 
 
Pten (Exon 5)  
Forward: 5’ AGACCATAACCCACCACAGC 3’ 
Reverse: 5’ TACACCAGTCCGTCCCTTTC 3’ 
Pten (Exon 9)  
Forward: 5’ GGTTCACGTCCTACCCCTTT 3’ 
Reverse: 5’ TCTGAGCATTCCCTCCATTC 3’ 
Dmbt1  
Forward: 5’ GTGAAGAAGCCAGCAAGCTC 3’   
Reverse: 5’ CACGGTCAATGTGTGTCCTC 3’ 
Gli1  
Forward: 5’ GCTCCGCAAACACGTGAAGA 3’ 
          Reverse: 5’ GCCGGATCCTCCTTCCCTTT 3’ 
Gli2  
Forward: 5’ TCTAGTCCACGTGTGACCCC 3’ 
          Reverse: 5’ AGGTCCGAATCATGCGTTGT 3’ 
N-Myc  
Forward: 5’ AGGAAGCACTCCCCCATATT 3’ 
Reverse: 5’ CCGCCGAAGTAGAAGTCATC 3’ 
Gapdh  
Forward: 5’ ACCCAGAAGACTGTGGATGG 3’ 
 Reverse: 5’ CACATTGGGGGTAGGAACAC 3’ 
β-Actin 
Forward: 5’ GACGTTGACATCCGTAAAGACC 3’ 
Reverse: 5’ AGGAGCCAGAGCAGTAATC 3’ 
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The CT values of the each gene listed above were normalized to the CT values of one of 
the internal control genes Gapdh and β-Actin. The average of the normalized readings 
from wild-type control tissue were set to “2” and all of the samples were calculated 
accordingly. The estimated copy numbers based on Gapdh and β-Actin were compared to 
each other to confirm the accuracy of the copy number calculations.  
 
5.9 RT-PCR for gene expression analyses 
 
Total RNAs were extracted from wild-type control brain tissue, high-grade gliomas and 
medulloblastomas by using AllPrep DNA/RNA Mini Kit (Qiagen). cDNA synthesis was 
performed using QuantiTect Reverse Transcription Kit (Qiagen) a long with 
approximately 300ng of RNA for each sample. RT-PCR experiments were carried out 
using the SYBR Select Master Mix (Applied Biosystems) and the following primers: 
 
Gli1  
Forward: 5’ CCAAGCCAACTTTATGTCAGGG 3’ 
Reverse: 5’ AGCCCGCTTCTTTGTTAATTTGA 3’ 
Gli2 
Forward: 5’ CGCACTCACTCCAATGAGAA 3’ 
Reverse: 5’ GGACATGCACATCATTACGCCT 3’ 
N-Myc 
Forward: 5’ AGGAAGCACTCCCCCATATT 3’ 
Reverse: 5’ CCGCCGAAGTAGAAGTCATC 3’ 
Atoh1 
Forward: 5’ GAGTGGGCTGAGGTAAAAGAGT 3’ 
Reverse: 5’ GGTCGGTGCTATCCAGGAG 3’ 
Ptch1 
Forward: 5’ CTCAGGCAATACGAAGCACA 3’ 
Reverse: 5’ GACAAGGAGCCAGAGTCCAG 3’ 
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Gapdh  
Forward: 5’ ACCCAGAAGACTGTGGATGG 3’ 
 Reverse: 5’ CACATTGGGGGTAGGAACAC 3’ 
 
The CT values of the each gene listed above were normalized to the CT values of the 
internal control gene Gapdh. The average of the normalized readings from the Ptch1+/- 
model medulloblastomas were set to “100” and all of the samples were calculated 
accordingly. Wild-type control brain tissue and gliomas were used as negative controls 
for medulloblastoma samples. 
 
5.10 Quantification and statistical analyses 
 
Kaplan-Meier survival curves were used to compare the survivorship of the mice 
sacrificed due to brain tumors, soft tissue sarcomas and/or other health concerns. The 
Mantel-Cox (Log-rank) test was used to compare the curves statistically. Anatomically 
comparable sections from control and mutant brains were visualized at 20X and 40X 
magnifications using Olympus BX51 or BX53 microscopes. Multiple images were 
captured, and subjected to double-blinded analysis to measure the specific areas (i.e. 
cerebellar surface area) and to quantify the number of the cells using ImageJ software. At 
least three animals were used from each group and two-tailed Student’s t-test was used to 
compare the number and percentage of the different cellular populations (i.e. Pax6+ cells, 
[Ki-67+/ DAPI], etc.). Fisher’s exact test was used to compare the mouse models in terms 
of the tumor location and tumor spectrum. Linear regression analysis was performed in 
RT-PCR experiments for copy number estimates comparing the readings based on two 
different reference genes. The coefficient of determination (R2) and p-values were 
calculated. Data were presented as mean ± Standard Deviation (SD) and p < 0.05 was 
considered to be statistically significant in all of the statistical analyses. 
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5.11 Bioinformatics 
 
Gene expression profiles and copy number analyses of GEM glioma samples and the 
detailed analyses of the human glioblastoma samples were performed by Dr. Roeland 
G.W. Verhaak and Dr. Siyuan Zheng at the University of Texas MD Anderson Cancer 
Center, Houston, TX. Gene expression profiles and low-coverage copy number analyses 
of GEM medulloblastoma samples were carried out by Dr. Stefan M. Pfister, Dr. Marcel 
Kool, Dr. Sebastian Stark and Susanne Gröbner at the German Cancer Research Center 
(DKFZ), Heidelberg, Germany.  
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Chapter VI: Discussion and future directions 
 
 
The main objective of my thesis work is to determine the cell-specific roles of 
Rictor/mTORC2, and by extension PI3K/Akt signaling, during the mutant-p53/Pten 
induced brain tumorigenesis and brain malformations. My projects can be described in 
three parts: In the first part, I aimed to understand the potential tumor suppressive activity 
of Rictor loss in mouse gliomas, which are characterized by their detrimental genomic 
alterations mimicking human glioblastoma. Second part was dedicated to uncovering a 
novel role of Rictor/mTORC2 signaling in the development of mutant-p53 driven 
medulloblastoma (Figures 17 and 22). Lastly, I studied the interplay between Pten and 
Rictor during the embryonic cortical development, and how loss of Pten leads to neuronal 
and glial defects that might reflect to the malformations of cortical development in PTEN 
Hamartoma Tumor Syndrome (PHTS) patients.   
 
6.1 Tumor suppressive activity of Rictor loss in high-grade gliomas 
 
6.1.1 Distinctive genomic aberrations in mutant-p53 GEM gliomas provide insights 
into the complexity of human glioblastoma  
 
Glioblastomas exhibit extreme degrees of genomic instability accompanied by gene 
amplifications/deletions, detrimental mutations, epigenetic deregulations, genomic 
rearrangements, and chromosomal loss/gain (Brennan et al., 2013; Cancer Genome Atlas 
Research, 2008; Noushmehr et al., 2010; Sturm et al., 2012). Of those, one particular 
attention has been drawn to large deletions in chr10, which was reported in as early as 
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1980s, and currently known as the most frequent genomic alteration (~90%) in 
glioblastomas regardless of their molecular subgroup (Bigner et al., 1984; Verhaak et al., 
2010). These deletions in chr10 exhibited losses that are either confined to 10q, or 
included essentially the entire chromosome. Entire chromosomal loss is observed in non-
G-CIMP (primary) glioblastomas, while restricted 10q loses are observed mostly in G-
CIMP (secondary) glioblastomas (Ozawa et al., 2014; Phillips et al., 2006). 
Consequently, loss of several tumor suppressor genes normally located on this 
chromosome has been thought to contribute to a greater malignancy in glioblastoma. 
Although PTEN gene (located at 10q.23) is considered to be the main target of chr10 
deletions, additional studies have also shown the presence of other putative tumor 
suppressor genes, including LGI1 (10q.24), MXI1 (10q.24-25), DMBT1 (10q.26), and 
WDR11 (10q.26), that might be involved in gliomagenesis (Chernova et al., 2001; 
Ichimura et al., 1998; Wechsler et al., 1997). Homozygous deletion of DMBT1, 
particularly, was associated with unfavorable clinical outcomes in glioblastoma patients 
(Motomura et al., 2012). In light of these findings, we aimed to reveal the genomic 
alterations in our mouse models carrying mutant-p53 genes with or without Nf1 
mutations. It should be considered that human chr10 is distributed into several different 
chromosomes in mouse genome. The human 10q loci that contain the aforementioned 
tumor suppressor genes mostly correspond to mouse chr19 and chr7. More specifically, 
while Pten, Lgi1, and Mxi1 genes are located in mouse chr19, Dmbt1 and Wdr11 are 
located in mouse chr7. Remarkably, our current study has demonstrated that mutant-p53 
driven high-grade gliomas undergo simultaneous deletions of genomic loci in chr7 and 
chr19 corresponding to human chr10q. I additionally showed that Pten and Dmbt1 genes 
are indeed concurrently lost in mutant-p53 GEM gliomas. Therefore, the independent but 
simultaneous deletions of mouse chr19 and chr7 in mutant-p53 GEM gliomas have three 
main interpretations: 1) Mouse models that allow the sporadic genomic alterations 
comparable to human counterparts are essential to understand the complexity of 
glioblastomas. 2) Our mutant-p53 glioma models, with or without Nf1 gene mutations, 
mimic human disease not only by gene expression profile but also at the genomic level. 
3) Concurrent loss of at least two tumor suppressor genes, which are located in human 
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chr10q and independently distributed to mouse chr19 and chr7, might exert an additive 
oncogenic effect that results in malignancy in glioblastomas.   
 
It should be noted that we did not detect simultaneous deletions of chr19 and chr7 in our 
other mouse models that already had a genetically mutated Pten allele. Similarly, 
previously reported GEM gliomas generated by deletions of p53 and Pten genes with or 
without Rb deletion did not exhibit noticeable losses in either of the chromosomes. These 
results suggest that despite the probable additional oncogenic effect of deletions in 
various tumor suppressor genes, the major target of chr10 loss in glioblastomas is PTEN 
gene. This finding also indicates a fine line between successfully inducing tumorigenesis 
by genetic modifications and nullifying the necessity to acquire critical genomic 
alterations frequently observed during the natural progression of human glioblastomas. 
Our mutant-p53 models are then unique in that they gain spontaneous genomic alterations 
that are equivalent to human counterparts. 
 
While providing novel insights, our findings here also raise new questions: If the 
simultaneous deletion of multiple tumor suppressor genes in human chr10q provides only 
a minor tumorigenic advantage, why then do the majority of the glioblastoma samples 
undergo whole chromosomal loss rather than confined deletions in PTEN gene? Is it 
possible that the oncogenic gain by loss of these tumor suppressor genes is masked by the 
PTEN alterations? If so, can recovering their function have more dramatic affect than 
their loss? Would this then imply a therapeutic approach?  
 
6.1.2 Rictor/mTORC2 activity is essential, but not absolutely required, for 
formation and progression of high-grade gliomas  
 
Several lines of evidence have shown that PI3K/RTK signaling is an essential survival 
pathway in many cancer types, and it is activated in approximately 90% of the 
glioblastomas regardless of their molecular subgroup (Brennan et al., 2013; Cancer 
Genome Atlas Research, 2008). There are multiple mechanisms for PI3K/RTK pathway 
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activation, and the most frequent ones include the loss of PTEN function (as described 
above), amplifications of or gain of mutations in PIK3CA and AKT genes, and 
hyperactivation of growth factor receptors (e.g. EGFR, PDGFR) via mutations or 
amplifications. As it serves as a convergence point for many growth stimuli, and activates 
a divergent set of downstream components that function in cell survival, cell 
proliferation, cell metabolism and angiogenesis, several studies investigated the potential 
therapeutic benefits of targeting PI3K/RTK signaling pathway and its major effector 
AKT (Bellacosa et al., 2005). Two of those studies took advantage of the fact that 
mTORC2, along with PDK1, is a kinase that directly phosphorylates and subsequently 
activates AKT. Accordingly, deletion of Rictor, which normally serves as a critical 
component of mTORC2, inhibited Pten deficiency driven tumorigenesis in mouse 
prostate epithelial cells and also hematopoietic stem cells (Guertin et al., 2009; Magee et 
al., 2012). These studies not only provided evidences for the essential role of 
Rictor/mTORC2 signaling in adult tumors, but also confirmed a previously raised theory 
addressing the oncogene addiction of tumor cells. According to this theory, tumor cells 
exhibit “oncogene addiction” to a signaling pathway for their malignancy, proliferation 
and/or survival, and identification of “Achilles’ heel” of the tumor cells is critical to 
attack cancer effectively (Sharma and Settleman, 2007; Weinstein, 2002).  
 
Supported by these findings, I aimed to test whether Rictor loss would provide similar 
anti-tumor activity in high-grade gliomas. As discussed earlier, high-grade gliomas of 
mutant-p53 mouse models recapitulated the key genomic events that are frequently 
observed in human glioblastomas. Since genetic removal of Pten gene nullified the 
necessity to go through these genomic abnormalities, I decided to test my hypothesis 
using mouse models that had tissue-specific mutation in p53 gene only. This was a 
different approach from the prostate cancer and leukemia studies performed by Guertin et 
al. and Magee et al., which relied on Pten deficiency driven tumorigenesis. In the present 
study, I showed that simultaneous loss of Rictor in mutant-p53 mice indeed exerts a 
tumor suppressive activity in mutant-p53 driven high-grade gliomas, as evidenced by a 
significant drop in the frequency of glioma formation, and the extended life span in the 
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remaining mutant mice that eventually formed high-grade gliomas. My subsequent early-
stage analyses aiming to understand the cellular mechanisms by which Rictor loss exerted 
an anti-glioma affect relied on the previous findings showing that tumor cells and early 
tumor-forming cells express mutant-p53 protein (Wang et al., 2009): Mutant-p53 gene in 
our mouse model has an in-frame deletion of exon-5 and -6, which normally express 
DNA-binding domain of p53 protein. Truncated p53 gene is still translated into protein, 
yet does not have a transcription factor activity. Therefore, both the cells that experience 
cellular stress and the end-stage tumor cells continuously express truncated mutant-p53 
protein - a phenomenon that was uncovered long ago in many human tumors that carried 
mutations in their TP53 gene (Anker et al., 1993). Based on this information, my 
colleague Dr. Yuan Wang previously demonstrated a linage relationship between mutant-
p53 expressing (p53+) “tumor-incipient” cells and the end-stage gliomas (Wang et al., 
2009). My additional analyses revealed that Rictor deficiency does not affect the 
generation of the p53+ cells within the germinal zone, which is defined by the 
Subventricular zone and Rostral migratory stream. But interestingly, it blocks the 
spreading of these p53+ cells into the surrounding areas, including corpus callosum, 
cerebral cortex, hippocampus, and olfactory bulb. Thus, these findings suggest that an 
intact Rictor/mTORC2 signaling is essential for the invading expansion of the p53+ cells 
throughout the brain, which is one of the central steps in gliomagenesis. In addition to the 
early stages of tumor formation, I analyzed the high-grade gliomas that formed even in 
the absence of functional Rictor gene.  It should be noted that these glioma bearing 
Rictor-deficient mice lived significantly longer (~50%), which suggests that Rictor loss 
still has a tumor suppressive effect on end-stage gliomas. As suggested by my following 
experiments, this suppression might be exerted by a reduction in tumor cell proliferation 
that is accompanied by alleviated mTORC2 and mTORC1 signaling pathways. Together, 
we believe that combinatory treatment strategies that involve Rictor/mTORC2 inhibitors 
will improve the clinical outcome during both the early and late stages of glioblastomas 
(Figure 22).  
 
	   194	  
Despite the presence of promising preclinical data, clinical trials utilizing 
PI3K/AKT/mTOR pathway inhibitors produced mostly infrequent and short-lived 
responses (Wen et al., 2012). There might be several reasons that led to this 
disappointment. 1) Regulation of numerous genes and networks is disrupted in 
glioblastomas, suggesting that targeting several molecular pathways is more likely to 
improve the clinical outcomes. For instance, a recent study showed that both AKT-
dependent and –independent mechanisms underlie the drug resistance in PTEN-deficient 
glioblastoma samples (Mellinghoff et al., 2005).  2) Patient selection is proven to be a 
critical step to reach the maximum benefit from a therapeutic agent. 3) Drug delivery 
through the blood-brain barrier can build further challenge. 4) Toxicity concerns are still 
a drawback, as evidenced by lipid-based AKT inhibitors exerting gastrointestinal toxicity 
(LoPiccolo et al., 2008; Wen et al., 2012). Our data in the present study confirm the first 
two issues, and provides future directions addressing them. As described earlier, a 
relatively lower percentage of Rictor-deficient mice succumbed to high-grade gliomas, 
despite a significant increase in their overall survival. This finding suggests that 
Rictor/mTORC2/Akt signaling pathway is essential for the development of high-grade 
gliomas, however, it is not absolutely required. Consistently, our parallel analyses of 
human glioblastomas showed that there is a significant variation among the samples with 
regards to their AKT activation, implying different levels of dependence to this 
oncogenic signal. Our findings, then, open up several future directions: 1) It is essential 
to uncover the predominant oncogenic pathway(s) in Rictor-deficient high-grade gliomas 
to design new therapeutic agents, especially for PI3K/AKT-resistant glioblastomas. 2) 
Comparison of several molecular signatures of Rictor-deficient high-grade gliomas to 
human glioblastoma samples will allow us to determine whether these mouse tumors 
represent a subgroup in their human counterparts. 3) Based on this information, we aim to 
stratify glioblastoma patients based on their plausible response to Rictor/mTORC2 
pathway inhibition, which will not only increase the potential of novel Rictor/mTORC2 
inhibitors, but also improve the success rate of the existing PI3K/AKT inhibitors.  
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6.2 Rictor deficiency facilitates mutant-p53 mediated medulloblastoma formation 
 
6.2.1 Rictor loss predisposes cerebellar progenitor cells to mutant-p53 mediated 
medulloblastoma formation 
 
Numerous studies have provided several lines of evidence that stem/progenitor cells are 
one of the major populations that can give rise to various tumors (Chaffer and Weinberg, 
2015). A recent study has also demonstrated a strong correlation between the total 
number of divisions in various stem cell pools and the lifetime risk of cancers in 
corresponding organs. Accordingly, medulloblastoma was considered as a “replicative” 
cancer, for which the risk factors are mostly determined by the stochastic events, such as 
errors during DNA replication, in contrast to “deterministic” cancers (e.g. lung cancer in 
smokers), for which the environmental mutagens or hereditary predispositions constitute 
the major risk factors. (Tomasetti and Vogelstein, 2015). Consistently, many of the well-
characterized mutations in medulloblastoma occur in genes that normally function in the 
proliferation and/or self-renewal of the cerebellar stem/progenitor cells (e.g. PTCH1, 
GLI1, GLI2, SMO, CTNNB1, N-MYC) (Gajjar and Robinson, 2014; Northcott et al., 
2012). However, the great portion of the cerebellar stem/progenitor cells exit cell cycle 
and differentiate into mature cells in a very rapid manner, leaving the cerebellum 
relatively a quiescent organ throughout the life of the organism. This biological 
phenomenon might also be responsible for the largely pediatric nature of 
medulloblastoma, as approximately 88% of the cases are observed in patients younger 
than 16 years of age (Kool et al., 2012). Therefore, both the presence and the replicative 
ability of the cerebellar stem/progenitor cells are among the main predispositions for 
medulloblastoma formation. In light of the knowledge listed here, I further demonstrated 
that inhibition of Rictor/mTORC2 can delay the natural differentiation of a pool of 
cerebellar progenitor cells, and provide a short but essential window leading to an 
increased incidence of mutant-p53 driven medulloblastoma formation (Figure 17). More 
specifically, I presented that Rictor-deficient cerebellar GNPs fail to differentiate and 
continue their temporary but abnormal proliferation in the EGL when wild type control 
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cells already generated fully differentiated neurons and disappeared. In the presence of a 
concurrent p53 mutation, a minor population of these ectopically proliferating cells 
acquires cellular stress, evidenced by their mutant-p53 expression, and accumulates over 
time resulting in malignant medulloblastomas. Rictor deficiency alone, however, does not 
cause medulloblastoma, which suggest that p53-dependent mechanisms induce cell cycle 
exit and differentiation of ectopically proliferating GNPs. It should be noted that despite 
the increased lifetime risk, medulloblastoma formation in Li-Fraumeni syndrome 
patients, who harbor germline TP53 mutations, is still a rare event. Similarly, 
medulloblastoma development in mutant-p53 mice is also a rare event (5-10%), as shown 
here and before (Wang et al., 2009). Therefore, it is remarkable that loss of 
Rictor/mTORC2, a well-known oncogenic molecule, predisposes cerebellar progenitor 
cells to mutant-p53 mediated medulloblastoma formation.  
 
My subsequent aim was to identify the downstream components of the mTORC2 
signaling, by which Rictor loss led to a temporary delay in GNP differentiation.  
mTORC2 activates several members of the AGC subfamily of kinases, including AKT, 
SGK1 and PKC-α (Foster and Fingar, 2010; Laplante and Sabatini, 2012), though AKT 
is considered to be the major mediator of the RTK/PI3K signaling pathway (Sparks and 
Guertin, 2010). Interestingly, pAktS473 levels were almost absent in the EGL, where 
GNPs are actively proliferating, however exhibited high/intermediate levels in ML and 
IGL – two layers that are occupied by newly differentiated neurons and mature neurons, 
respectively. Based on these findings, one likely explanation is that absence of Akt 
signaling is required for the continuous proliferation of the cerebellar progenitor cells, 
nevertheless its activity is essential for at least a subset of these cells to exit cell cycle and 
differentiate into mature neurons. We should note that other aforementioned downstream 
components of mTORC2 might also have roles in this phenomenon. Furthermore, recent 
studies have suggested that Rictor has mTORC2-independent roles, which includes, 
surprisingly, SGK1 ubiquitination and destruction (Gao et al., 2010). It is, therefore, 
likely, and remains to be tested, that multiple downstream effectors of Rictor and 
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previously identified signaling pathways (e.g. Fgf, Shh) function synergically to regulate 
the proper lineage progression of GNPs towards mature neurons.  
 
6.2.2 Rictor loss promotes mutant-p53 driven SHH medulloblastomas with unique 
genomic and chromosomal alterations 
 
Molecular categorization of medulloblastomas has been proposed to improve our 
understanding of the molecular nature of the disease, which would then allow us to tailor 
precise therapies based on the genetic makeup that defines individual cases (Gajjar and 
Robinson, 2014). Two independent analyses, one performed by me and the other one by 
our collaborators at the German Cancer Research Center (DKFZ), indicated that 
regardless of the Rictor status, mutant-p53 mediated medulloblastomas have prominent 
Shh signature, and they actually resemble SHH medulloblastoma models that were 
generated in earlier studies. This finding is also consistent with the fact that TP53 
mutations are enriched in SHH medulloblastomas (~21%), and these tumors have been 
shown to arise from cerebellar GNPs (Northcott et al., 2012; Zhukova et al., 2013). SHH 
medulloblastoma is probably the most studied subtype among the four molecular groups, 
and the mouse models recapitulating human counterparts have been the main tools of 
medulloblastoma research for more than a decade (Northcott et al., 2012). Virtually all of 
these SHH models were generated by genetic manipulations in Ptch1 (deletion) or Smo 
(constitutive activation) genes resulting in elevated Shh signaling pathway. These models 
have been shown to be inherently sensitive to SMO-inhibitors, supporting several clinical 
trials and pharmaceutical research that involve SMO-inhibitors (Berman et al., 2002; Ng 
and Curran, 2011; Romer et al., 2004). However, it should be noted that approximately 
half of the SHH medulloblastomas acquire Shh signaling activation without an alteration 
in PTCH1, SMO or SUFU genes. Furthermore, even in the patients or mouse models that 
showed initial response to SMO-inhibitors, tumors acquired resistance to these agents, 
leading to lethality (Ng and Curran, 2011; Rudin et al., 2009). It is, therefore, important 
to utilize novel mouse models for SHH medulloblastoma that do not rely on genetically 
engineered Ptch1 or Smo mutations in order to uncover the divergent complexities of 
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human medulloblastomas, and design therapeutic agents that are independent of Smo 
activation. We believe that the mutant-p53 driven medulloblastomas presented here, 
especially those that are facilitated by concurrent Rictor loss, fulfill this need, as they do 
not have initial mutations in Shh pathway, and undergo spontaneous genomic alterations 
over the long course of the tumor initiation and progression. The future directions based 
on our findings would include; 1) testing whether mutant-p53 medulloblastomas are 
actually resistant to SMO-inhibitors, and 2) determining whether there is a cross talk 
between Shh and Akt signaling pathways that may correlate with the tumor response to 
Shh antagonists. Pertinently, absence of Akt activation in medulloblastoma is our 
particular interest, as I surprisingly observed that the majority of the mouse 
medulloblastomas available in our laboratory exhibited very low levels of pAktS473 
regardless of their Rictor status. As shown previously by Kool et al. (2014), even though 
almost half of the childhood SHH medulloblastomas undergo 10q loss accompanied by 
PTEN mutations and deletions, pAKT is detected in less than 10% of the cases. These 
two observations suggest that inactivation of PTEN signaling in childhood SHH 
medulloblastomas has AKT-independent consequences leading to tumorigenesis. For 
instance, loss of nuclear functions or protein phosphatase functions of PTEN might have 
roles in medulloblastoma development. 3) Lastly, we aim to test whether Akt signaling 
exerts a tumor suppressive effect in a certain group of medulloblastomas.  
 
Approximately 10% of the human medulloblastomas carry TP53 mutations, which are 
almost exclusive to WNT (~16%) and SHH (~21%) subgroup tumors. Interestingly, 
while TP53 mutations do not produce an observable effect on the overall survival of the 
WNT patients, its presence has been implicated as the most important risk factor leading 
to early recurrence and extremely poor outcome in SHH patients (Tabori et al., 2010; 
Zhukova et al., 2013). Parallel studies with regards to the role of TP53 mutations in 
medulloblastoma revealed a strong link between SHH/TP53mut tumors and “tetraploidy” 
(having a chromosome number four times the monoploid number), and  “chromothripsis” 
(concurrent severe fragmentation of chromosomal regions and a subsequent reassembly 
in an imperfect or random manner) (Jones and Jallepalli, 2012; Rausch et al., 2012). 
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Despite the presence of TP53 mutations, virtually none of the WNT medulloblastomas 
exhibited tetraploidy or chromothripsis, underlining the context dependent role of TP53 
mutations and subsequent genomic abnormalities (Rausch et al., 2012). These findings 
are also consistent with the aforementioned observations that the presence of TP53 
mutation is associated with a poor clinical outcome only in SHH, but not in WNT 
medulloblastomas. Functional consequences of these chromosomal aneuploidies and 
catastrophic DNA rearrangements uncovered the presence of gene amplifications in Shh 
signaling downstream components, including N-MYC, GLI1, GLI2, and BOC. These 
genomic events are further correlated with inherent resistance to SMO-inhibitors and 
consequential poor clinical outcome (Gajjar and Robinson, 2014; Northcott et al., 2012). 
In light of these findings, I investigated whether our mutant-p53 medulloblastomas 
exhibited similar genomic alterations. My results suggested that while approximately 
80% of the Rictor-deficient/mutant-p53 medulloblastomas exhibited noticeable 
amplifications in N-Myc gene, almost none of the other mutant-p53 mice (i.e. with an 
intact Rictor allele(s)), including Ptch1+/- models, displayed similar genomic alterations. 
Furthermore, I also detected Gli2 amplifications in approximately 30% of the mutant-
p53-Rictor medulloblastomas. Our collaborators in DKFZ analyzed another set of 
mutant-p53 mediated medulloblastomas and showed comparable results, though Gli2 
amplification was more noticeable than N-Myc amplification. It should, however, be 
noted that their findings were based on low-coverage copy number analyses, which may 
represent less accurate results. Having shown that Rictor-deficient/mutant-p53 
medulloblastomas carry gene amplifications in key Shh components, I analyzed the 
chromosomal status of these tumors. Remarkably, approximately 65% of the Rictor-
deficient/mutant-p53 medulloblastomas had noticeable increase in their chromosome 
number, reminiscent of tetraploidy. Based on these results, I concluded that Rictor 
deficiency facilitates the formation of mutant-p53 mediated medulloblastomas, which 
exhibit characteristic genomic and chromosomal abnormalities that are associated with 
poor clinical outcome and resistance to SMO-inhibitor therapy.   
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While these findings provide novel insights into the role of Rictor/mTORC2 and p53 
signaling in medulloblastoma formation, they also open up several future directions: 1) I 
showed that Rictor-deficient/mutant-p53 medulloblastomas have increased numbers of 
chromosomes similar to tetraploidy. The question is, then, whether they also exhibit the 
features of chromothripsis that might explain their gene amplifications. 2) My copy 
number analyses and our collaborators’ results suggested that N-Myc amplification is an 
exclusive event for Rictor-deficient medulloblastomas. Does particular absence of Rictor 
signaling promote N-Myc amplification and possibly other key oncogenes involved in 
Shh signaling? 3) As the previous studies suggested, are these mouse medulloblastomas 
with gene and chromosome amplifications resistant to SMO-inhibitors? If so, can we use 
them in in vivo and in vitro drug screening analyses to identify novel agents for SMO-
inhibitor resistant medulloblastomas? 
 
6.3 Intact Pten signaling regulates cortical neuronal layering and maintains 
neuronal subpopulations 
 
Apart from its role in brain tumorigenesis, I also studied Rictor/mTORC2 and Pten 
signaling pathways in cortical development during the embryonic stages. The starting 
point of my research was based on three previous findings: 1) Pten deficiency in mice 
causes severe increase in head circumference (macrocephaly) (Fraser et al., 2004; 
Groszer et al., 2001). 2) Macrocephaly is the most consistent physical characteristic of 
children with autism. 18-24% of the autism patients exhibited macrocephaly, and 80% of 
the patients had head circumferences above the mean (Davidovitch et al., 1996; Orrico et 
al., 2009; Stevenson et al., 1997). 3) PTEN mutations in PHTS patients are strongly 
associated with autism spectrum disorders (ASD), developmental delay, and 
macrocephaly. Accordingly, macrocephaly is the most common abnormality in PHTS 
patients, 20-50% of whom are also diagnosed with ASD (Lynch et al., 2009; Varga et al., 
2009).  In light of these studies, I aimed to understand how elevated Akt signaling as a 
result of Pten deficiency affect different neuronal populations in the cerebral cortex that 
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might be relevant to the cognitive defects observed in PHTS patients. I also investigated 
the therapeutic impacts of simultaneous Rictor loss on Pten deficiency phenotypes.   
 
In addition to severely increased size, my initial observation in Pten-deficient brains was 
the presence of blood spots that were randomly distributed on the cortex. I subsequently 
found that large areas of tissue degeneration and apoptosis accompanied these blood 
spots. I also detected significant number of reactive astrocytes infiltrating the cerebral 
cortex, which might have contributed to the progressive brain enlargement during the 
neonatal stages.  One likely explanation for all these observations is that initial increase 
in brain size as a result of Pten loss leads to an elevated intracranial pressure due to the 
physical limitations of the skull, which in turn causes tissue bleeding and cell death. 
These brain abnormalities may then trigger a tissue healing process accompanied by an 
increase in astroglial population. It is, therefore, essential to examine not only the PHTS 
patients but also the other syndromes associated with macrocephaly (e.g. 
Neurofibromatosis type 1 - NF1) to determine whether a traumatic tissue injury leads to 
an irreversible loss in certain neuronal and/or glial populations. It is only surprising that 
such loss in essential brain cells will not result in neurodevelopmental deficits.  Of note, 
these brain abnormalities, including increased brain size, cortical bleeding and infiltrative 
reactive astrocytes were noticeably alleviated by simultaneous Rictor loss. These results 
implicate a therapeutic potential of targeting Rictor in megalencephaly syndrome 
(abnormally large brain) patients, who carry mutations in PTEN, PIK3R2, PIK3CA, 
MTOR, AKT, TSC1/2, and FGFR3 genes (Guerrini and Dobyns, 2014). 
 
In order to understand how distinct populations of cortical neurons are affected by the 
brain defects listed above, I specifically examined pyramidal neurons of the cerebral 
cortex. These neurons are glutamatergic projection neurons, and they are arranged into 
morphologically distinguishable six layers (I: surface of the brain – VI: inner cortex). 
Late-born superficial cortical layers (II-IV) comprise corticocortical “upper layer 
neurons” (ULNs), and early-born more apical layers (V-VI) consist of subcortical 
“deeper layer neurons” (DLNs) (Britanova et al., 2008; Leone et al., 2008). It should be 
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noted that the majority of the cortical neurogenesis takes place between E12-E17 
(Hartfuss et al., 2001), therefore, my results were mainly based on P0.5 brains and to a 
lesser extent neonatal stages. The pyramidal neurons are generated in an inside-out 
manner - formation of DLNs is followed by addition of more superficial ULNs on top of 
the existing neurons (Britanova et al., 2006; Tarabykin et al., 2001). In Pten-deficient 
brains, I found that a great portion of the ULNs failed to migrate to more superficial 
layers, and they were located below or mixed with the DLN populations. Consequently, 
proper neuronal layering was severely damaged, as Pten-deficient brains appeared to 
have three abnormal layers from the surface of the brain to the inner cortex: ULN-DLN-
ULN. My subsequent analyses indicated that neuronal layering defects were 
accompanied by a glial scaffold collapse in Pten-deficient brains. These long fibrous 
processes normally stretch from the lateral ventricle (LV) to the meninges at the surface 
of the cortex, and they serve as a migratory scaffold for newly generated neurons during 
their migration to more superficial layers (Molyneaux et al., 2007). My findings are then 
more consistent with a model where destruction in fibrous glial scaffold as a result of 
Pten loss blocks the proper migration of the ULNs, leads to their abnormal accumulation 
surrounding or below the DLN population, and consequently causes neuronal layering 
defects. Having shown that ULNs are properly generated but failed to migrate up to more 
superficial layers, I aimed to examine how DLNs, the second major population of 
pyramidal neurons, are affected by Pten loss. Interestingly, Pten-deficient brains 
exhibited a significant loss in DLN populations, despite their proper localization. 
Concurrent Rictor loss rescued some, but not all, of the neuronal phenotypes in Pten-
deficient brains, suggesting that both Akt-dependent and -independent functions of Pten 
regulate migration and maintenance/generation of pyramidal cortical neurons.  Together, 
my findings reveal distinct roles of Pten in different neuronal populations of the cerebral 
cortex: While ULNs require intact Pten signaling for their proper localization but not 
formation, positioning of DLNs is unaffected by Pten loss, however their generation 
and/or maintenance is severely disrupted. It is, therefore, important to isolate the specific 
neuronal defects in PHTS patients prior to applying an “all-in-one” treatment plan.   
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This part of my thesis provides novel findings that will considerably increase our 
understanding of the neurological and cognitive deficits in PHTS patients, however, 
many questions remain to be answered: 1) What is the main event that stimulates the 
extensive glial response in Pten-deficient brains? 2) Are ectopically located ULNs 
construct functional neural networks? 3) Can we reestablish the fibrous network to 
facilitate the migration of Pten-deficient ULNs, or are there other cell-autonomous 
mechanisms behind this defect? 4) Which of the neurogenic paths does Pten mutation 
affect that leads to a substantial loss in DLNs, direct or indirect? 5) Do the layer V and VI 
DLNs respond the same to Pten loss? Addressing these questions is also essential for 
understanding the other malformations of cortical development and paving the way for 
novel therapeutic strategies.   
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